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ABSTRACT 
 Gene delivery is a broadly applicable tool that has applications in gene therapy, 
production of therapeutic proteins, and as a study tool to understand biological pathways.  
However, for successful gene delivery, the gene and its carrier must bypass or traverse a 
number of formidable obstacles before successfully entering the cell’s nucleus where the 
host cell’s machinery can be utilized to express a protein encoded by the gene of interest.  
The vast majority of work in the gene delivery field focuses on overcoming these barriers 
by creative synthesis of nanoparticle delivery vehicles or conjugation of targeting 
moieties to the nucleic acid or delivery vehicle, but little work focuses on modifying the 
target cell’s behavior to make it more amenable to transfection.  
 In this work, a number of kinase enzymes have been identified by inhibition to be 
targets for enhancing polymer-mediated transgene expression (chapter 2), including the 
lead target which appears to affect intracellular trafficking of delivered nucleic acid 
cargo.  The subsequent sections (chapters 3 and 4) of this work focus on targeting 
epigenetic modifying enzymes to enhance polymer-mediated transgene expression, and a 
number of candidate enzymes have been identified.  Some mechanistic evaluation of 
these targets have been carried out and discussion of ongoing experiments and future 
directions to better understand the mechanistic descriptions behind the phenomena are 
discussed.  The overall goal is to enhance non-viral (polymer-mediated) transgene 
expression by modulating cellular behavior for general gene delivery applications. 
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CHAPTER 1 - INTRODUCTION 
1.1 GENE DELIVERY IN MAMMALIAN SYSTEMS 
The transfer of nucleic acids from an exogenous source to a target cell for the 
expression of a desired protein, or gene delivery, is a concept which has value in a broad 
range of applications.  In biotechnology, gene delivery both for transient and stable 
recombinant protein expression, is utilized in mammalian systems for the purpose of 
expressing proteins that can be used as therapeutics.  This approach was carried out in 
2002 for the first successful production of a fully human antibody, HUMIRA, used as a 
therapeutic for eliminating the inflammatory response associated with the autoimmune 
disorder rheumatoid arthritis [2]. Mammalian production systems have also been applied 
to produce protein vaccines, such as Provenge, approved for the treatment of prostate 
cancer in 2010 [3], and a new seasonal flu vaccine produced in canine kidney cells [4].  
While most mammalian-produced commercial protein therapeutics are synthesized in 
stably-expressing cell lines, the development of stable and high-producing cell lines is a 
time and cost intensive process.  Consequently, it is valuable to carry out transient 
expression for the rapid production and screening of protein products prior to stable cell 
line development [5] [6]. It is important to acknowledge that production of relatively 
simple proteins is commonly carried out in non-mammalian cell hosts (such as bacteria), 
and these cell systems are important in protein production given their ease of use and, in 
the case of bacteria, short generational time.  However, mammalian cells are capable of 
carrying out posttranslational modifications, such as glycosylation, that are often 
necessary for active proteins used as human therapeutics [7]. Taking together the 
advantages associated with the use of mammalian systems for protein production and the 
2 
 
modes in which proteins are produced in these systems, the importance of research both 
into stable and transient expression strategies for improving commercial (as well as lab-
scale) mammalian protein production is evident.   
In addition to applications in commercial protein production, in which 
recombinant protein products are processed for downstream applications, nucleic acid 
delivery is also useful for gene therapy.  In gene therapy, the host cell in which the 
recombinant protein product is expressed is the target destination for activity.  This 
activity can be the correction of a genetic mutation that rescues a cell or organ system; 
examples include the delivery of a gene expressing an enzyme facilitating proper cytosol 
to sarcoplasmic reticulum calcium signaling in patients with advanced heart failure [8] 
and correction of a mutation causing choroideremia, a condition commonly leading to 
legal blindness between 40 and 50 years of age [9].    
Another gene therapeutic use is the destruction of target cells, as opposed to their 
rescue as referenced above.  This is a common approach in cancer gene therapy, which 
constitutes over 64% of all current gene therapy clinical trials [10]. The delivery of an 
oncolytic virus is one approach for targeted cancer gene therapy. While the virus does not 
express a transgene, it contains its own genome and becomes lethal towards the tumor 
target through replication.  This scheme works in a two-fold manner: first, the delivered 
virus replicates in cancer cells, resulting in cell lysis and release of newly produced virus 
to surrounding tumor cells which may not have taken up the virus initially.  Second, the 
aforementioned lysis of the cancer cells results in release of immune signals, initiating an 
immune response against the tumor cells [11].  Herpes simplex virus, commonly 
employed for oncolysis, has been shown to have applications in treatment of 
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glioblastoma [12] and prostate cancer [13], among other malignancies. Additional gene 
therapeutic tactics for cell ablation involve delivery of a suicide gene, which initiates 
targeted cell death upon treatment with a second agent, or transfer of a tumor repressor 
gene, which itself has growth reduction or toxic effects on the target cells; both of these 
techniques are common in cancer gene therapy.   
A prominent example of the delivery of a cancer-targeted “suicide” gene therapy 
is the combination treatment with the herpes simplex virus thymidine kinase (HSV-TK) 
gene and the anti-viral drug, ganciclovir [14, 15]. Briefly, cells are transfected with a 
vector expressing HSV-TK which phosphorylates the prodrug ganciclovir, ultimately 
leading to the formation of ganciclovir triphosphate in future steps. This incorporates into 
DNA and acts as a poor substrate for chain elongation during DNA replication, ultimately 
leading to cell apoptosis. This effect is imposed most prominently on cancer cells, which 
divide rapidly and must replicate DNA quickly. An alternative to the delivery of suicide 
genes is wild type tumor suppressor gene delivery to correct a mutated or deleted form of 
a gene, whose modification activates or promotes cancerous character.  A few genes that 
are commonly affected through loss-of-function mutation or deletion and have been 
studied in vivo or in clinical trials for cancer gene therapy applications are p53 [16, 17], 
breast cancer 1, early onset (BRCA1) [18], and phosphatase and tensin homolog (PTEN) 
[19, 20].  
Another use for nucleic acid delivery is for target gene silencing, which can be 
used as a study tool to determine protein function, as well as for therapeutic applications.  
Gene silencing can be carried out using the process of RNA interference (RNAi) using 
small interfering RNA (siRNA) or small hairpin RNA (shRNA)-expressing nucleic acids.  
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The activity of siRNA occurs in the cytoplasm, where it is processed into an active 
molecule that binds with and degrades mRNA of the target protein. shRNA is generally 
expressed in the nucleus from a DNA cassette, before being processed and exported to 
the cytoplasm for further processing and silencing of target protein expression. There are 
many informative review articles on the mechanism of RNA interference [21-23].  RNAi 
through nucleic acid delivery has been studied for use in treatments for cancer [24, 25], 
HIV [26], and rheumatoid arthritis [27], along with many other diseases. 
 
1.2 INTRACELLULAR BARRIERS TO GENE DELIVERY 
Gene delivery is a dynamic strategy that can clearly be useful in a plethora of 
applications, but successful gene delivery suffers from a multitude of physical hurdles.  
With the exception of cases in which a delivered nucleic acid’s activity occurs in the 
cytoplasm, successful gene delivery requires the delivered cargo’s successful traverse or 
circumvention of several intracellular barriers, including most prominently overcoming 
exclusion from the target cell nucleus. Gene delivery vectors are classified, at the most 
general level, as viral and non-viral.  Viral gene delivery boasts the major advantage of 
efficacy over non-viral gene delivery, but certain safety and nucleic acid size limit issues 
associated with viral gene delivery warrant deeper exploration into improving non-viral 
gene delivery vectors and methods.  The focus henceforth will be on non-viral gene 
delivery and its barriers (Figure 1.1).  Non-viral gene delivery vectors constitute a wide 
range of cationic materials, including lipids[28], polymers [29, 30], functionalized carbon 
nanotubes [31], and calcium phosphate nanoparticles [32], among many others.   
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1.2.1 Pre-Cellular Uptake Barriers 
Depending on the application being executed, a variety of obstacles may be 
present for successful gene delivery that precede uptake of the recombinant nucleic acid 
into the target cell.  For gene therapy applications, the injection site or delivery site will 
vary depending on the ultimate treatment goal, and this will drastically affect the success 
of target cell transfection.  However, two major issues generally arise when carrying out 
Figure 1.1 Intracellular barriers to successful endocytic non-viral gene delivery, with cationic 
polymer used as delivery vector: Cationic gene delivery vehicles (liposomes, polymers, calcium, 
and many others) can be used to condense negatively charged DNA to form deliverable 
nanoparticles. In addition to condensing the DNA to be delivered, cationic delivery vehicles can 
assist in binding to negatively charged proteoglycans on the cell membrane to facilitate uptake and 
shielding DNA from degrading enzymes [1].  Once the cargo enters the cell, it must escape the 
vesicle which facilitated its cellular entry before it fuses with degradative lysosome compartments.  
Following vesicle escape, DNA must traffic toward and enter the nucleus, the latter which is 
commonly acknowledged as the most formidable barrier to successful gene delivery  
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systemic gene delivery; detection and elimination by the reticuloendothelial (RES) 
system, in which phagocytic cells eliminate the delivered DNA (discussed later) and 
delivery vector destabilization by serum albumin [33].  Strategies by which these issues 
are overcome will be discussed in Section 1.3.   
1.2.2 Cellular Uptake 
Cellular uptake mechanisms can be endocytic or non-endocytic. Creative non-
endocytic strategies, such as microinjection, electroporation, and chemical pore-forming 
have been employed for successful gene delivery, allowing nucleic acids to bypass many 
barriers associated with endocytic gene delivery, including the need to escape endocytic 
vesicles following cellular uptake.  However, applications of these invasive methods are 
limited, especially in the scope of gene therapy and industrial scale protein production.  
Cargo entering cells in an endocytic manner can enter through phagocytosis, 
clathrin-mediated endocytosis, caveolae-mediated endocytosis, or pinocytosis. The 
pathway by which cargo enters a target cell is a complex function of the cell itself as well 
as the size and charge of the delivery vehicle/nucleic acid complex, and due to the 
heterogeneity of these delivery particles, multiple cell entry mechanisms can 
simultaneously occur [34].   
Phagocytosis is a specialized method of endocytosis, in which cells engulf 
surrounding cargo.  This is most commonly carried out by cells of the immune system, 
which engulf large particles, greater than 0.5 μm (eg. pathogens) in a vesicle referred to 
as a “phagosome”, ultimately fusing with the lysosome and degrading the engulfed 
contents [35].  However, phagocytosis can occur in cells outside of the immune system, 
and may potentially be applied for gene delivery particles that are too large to be taken up 
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by the other processes discussed below; a model has been proposed for phagocytic uptake 
of cationic polyethyleneimine (PEI) – DNA nanoparticles into HeLa cells [36], an 
epithelial cell line not directly associated with the immune system.  However, while 
phagocytosis may be useful for gene delivery applications, the presence of phagocytic 
cells in the immune system can actually limit the efficacy on systemic in vivo gene 
delivery by scavenging delivered DNA present in the blood [37].    
Clathrin-mediated endocytosis is a receptor-dependent mode of cellular uptake, in 
which complexes of the protein clathrin enable invagination of the cell membrane and 
facilitates cargo uptake.  In response to binding of ligands to cell surface receptors, 
adaptor associated protein complexes which simultaneously bind receptors, membrane 
lipids, and clathrin facilitate the formation of clathrin coats around cargo to be taken up 
by the cell [38].  Dynamin-2 then polymerizes and results in the detachment of the 
clathrin-coated vesicle, containing the newly endocytosed cargo, from the cell membrane 
[39].  This vesicle ultimately loses its clathrin-coating and fuses with other similar 
vesicles to form early endosomes [40], ultimately leading to cargo degradation in the 
lysosome unless it can escape the vesicle (discussed in next section).  Additionally, some 
cargo may be recycled to the cell membrane by recycling endosomes, which could 
detrimentally affect gene delivery efficacy. The most prominent example of a protein 
taken up by this receptor-dependent pathway is transferrin [41].    
Caveolae-mediated endocytosis is a clathrin-independent and receptor-mediated 
mechanism of cargo uptake, facilitated by the formation of cave-like structures called 
caveosomes.  The protein caveolin-1 oligomerizes in the cell and locates to the cell 
membrane at areas of high sphingolipid and cholesterol content (lipid raft domain) [42], 
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to which it binds and assists in formation of caveosomes.  In a similar manner as clathrin-
mediated endocytosis, dynamin appears to be involved with the pinching off of the 
endocytic vesicles, but the intracellular fate is different in that cargo taken up by the 
caveolae pathway generally can be transported directly to the Golgi or ER for sorting, 
thus avoiding the degradative lysosomal pathway associated with clathrin-mediated 
endocytosed materials [43].  However, there are reports contrary to this notion, 
supporting that cases do exist in which caveolae-endocytosed materials can interface with 
the endolysosomal pathway [44, 45].  Common receptors involved in caveolae-mediated 
endocytosis are insulin and TGF-β.   
   While a significant amount of research efforts have been focused on associating 
particular systems with corresponding modes of cellular cargo entry, there remains much 
to be learned. Interestingly, DNA carried by related delivery vectors can be taken up by 
cells and trafficked in the cell in different manners.  For instance, DNA delivered in 
Chinese Hamster Ovary (CHO) cells using two commercially available cationic 
liposomes displayed very different modes of cellular uptake.  In the case of DMRIE-C, 
DNA enters cells through a caveolae pathway subsequently dependent on intracellular 
microtubule trafficking; however, when Lipofectamine LTX was used as a carrier, DNA 
was taken up via clathrin mediated endocytosis [46]. In another study in HeLa cells, 
DOTAP-DNA lipoplexes were taken up exclusively by clathrin-mediated endocytosis, 
however PEI polyplex uptake proceeded by both clathrin-mediated endocytosis and 
caveolae mediated endocytosis [47].  These observations indicate that subtle differences 
in the delivery vector can alter the manner in which materials enter cells. 
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Mode of endocytosis has also been demonstrated to have dependence on the size 
of the internalized cargo. In a murine melanoma cell line, latex beads of less than 200 nm 
were taken up by clathrin-coated pits, while larger beads (up to 500 nm) were taken up by 
caveolae [48].  Given that caveolae dependent endocytosis generally bypasses 
degradative lysosomes, this pathway can be advantageous in preserving nucleic acid 
cargo en route to the nucleus.   
Pinocytosis, is another mode of cellular uptake which differs from clathrin and 
caveolae-mediated pathways in that receptors are not involved.  This mode of uptake 
generally facilitates entry of larger materials than the former pathways.  
1.2.3 Endosomal Escape and Cytoplasmic Trafficking 
As was acknowledged in the previous section, genes taken up by clathrin-
mediated endocytosis and in some cases caveolae-mediated endocytosis must escape the 
vesicles through which they entered the cell before endosomal maturation/lysosomal 
fusion occur, resulting in cargo degradation.  As early endosomes fuse with late 
endosomes, eventually maturing into lysosomes, a concomitant drop in pH occurs.  While 
this promotes a rugged environment for the transgene cargo, this very property can be 
used to assist in endosomal escape (discussed in following section).   
Transport of gene delivery vectors has also been associated with trafficking along 
microtubules, although in many cases, it is not clear whether this occurs while vectors are 
inside or outside of endocytic vesicles.  PEI polyplexes have demonstrated the capability 
to be actively transported through the cytoplasm along microtubules through interactions 
with cytoskeleton-dependent motor proteins [49], further evidenced by the alteration of 
exogenously delivered cargo trafficking by disruption of microtubules with nocodazole 
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[50].  This process has been shown to play a role in transgene expression, and two ways 
to improve cytoplasmic trafficking to the nucleus will be discussed in Section 1.3.   
1.2.4 Nuclear Entry 
Transgenes which successfully reach the doorstep of the nucleus by overcoming 
the aforementioned intracellular obstacles must ultimately enter the nucleus to allow 
transcription of the gene of desire; this step is extremely inefficient for non-viral vectors.  
The nuclei of cells that are actively dividing are generally more permeable to exogenous 
DNA, possibly by the nuclear membrane breakdown which occurs prior to each cell 
division [33].  However, the nuclei of cells which are not actively dividing are extremely 
difficult to penetrate, as diffusion through nuclear pore complexes only allow particles of 
about 9 nm in size to enter without energy-facilitated transport [51].    
1.2.5 Delivery Vector/Nucleic Acid Dissociation  
The aforementioned barriers to gene delivery are the preeminent barriers to gene 
delivery. However, unpackaging of the transgene from the delivery vehicle has also been 
acknowledged as a formidable barrier to successful gene delivery, as the gene must be 
accessible by the transcription machinery of the target cell in order for successful 
transgene expression.  This is a very tricky obstacle in gene delivery that must be taken 
into account when synthesizing delivery vectors, as it works against the preceding steps 
of gene delivery, in which nucleic acid protection through strong carrier/exogenous DNA 
interaction is desirable [1].  Interestingly, RNA present in the cytoplasm [52] and 
chromosomal DNA in the nucleus [53] have both demonstrated the ability to remove 
cationic carriers from exogenous DNA through ion-exchange, suggesting that delivery 
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vehicle-nucleic acid nanoparticles can be dissociated either in the cytoplasm or following 
nuclear entry.   
 
 
1.3 METHODS FOR OVERCOMING GENE DELIVERY BARRIERS 
1.3.1 Non-viral Delivery Vehicles and Vector Modifications  
1.3.1A Use of Efficient Delivery Vehicles – 
Although naked nucleic delivery has its applications in specific in vivo 
applications and for siRNA delivery (which does not require nuclear entry) [54], for most 
purposes a delivery vector is required to obtain efficacious transgene expression. 
Generally, gene delivery vectors are polycations, and by far the most common non-viral 
vector classes are cationic lipids and cationic polymers, which can spontaneously 
complex with DNA through electrostatic interactions.  Although polycations have been 
used for delivering DNA to target cells (E. coli) since the 1970s [55], the introduction in 
the mid-1990s of polyethyleneimine (PEI), an efficacious cationic polymer gene delivery 
vehicle initiated an unmistakable effort towards discovering and designing new gene 
delivery vehicles, as well as improving on PEI.  PEI is especially attractive as a gene 
delivery vector because of its ability to escape from endosomes via the “proton sponge 
effect” due to its high cationic charge through the presence of protonable amines.  The 
proton sponge effect is a controversial theory in the gene delivery field, albeit with strong 
evidence.  Briefly, molecules with protonable amines, with pKa nearly neutral, will 
become more protonated as the pH decreases from just above neutral to acidic along the 
endocytic pathway (early endosome to lysosome).  The abundance of protonable amines 
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will continue to “absorb” protons, increasing their flux into the endosome, bringing about 
negative counterions (Cl-), ultimately leading to an increase in osmotic pressure 
compromising the endosomal membrane and releasing the polyplex [56]. Due to the 
relatively high efficiency of PEI as a vector, many studies have been conducted to 
improve on the parental structure of PEI to improve transfection efficacy and reduce 
toxicity [57, 58], including jetPEI, a linear (unbranched) PEI derivative.  Another group 
of delivery vectors, fusogenic peptides, are efficient at inducing endosomal escape 
through fusing with lipid membranes and facilitating cargo release into the cytoplasm.  
These commonly employed peptides mimic a membrane fusion domain common in 
viruses [59].   
In addition to PEI and other synthetic polymers, natural polymers (including 
polypeptides) such as collagen [60], histones [61, 62], and chitosan [63] have been 
successfully used for carrying out transfections.  These polymers have the advantage of 
being biocompatible [64] given they are found in humans or other eukaryotes (in the case 
of chitosan).   Rational high throughput polymer design and screening approaches have 
been applied to discover non-viral polymer vectors [30, 65], combined with quantitative 
structure activity relationship (QSAR) regression modeling to not only identify effective 
delivery vectors, but to ascertain physicochemical characteristics that make the polymers 
efficacious to assist in future polymer design [66].  
In addition to cationic polymers, cationic lipids are very commonly used as gene 
delivery vehicles.  Lipids are advantageous in that they possess hydrophobic moieties that 
can interact with cell and endosomal membranes.  The most common cationic gene 
delivery lipid used for lipoplexes is 1,2-Dioleoyl-3-trimethylammonium-propane 
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(DOTAP), and the helper lipid 1,2-Dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) 
is often added to improve transfection [67]. Lipofectamine® is a commercially available 
cationic lipid based transfection reagent manufactured by Thermo-Fisher with very high 
transfection efficiencies, often used as a standard when comparing other gene delivery 
vehicles.      
1.3.1B Functionalization of Delivery Vehicles -     
Even the most efficacious cationic gene delivery vehicles can be modified to 
improved general transfection, or modified to cater to specific applications such as cell 
targeted gene delivery.  For gene delivery applications that must deal with systemic 
barriers such as RES clearance or aggregation due to interactions with serum proteins, 
delivery vehicles can be functionalized to mitigate these issues.  The most common 
modification is the addition of polyethylene glycol (PEG), a process referred to as 
PEGylation.  The addition of this hydrophilic group shields the cationic vehicle’s charge 
from surrounding proteins and reduces interaction with surrounding erythrocytes [68], 
ultimately increasing circulation time and increasing the probability of cellular uptake.  
While PEGylation is a well-studied and commonly employed tactic for improving in vivo 
gene delivery, due to potential problems with oxidation, the introduction of zwitterions to 
delivery vehicles can be employed to buffer or absorb any non-specific interactions with 
serum proteins [33].   
Cellular localization/uptake can be improved by conjugating antibodies or other 
ligands that are recognized by cell receptors.  For example, transferrin, generally taken 
into cells via clathrin-mediated endocytosis, has been shown to improve gene delivery 
when conjugated to liposomes [69]. A similar approach has also been carried out by 
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conjugating recombinant epidermal growth factor (EGF) to the polymer poly-L-lysine, 
improving gene delivery to lung cancer cells which overexpress EGF receptor (EGFR) 
[70], an example of modifying a vector to carry out cancer-targeted gene delivery.   
Modifications can be made to cationic delivery vehicles to overcome endosomal 
entrapment, such as the addition of imidazole groups, which contain protonable amines to 
efficient gene delivery polymers such as cyclodextrin as carried out by Davis et al [71].  
However, a common approach for overcoming this barrier is the direct addition to cells of 
4-amino quinoline molecules such as chloroquine [72], which themselves have 
protonable amines and can have drastic enhancing effects on transgene expression by 
promoting the proton sponge effect.   
Unpackaging of cationic delivery vehicles and nucleic acids is essential for 
transcription to occur, which generally requires compromise in using a vehicle that 
sufficiently protects the nucleic acid cargo, but liberates it prior to or following nuclear 
entry.  It is very difficult to change molecular structure to decrease DNA binding 
capabilities in such a way that will not affect other key factors such as cellular uptake or 
endosomal escape.  Potential methods to overcome this issue include use of 
environmentally sensitive carriers, such as those that may release DNA in low pH 
environment (eg. in cancer cells or in late endosomes) or temperature sensitive 
environment that will only dissociate in response to an external heat stimulus [73]. 
Although it is difficult to account for this barrier in parallel with many others, it is 
important that vectors are designed with eventual release of its nucleic acid cargo in 
mind.   
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1.3.1C Modification of Exogenous DNA Sequence or Addition of Biologically Relevant 
Amino Acid Sequence -  
In addition to modifying delivery vectors, transgene expression can be improved 
by incorporating particular nucleic acid sequences on the delivered DNA that can 
promote trafficking towards the nucleus or nuclear translocation.  One strategy that has 
been employed by Dean et al is the utilization of transcription factor binding sites.  In 
these studies, it has been shown that plasmid DNA indirectly interacts with microtubules 
during gene transfer [74] and plasmids containing binding sites for the transcription 
factor cyclic AMP response-element binding protein (CREB, present on the CMV 
promoter), displayed increased trafficking velocity toward the nucleus and ultimately 
increased rate of nuclear entry following microinjection [75] (i.e. avoiding endocytic 
vesicles altogether).  This is a potentially promising strategy, essentially allowing DNA 
to piggyback a transcription factor to the nucleus. 
The most common strategy for overcoming the nuclear exclusion hurdle is 
conjugation to the DNA vector or cationic carrier of a nuclear localization signal (NLS), 
a short peptide sequence originally found in the SV40 large T antigen that interacts with 
karyopherins, promoting nuclear entry through the nuclear pore.  While this NLS-
conjugation strategy has shown potential when applied to linear DNA in HeLa and NIH 
3T3 cells[76], it lacks promise when delivering plasmid DNA [77, 78].  Additionally the 
SV40 enhancer DNA sequence, which binds many transcription factors containing NLS 
sequences [75], is a useful sequence for gene delivery; this sequence is provided on many 
commercially available DNA plasmids, facilitating increased nuclear uptake. Also 
important in efficacious transgene expression are promoter choice and codon 
optimization for the gene of interest.  In many cases, a constitutive promoter such as 
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CMV, ubiquitin, or EF1α is desired in order to drive expression to its highest possible 
level.  However, careful promoter selection can also be enforced for efficacious and 
targeted transgene expression.  For example, Hochberg et al created the BC-819 plasmid, 
now in clinical trials, which expresses the potent diphtheria toxin A (DTA) under the 
control of the H19 long non-coding RNA promoter which is only active in cancer cells 
[79], allowing for selective ablation of cancer cells.  Finally, codon-optimization is an 
important consideration when carrying out gene delivery when delivering a gene 
originating from one species to a cell of another.  Certain codons are highly present in 
one species and rare in another, and the efficiency of transcription if transferring a gene 
from the former species to a cell of the latter may be reduced, because the codon in the 
target cell matching the recombinant DNA codon may be lacking.  Species specific codon 
optimization can circumvent this issue, with one example being the successful production 
by Zolotuhkin et al in 1996 of humanized green fluorescent protein (GFP), a gene 
originally from jellyfish [80].   
1.3.2 Modification of Mammalian Cell Behavior by Intracellular Protein Activation, 
Inhibition, or Silencing  
Much investigation in the field of gene delivery has focused on enhancing 
efficacy by synthesis and optimization of nucleic acid delivery vehicles or nucleic acids, 
but fewer investigations have studied the effects of modulating cell behavior for 
enhancing transgene expression.  The current general approach is to tailor gene delivery 
vectors to fit the cell’s machinery, but a second approach is to tailor the cell’s machinery 
in such a manner that the cell becomes conducive to transfection through activation, 
inhibition, or silencing of proteins.   
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One example of this approach is through modulating cell cycle for optimal 
transgene expression. Polyplex transgene expression has been reported by Brunner et al 
to be optimal in the late G2 or S phase (just preceding mitosis), and relatively poor in the 
G1 phase (just following mitosis) [81].   Growth arrest and DNA-damage-inducible 
protein Gadd45 is expressed in response to DNA damage, leading to G2/M arrest.  Kim 
et al produced a Chinese hamster ovary (CHO) cell line that inducibly over-expressed 
Gadd45, leading simultaneously to G2/M cell cycle arrest and enhanced PEI-mediated 
transgene expression [82].  A study carried out in 2012 indicated that hyperacetylation of 
microtubules by inhibition of the cytoplasmic enzyme histone deacetylase 6 (HDAC6) 
leads to an increase in plasmid/microtubule interactions, increased rate of plasmid 
movement towards the nucleus, and increased transgene expression [83], the final 
phenomenon which has also been shown in our laboratory [84].  These are examples of 
modulating cell behavior to become more conducible to transfection, providing insight 
into mechanisms which can be exploited for successful gene delivery through enzyme 
inhibition.  
While there exists a general understanding of the obstacles to efficacious gene 
delivery (as summarized above and in Figure 1.1), the molecules and mechanisms behind 
these barriers are very poorly understood.  A more thorough understanding of the 
molecules responsible for these pathways that regulate gene delivery will lead to 
improvements in gene therapy and transient protein production.  In the following 
chapters, the focus will be identification of exploitable enzyme targets for enhancing 
transgene expression and mechanistic evaluation of these targets’ effects on transgene 
expression. 
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CHAPTER 2 - KINOME-LEVEL SCREENING IDENTIFIES INHIBITION OF 
POLO-LIKE KINASE-1 (PLK1) AS A TARGET FOR ENHANCING NON-VIRAL 
TRANSGENE EXPRESSION 
2.1 INTRODUCTION 
While the physical barriers discussed in chapter 1 formidably combat successful 
transfection, there also exist biochemical defenses that reduce promiscuity of cells to 
foreign DNA.  For example, Toll-Like Receptor 9 (TLR9) of immune cells provide defense 
against bacteria and viruses by binding unmethylated cytosine-guanine (CpG) base pairs 
on foreign DNA (host CpGs are methylated and do not activate TLR9) [85, 86]. Upon 
TLR9 binding, a signal is transduced by means of several kinases (IRAK-1, IRAK-4, 
TAK1, IKK, and MAPK) which subsequently activates a number of transcription factors 
(NF-κB, AP-1, and IRF7), leading to expression of interleukins and interferons, inducing 
an immune response [87]. Activation of TLR9 has been shown to reduce plasmid transgene 
expression [88], an effect that can be partially obviated by design of plasmids lacking CpGs 
[89]. 
The kinases involved in the TLR9 pathway are just one example of greater than 500 
kinases in the human kinome [90] that play key roles in intracellular processes, including 
endocytosis (PI3K [91], EGFR [92], AAK [93], mTOR [94]), cell cycle progression (CDK, 
PLK, Aurora)[95], and gene transcription (JAK/STAT [96] and JNK[97]) among many 
others. Due to the prominent role of kinases in mammalian processes, it is very likely that 
kinases are directly or indirectly involved in gene delivery, including the barriers discussed 
in chapter 1.  There have already been demonstrated cases of kinase inhibition directly 
affecting gene delivery.  For example, ur Rehman et al. showed that inhibition of Protein 
Kinase A (PKA) enhances gene delivery 2-3 fold by promoting lipoplex and polyplex 
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uptake through the generally more efficient caveolae-mediated endocytic route from the 
less efficient clathrin-mediated endocytic route [98]. Inhibition of Rho kinase by Y-27632 
also increases lentiviral transduction by 20% in keratinocytes[99]. In contrast, inhibition 
of PI3K has been shown to reduce adenoviral transduction, since PI3K plays a key role in 
 integrin-associated endocytosis of viruses [91]. Adaptor-associated protein kinase 1 
(AAK1) has been demonstrated to play a regulatory role in clathrin-mediated endocytosis.  
Through phosphorylation of the adaptor protein 2 (AP2) complex, which along with 
clathrin complexes forms the major protein coat around endocytic vesicles, AAK1 has an 
inhibitory effect on clathrin-mediated transferrin uptake [93]. Additionally, kinases 
involved in the mTOR pathway have been demonstrated to affect microtubule trafficking 
of caveolin-1 [94], a key component in the formation of cell membrane caveolae for 
caveolae-mediated endocytosis.   
Given these examples of kinases demonstrated to affect transgene expression or 
endocytic processes that are likely involved in gene delivery, there exists some evidence 
to indicate that inhibition or activation of other kinases has the potential to either increase 
or decrease the efficacy of transgene expression. The experiments carried out in chapter 2 
involve a kinome-level screen of small molecule inhibitors, with an output of normalized 
transgene expression observed with inhibition of many kinases. Many kinase targets were 
identified that enhance polymer-mediated transgene expression when inhibited; most 
prominently, the cell cycle regulatory protein polo-like kinase 1 (PLK1). 
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2.2 METHODS 
2.2.1 Cell Culture 
PC3-PSMA prostate cancer cells [100], derived from PC3 cells, were kindly 
provided by Michel Sadelain, MD, PhD, Memorial Sloan–Kettering Cancer Center (New 
York, NY).  MB49 cells were kindly provided by Dr. Christina Voelkel-Johnson (Medical 
University of South Carolina) as part of an existing collaboration. PC3-PSMA cells were 
cultured in RPMI 1640 Medium (Hyclone®), containing 10% fetal bovine serum 
(Hyclone®) and a Penicillin (100 units/mL) – Streptomycin (100 µg/mL) antibiotic 
combination (MP Biomedicals, LLC). MB49 cells were maintained in Dulbeccos Modifed 
Eagle’s Medium (Life Technologies) with the same serum and antibiotic content. Cells 
were grown in an incubator maintained at 37oC and 5% CO2. 
2.2.2. Polymers 
The 1,4C-1,4bis polymer was synthesized by mixing the monomers 1,4-
cyclohexane dimethanoldiglycidyl ether (1,4C, Sigma) and 1,4-bis(3-aminopropyl)-
piperazine (1,4Bis, Sigma) at a 1:1 molar ratio as described previously [30].  25 kDa 
branched polyethyleneimine (PEI) was purchased from Sigma.  Polymers were 
solubilized in 1X phosphate buffered saline (1X PBS, 10 mM PO4
-, 137 mM NaCl, 2.7 
mM KCl) following 16 hours of polymerization, and the pH was adjusted to 7.4. 
2.2.3 Parallel Screening of Small Molecule Kinase Inhibitors  
A library of kinase inhibitors pre-dissolved in DMSO at 10 mM was purchased 
from Selleck Chem (Cat# L1200, Houston, TX). A complete list of the kinase inhibitors 
and their known kinase targets can be found in Appendix I. PC3-PSMA cells were seeded 
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in 96 well plates (15,000 cells/well) and incubated overnight (~18 hrs) at 37oC in serum-
containing RPMI media (SCM). Polyplexes were prepared by mixing the polymer 1,4C-
1,4Bis [30] with pGL3.0 plasmid DNA (Promega; luciferase expression plasmid with an 
SV40 promoter) at a 10:1 mass ratio and incubating the solution at room temperature for 
20 minutes. SCM media was then removed from cells and replaced with SFM media. 
Polyplexes (60 ng plasmid DNA/well) and kinase inhibitors (final concentration of 10 x 
IC50 with 0.5% DMSO) were simultaneously added to each well using a Biomek NXP 
laboratory automated liquid handling station (Beckman-Coulter). Cells were incubated 
with polyplexes and inhibitors for 6 hours at 37oC. The media was then changed to SCM 
(with a unique kinase inhibitor in each well) and the cells were incubated at 37oC for an 
additional 48 hours to allow for transgene (luciferase) expression.   
2.2.4 Dose Response Optimization of Kinase Inhibitor Leads 
Small molecule PLK1 inhibitors (drugs) BI 2536, BI 6727, HMN-214, and 
ON01910 used for dose response optimization studies were all purchased from Selleck 
Chemicals, and stored at -80oC. Optimization experiments with inhibitor leads were carried 
out in a similar fashion to screening experiments, but in 24 well plates with 200 ng pGL3.0 
or pEGFP-C1 (Clontech; an EGFP expression plasmid with a CMV promoter) plasmid 
DNA/well, at various concentrations of each inhibitor with various polymers (10:1 w/w 
1,4C-1,4Bis or 1:1 w/w PEI) and cell lines (PC3-PSMA or MB49, both seeded at 50,000 
cells/well).   
2.2.5 Determination of Cell Viability Using MTT Assay  
Cell proliferation in case of different treatment conditions, relative to untreated 
control cells (treated as 100% viable, or a live control), was quantified using 3-(4,5-
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Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a yellow colored reagent 
which is converted to formazan (a purple dye) by living cells. For screening experiments, 
transfections were carried out in 96-well cell culture plates, seeding 15,000 cells.  
Following 48 hours of transfection, ten microliters of MTT reagent was added to the cells 
and incubated at 37oC for 2-4 hours, and the cells were then lysed by adding 20 microliters 
of MTT detergent and incubated for an additional 2 hours at room temperature. Inhibitor 
dose-optimization transfections were carried out in 24-well plates, seeding 50,000 cells.  
After 48 hours, 20 microliters MTT reagent was added, followed by 100 microliters of 
MTT detergent for lysis for 2 hours.   
In both cases, the concentration of formazan was then determined by measuring the 
absorbance of each well at 570 nm (A570).  Cell proliferation (PRO) was calculated by 
dividing the A570 of each sample by the A570 of the live cell control (no inhibitor or polyplex 
added), after subtracting blank absorbance. 
2.2.6 Quantification of Luciferase Expression  
Luciferase expression was quantified using the Luciferase Assay Kit from Promega 
(Madison, WI).  Media was removed from the plates and cells were washed once with PBS 
before adding cell culture lysis reagent (Promega) to each well and incubating the plates at 
37oC for 20 minutes.  Cell lysate (15 L) was then mixed with luciferin solution (30 L) 
and luminescence (LUM) was immediately measured using a Synergy 2 plate reader 
(Biotek, Winooski, VT). Luminescence units accounting for changes in proliferation 
(LUV) were calculated by dividing luminescence values (LUM) by relative cell 
proliferation (PRO).  The LUV values of each sample were then divided by the LUV value 
of the control sample (no drug) to provide the RLUV values shown in each figure.  
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Therefore, the RLUV values presented here account for changes in cell density (e.g. a 
condition with luminescence similar to the control but with 50% relative cell proliferation 
will be multiplied by a factor of two) and illustrate the degree of enhancement for each 
condition relative to the control. 
2.2.7 Quantification of EGFP Expression  
At 48 hours post-transfection, cells were washed with 1X PBS, trypsinized, and 
pelleted via centrifugation at 500 X g for 5 minutes.  Pellets were resuspended in 1X PBS, 
and flow cytometry analysis, carried out using a FACSCalibur (Benton Dickinson) 
machine, was used to quantify intracellular EGFP fluorescence, as detected by the FL1 
emission filter.  PMT voltage settings were adjusted based on live cell controls.  
Fluorescence gating was performed such that control samples (at each drug concentration, 
lacking polyplex treatment) showed 0.1% fluorescence-positive cells.  Side and forward 
scatter plots for the live cell control were also used for live/dead gating to ensure that only 
live cells were included in the final flow cytometry analyses.  Calculations for fluorescence 
intensity per cell involved subtraction of the drug only conditions (no transfection) 
arithmetic average cell fluorescence from the transfected counterpart to avoid including 
drug background fluorescence or autofluorescence in reported values.  In PC3-PSMA cells, 
all experiments involving the BI 2536 inhibitor were carried out three times. For all other 
conditions in PC3-PSMA and MB49 cells, at least two independent experiments (in some 
cases three) were carried out.  
2.2.8 Production and Evaluation of Lentiviral Particles for PLK1 Knockdown  
Plasmids expressing shRNA for knocking down PLK1 (total=20) were selected 
from the shRNA collection library (The RNA Consortium (TRC)) in Dr. Joshua LaBaer’s 
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laboratory at The Biodesign Institute, Arizona State University. From these 20 clones, 4 
(TRCN0000006246-6249) were selected based on target knockdown efficiency reported 
in previous publications [101-104]. cDNA was produced (Qiagen Maxiprep kit), and 
lentiviral particles were produced by transfecting LentiX-293T cells (Clontech) with either 
PLK1 or scramble control-shRNA and packaging plasmids using established SOPs [105]. 
After finalizing viral production, the resulting virus was used to infect PC3-PSMA cells.  
To evaluate the silencing of PLK1 using the lentiviral particles, immunoblotting 
experiments were carried out on PC3-PSMA cell lysates after cells were infected with 
either a scramble control or each lentiviral clone for PLK1 knockdown (total=4). The 
GAPDH (loading control) and PLK1 antibodies were purchased from Cell Signaling and 
used at a working dilution of 1:1000.  Following transfer, membranes were blocked with 
5% milk in TBS-Tween (TBS-T, 0.2% tween), and incubated in primary antibody 
overnight at 4oC. Membranes were then washed with TBS-T, and incubated with an HRP-
conjugated secondary antibody (1:1000 dilution) for one hour at room temperature. 
Following additional washes, membranes were treated with SuperSignal West Femto 
Chemiluminescent substrate (Thermo) for antibody detection.  Based on literature and our 
own results, it was determined that the virus correspondent to clone PLK1-shRNA 6247 
would be used for further experiments. This virus successfully knocked down PLK1 in 
PC3-PSMA cells and affected cell growth.  
2.2.9 Combined PLK1 Silencing and Transgene (pGL3 Plasmid) Delivery to PC3-PSMA 
Cells  
PC3-PSMA cells were infected with either PLK1 or a scramble control lentivirus. 
In brief, 12,500 cells were plated in a 24 well plate, and on the following day, polybrene 
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(8 μg/mL) was added, followed by lentivirus (200 l) or no further treatment (i.e. 
equivalent volume media).  Plates were centrifuged for 30 minutes at 2250 rpm and 
incubated at 37oC and 5% CO2. Following 48 hours, transfection experiments and 
luminescence-quantifying assays were carried out as previously described.  Experiments 
were carried out using 1,4C-1,4bis and PEI as polymer carriers at polymer to DNA weight 
ratios of 10:1 and 1:1, respectively. 
2.2.10 Cell Cycle Analysis 
Propidium Iodide (PI) staining was carried out in order to determine relative cell 
cycle proportions of the PC3-PSMA cell population in the presence and absence of PLK1 
inhibitors, BI 2536 and HMN 214. Briefly, 250,000 PC3-PSMA cells were plated per well 
in a 6 well plate and allowed to attach and grow overnight. Cell culture media was removed 
and replenished with fresh SCM containing drug or vehicle control. After 48 hours, cells 
were washed with 1X PBS harvested via trypsinization, and resuspended in a small amount 
of 1X PBS. Pure ice-cold ethanol was added dropwise to the PBS cell suspension, resulting 
in a final EtOH concentration of 70%, at which point, cells were stored at 4oC for 1 hour 
to allow for fixation. Cells were then washed with 1X PBS/2% FBS/0.001% Triton X, 
followed by a wash with 1X PBS/2% FBS.  Cells were then incubated with a PI (Sigma) 
staining solution prepared in 1X PBS (5% FBS, 50 µg/mL PI, 100 µg/mL RNase A). Cells 
were then analyzed in a FACS Attune® acoustic focusing flow cytometer, with PI signal 
detection through the B3 emission filter. Live/Dead gating was carried out using a 
side/forward scatter dot plot, and only live cells were included in final analysis. Cell 
doublets were gated out of analysis, as determined by high fluorescent width (B3-W) 
values, indicative of long detector residence time. Cell cycle percentages given are 
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representative of percentage of cells falling in the subG1 (<2N DNA content; typically 
apoptotic fraction), G0/G1 (2N DNA content), S (between 2N and 4N DNA content), 
G2/M cycles (4N DNA content). A small portion of the cell population shows fluorescence 
greater than that represented by 4N DNA content. Some of these cells may actually have 
greater than 4N DNA content, while a proportion is likely cell doublets that are not 
eliminated by gating.     
2.2.11 Intracellular Trafficking of Polymer-Plasmid DNA Polyplexes  
The Label IT® fluorescein-conjugated plasmid from Mirus was used to monitor 
plasmid DNA intracellular trafficking. PC3-PSMA prostate cancer cells were plated in 24 
well plates at a density of 50,000 cells per well on top of coverslips, and allowed to attach 
overnight. On the following day, cells were incubated with 10 μg/mL DAPI and allowed 
to stain overnight at 37oC.  The following day, several washes with 1X PBS were carried 
out in order to remove residual DAPI, thus avoiding false nuclear detection by staining the 
plasmid DNA. Serum-free media containing the drug or 0.2% DMSO control was added 
to the cells while polyplexes were formed by mixing PEI with 2 μg of fluorescein-labeled 
plasmid DNA at a 1:4 polymer to DNA mass ratio. Polyplexes were added to the cells and 
allowed to be internalized for 6 hours after which, cells were replenished with serum-
containing media containing drug or DMSO. Following 48 hours of transfection, cells were 
washed twice with 1X PBS, and fixed with 2% formaldehyde for 20 minutes. Cells were 
then washed 5 times with 1X PBS, and mounted using a 90% glycerol solution containing 
n-propyl gallate. Confocal microscopy was carried out with a Nikon C2 Confocal equipped 
with a 60X water immersion objective, which was utilized to determine polyplex 
trafficking relative to the nucleus. Laser excitation of 488 nm was used and emission at 
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525 nm was captured for fluorescein detection. Z-stack images were taken with a step size 
of 0.330 μm, with the images displayed representing a maximum projection signal through 
the z-axis, unless otherwise noted. 
 
2.3 RESULTS 
2.3.1 Kinase Inhibitor Screen 
A library of 182 kinase inhibitors was screened in order to identify leads that 
enhance polymer-mediated transgene (luciferase) expression in PC3-PSMA prostate 
cancer cells (complete list of kinase inhibitors tested in Appendix I [106]). Fifteen 
different inhibitors enhanced luciferase expression by a factor of 4-fold or greater relative 
to the vehicle control (1,4C-1,4Bis polymer [30] complexed with pGL3.0 plasmid DNA in 
0.5% DMSO); a concentration of 10 times the reported IC50 value for each inhibitor was 
employed in the screen (Table 2.1 for 15 inhibitor leads, Appendix I [106] for a complete 
list of screening results).  Luminescence values were normalized to total protein (eg. 
luminescence/mg protein) to account for any differences in cell plating, and further 
normalized to viability, yielding relative luminescence units normalized to viability 
(RLUV in Table 2.1). Interestingly, some inhibitors, including two PI3K inhibitors (TGX-
221 and AS252424), two CDK inhibitors (AZD5438 and Flavopiridol HCl), and a single 
JAK inhibitor (LY2784544), decreased luciferase expression to less than 50% of the 
control in cells.  
Since many kinase targets were represented by multiple small molecule inhibitors, 
the data were organized by target with an average RLUV represented for each target 
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(Figure 2.1 [106]).   The clear top screen identified target for enhancing transgene 
expression is polo-like kinase 1 (PLK1), a cell cycle regulatory kinase, with expression 
strongly enhanced at 9.5 ± 3.7 fold relative to the vehicle control, with the top four 
individual inhibitors all targeting PLK1 (Table 2.1).  These four PLK1 inhibitors constitute 
four of five total PLK1 inhibitors tested, with the fifth one also performing well (ON-
01910, 3.2 ± 1.5 RLUV). 
Table 2.1 – Enhancement of luciferase transgene expression (RLUV) by the 15 most 
effective small-molecule kinase inhibitors identified from the screen 
Inhibitor Kinase Target(s) RLUV 
BI 6727 PLK1 12.4 ± 13.8 
BI 2536 PLK1 12.3 ± 5.3 
GSK 461364 PLK1 9.9 ± 4.8 
HMN-214 PLK1 9.5 ± 8.3 
SKI-606 Src/Abl 6.6 ± 11.0 
AG-490 EGFR/JAK/ErbB2 6.4 ± 10.7 
PD0332991 CDK 4,6/Cyclin D1,2 6.1 ± 5.6 
SNS-314 Auroras A, B, C 6.0 ± 6.1 
Imatinib Abl/c-Kit/PDFGR 5.3 ± 4.7 
Vinorelbine p38 MAPK 4.9 ± 2.5 
VX-702 p38 MAPK 4.8 ± 4.1 
PHA-680632 Auroras A, B, C 4.4 ± 5.5 
KW 2449 FLT-3/Abl/Aurora A 4.4 ± 4.1 
NVP-ADW742 IGF-1R 4.4 ± 5.9 
SNS-032 CDK 2, 7, 9 4.1 ± 2.4 
 
In addition to PLK1 inhibitors, several other inhibitors for kinases involved in the 
cell cycle (CDK, Cyclin, p38 MAPK, and Aurora) also showed 2-fold enhancement or 
higher. These include PD0332991 (CDK/Cyclin inhibitor, RLUV = 6.1 ± 5.6), SNS-314 
(Aurora inhibitor, RLUV = 6.0 ± 6.1). Additionally, an inhibitor of p38 MAPK, involved 
in stress response, enhanced transgene expression drastically (Vinorelbine, RLUV = 4.9 ± 
2.5).  Inhibition of the cell cycle kinases reduced cell proliferation by at least 20% (Aurora 
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kinase) relative to the control, while some PLK1 inhibitors decreased proliferation by up 
to 36% (data not shown).   
 
In addition to cell cycle kinases, 4 out of the 9 JAK inhibitors tested showed greater 
than 2.4-fold enhancement (AZ960, AZD1480, AT9283, and AG-490), with the JAK2 
inhibitor AG-490 (IC50 = 10 μM) showing the highest enhancement of 6.4-fold relative to 
the polyplex control.  Interestingly, AG-490 also inhibits the membrane-bound growth 
factor receptors EGFR (IC50 = 0.1 μM) and HER2 (IC50 = 13.5 μM)[107]. Several other 
growth factor receptor inhibitors also showed significant enhancement of luciferase 
expression compared to the polyplex control, including two additional EGFR inhibitors, 
CI-1033 and Neratinib, which showed 2.7 and 3.8-fold enhancement, respectively. Several 
different PDGFR inhibitors also enhanced luciferase expression (AP24534, Crenolanib, 
TSU-68, Masitinib showed 2.1-2.3 fold enhancement), while Imatinib (aka Gleevec) 
Figure 2.1 Identification of kinase targets that influence transgene expression. The enhancement values 
of individual inhibitors with the same kinase target were pooled together to prepare this figure.  The y-
axis shows enhancement relative to the polyplex control (RLUV = 1), while the x-axis indicates the kinase 
enzyme targeted by the inhibitor(s)  
 
30 
 
demonstrated the strongest enhancement (5.3-fold). It is important to note that multiple 
PDGFR inhibitors also inhibit FGFR (AP24534, TSU-68, and Masitinib) and VEGFR 
(AP24534 and TSU-68). Three VEGFR-specific inhibitors also showed 2.3-2.6 fold 
enhancement (Axitinib, MGCD-265, and Vatalanib). Finally, the IGF-1R inhibitor NVP-
ADW742 and the TGF-β inhibitor SB525334 exhibited 4.4- and 2.3-fold enhancement of 
luciferase expression, respectively. While these results suggest that growth factor receptor 
inhibition enhances transgene expression, several other growth factor receptor inhibitors 
showed no significant enhancement of luciferase expression (RLUV < 1.0). 
While this screen revealed a number of kinase targets for enhancing polymer-
mediated transgene expression, it is important to point out that the kinases covered 
constitute less than 10% of the 518 known human kinases.  Thus, this screen is not 
exhaustive, and there are likely many other kinase targets that we have not identified. 
Nonetheless, the screen revealed several kinase targets for enhancing transgene expression, 
mainly in the classes of cell cycle, signal transduction, and growth factor receptor kinases.  
The most promising target, PLK1, was selected for further investigation. 
2.3.2 Dose-Optimization of Lead Inhibitors – PLK1 and JAK2 (Luciferase Expression)  
Two of the most effective PLK1 inhibitors were evaluated at various concentrations 
in order to further investigate the effects of PLK1 inhibition on transgene (luciferase) 
expression in the original screening cell line (PC3-PSMA) as well as a murine bladder 
cancer cell line (MB49). HMN-214 consistently showed high enhancement of luciferase 
expression relative to vehicle control with the 1,4C-1,4Bis polymer (11-fold) and PEI (37-
fold) at an optimum concentration of 3.3 μM in PC3-PSMA cells (Figure 2.2).  HMN-214 
also demonstrated greater enhancement with PEI than 1,4C-1,4Bis in MB49 cells, but to a 
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lesser extent (6 and 12-fold enhancement with 1,4C-1,4Bis and PEI, respectively) at an 
optimal concentration of 1 μM. As expected for PLK1 inhibition, HMN-214 also 
significantly reduced cell proliferation, with the lowest viabilities (40-50%) at 
concentrations above 3.3 μM.  Interestingly, a sharp drop in proliferation was observed in 
MB49 cells at the same HMN-214 concentration which maximally enhances transgene 
expression (1 μM).  This anti-proliferative activity of the drug can be useful in cancer gene 
therapy applications. 
Figure 2.2 Dose-dependent enhancement of luciferase transgene expression by the PLK1 inhibitor 
HMN-214 in PC3-PSMA human prostate cancer and MB49 murine bladder cancer cells following 
delivery of pGL3.0 plasmid DNA using PEI and 1,4C-1,4Bis polymers. Relative enhancement of 
luciferase expression (RLUV) compared to the polyplex control is shown in the left panels, while effects 
of the drug on cell proliferation are shown in the panels on the right side. Asterisks (*) indicate 
statistically significant difference (student’s T-test) from the corresponding polyplex control (n = 3 
independent experiments; p < 0.05) 
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The dose optimization of another effective PLK1 inhibitor, BI 2536, is shown in 
Figure 2.3.  BI 2536 increased luciferase expression 3-6 fold at concentrations of 10 and 
100 nM in PC3-PSMA and MB49 cell lines, respectively. While the optimal concentration 
for enhancing luciferase expression differs by a factor of 10 between the two assayed cell 
lines, it is interesting to note that the optimal concentration in both cell lines coincides with 
the point at which cell proliferation is reduced by 40% (Figure 2.3 [106]), suggesting that 
inhibition of cell division by the drug is necessary for the enhancement of gene delivery. 
Concentrations of BI 2536 above 1 μM (1000 nM) drastically reduced MB49 cell viability 
to approximately 20%.  Additionally, a lead inhibitor targeting another cell-cycle 
regulatory kinase, Aurora kinase, was dose-optimized for transgene expression (Appendix 
I, Figure A1).   
Another interesting target identified in the kinase inhibitor screen is the Janus-
Kinase Signal Transducer and Activator of Transcription (JAK-STAT pathway).  Although 
Figure 2.3 Dose-dependent enhancement of luciferase transgene expression by the PLK1 inhibitor 
BI 2536 in PC3-PSMA human prostate cancer and MB49 murine bladder cancer cells following 
delivery of pGL3.0 plasmid DNA using PEI and 1,4C-1,4Bis polymers. Relative enhancement of 
luciferase expression (RLUV) compared to the polyplex control is shown in the left panels, while 
effects of the drug on cell proliferation are shown in the panels on the right side.  Asterisks (*) 
indicate p-values <0.05, which show statistically significant enhancement relative to vehicle 
control (Student’s t-test) 
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only one inhibitor from this group, AG-490, appeared in the top 15 (Table 2.1), five of the 
nine tested inhibitors showed greater than 2-fold enhancement in transgene expression 
(Table 2.2). However, four of these five inhibitors possess known inhibitory activity 
against non-JAK targets, while TG101209, the mild enhancer of transgene expression of 
this group, is a JAK2-specific inhibitor. Each of these four non-specific JAK inhibitors in 
Table 2.2 also inhibit a growth factor receptor or the cell cycle regulating Aurora kinase, 
both sets of kinases which were also identified as leads for enhancing transgene expression.  
Due to the difficulty of attributing the effects of these inhibitors with one target, each 
possessing multiple kinase inhibition activities, a dose-response set of transfections was 
carried out with the JAK2-specific inhibitor TG101209 (Figure 2.4).  It is important to 
note that the plasmid used for this experiment is the pGL4.50 plasmid (Promega), which is 
driven by the CMV promoter as opposed to the SV40 promoter present on the pGL3 
plasmid used for the initial screening.  Using 1,4C-1,4Bis as the plasmid carrier, RLUV 
values reached 6-fold enhancement relative to treatment with the polyplex vehicle control, 
while moderate enhancement was observed with PEI as the delivery vector.  This 
observation further evidences JAK-STAT as a target for enhancing transgene expression.   
The JAK-STAT pathway is a signal transduction pathway, which translates signals 
from the extracellular environment through cytokine binding to receptors, into a 
Table 2.2 – Lead JAK inhibitors identified in screening and their targets 
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transcriptional response at the nuclear level. It is not currently clear how inhibiting this 
pathway enhances transgene expression. 
 
2.3.3 Dose-Optimization of Lead PLK1 Inhibitors – GFP Expression  
The previous luciferase-plasmid observations were expanded by testing the effects 
of the PLK1 inhibitors on expression of a GFP-expressing plasmid driven by a different 
promoter (CMV as opposed to SV40).  Table 2.3 [106] shows the fold increase (FI) of 
EGFP expression per cell (Fluor/cell) and of percentage of cells expressing EGFP 
(EGFP+%), quantified by flow cytometry, for the optimum concentration of each drug. 
Both BI 2536 and HMN-214 showed consistently strong enhancement of transgene 
expression. BI 2536 strongly enhanced the fluorescence per cell with the 1,4C-1,4Bis 
polymer (15.8±4.2), but showed a more modest effect with PEI (3.6±1.6). The same 
phenomenon was also observed with BI 2536 in MB49 cells, where enhancement was 
strong with 1,4C-1,4Bis (9.7±3.2), but not with PEI (0.4±1.7). In contrast, HMN-214 
showed the opposite effect in PC3-PSMA cells, with higher enhancement of transgene 
Figure 2.4 Dose-dependent enhancement of luciferase transgene expression by the JAK2-specific 
inhibitor TG101209 in PC3-PSMA human prostate cancer cells following delivery of pGL4.5 plasmid 
DNA using PEI and 1,4C-1,4Bis polymers. Relative enhancement of luciferase expression (RLUV) 
compared to the polyplex control is shown in the left panel, while effects of the drug on cell 
proliferation are shown in the panel on the right side.  Asterisks (*) indicate p-values < 0.05, which 
show statistically significant enhancement relative to vehicle control (Student’s t-test) 
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expression with PEI than 1,4C-1,4Bis polymers. It is possible that these drugs differentially 
affect the ability of different polymer carriers to enter cells, perhaps as a function of N to 
P (nitrogen to phosphate) ratio. It is worth noting that BI 6727 also showed significant 
enhancement of EGFP and luciferase expression, but this effect was inconsistent (hence 
the large standard deviation). The effects of ON01910 were also somewhat inconsistent 
(32.3±17.0) and sharply decreased cell viability. Taken together, it can be seen that 
inhibition of PLK1 using different small molecules increases GFP expression across the 
cell population, and also increases fluorescence / cell in cells that express the protein. 
Representative fluorescence microscopy images for PC3-PSMA cells treated with 
each of the four PLK1 inhibitors and 1,4C:1,4Bis-pEGFP polyplexes are shown in Figure 
2.5 [106]. Both BI 2536 and HMN-214 exhibit moderate enhancement of EGFP expression 
in these cells. Interestingly, the baseline EGFP expression using 1:1 PEI was low enough 
that enhancement in transfection was undetectable using the flow cytometry assay, but 
results are shown in Table 2.3.  Visually, cell fluorescence was almost non-existent with 
Table 2.3 - Fold increase (FI) of polymer-mediated EGFP Expression by 
PLK1 inhibitors identified as leads from the screen 
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or without drug when PEI was used as the vehicle for pEGFP delivery. It is important to 
note that optimal weight ratios of 1:1 PEI to plasmid DNA and 10:1 1,4C-1,4bis to plasmid 
were employed in these studies. 
  
 
Taken together, the above results with two different reporter genes (firefly 
luciferase and EGFP), two different cationic polymers, and treatment with several PLK1 
inhibitors, PLK1 as a target for enhancement of polymer-mediated transgene expression is 
likely a generalizable phenomenon.  
2.3.4 Effects of PLK1 Silencing on Transgene Expression 
 Previous results clearly showed that multiple small-molecule inhibitors of PLK1 
enhanced the delivery of multiple transgenes with two cationic polymers in different cell 
Figure 2.5 Representative fluorescence microscopy images of PC3-PSMA 
cells transfected with polyplexes formed with a 10:1 mass ratio of 1,4C-1,4Bis : 
pEGFP DNA, in the presence of no drug (DMSO) or with PLK1 inhibitors, BI 
2536, BI 6727, HMN-214, ON01910.  Images were obtained using a Zeiss 
inverted fluorescence microscope 48 hours post-transfection. 
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lines. We therefore investigated if PLK1 silencing / knockdown using a lentiviral vector 
could enhance transgene expression in cells. Viruses with four different shRNA 
constructs were designed and investigated for PLK1 knockdown in PC3-PSMA cells. The 
efficacy of each construct was tested by immunoblotting cell lysates in order to determine 
PLK1 expression levels (not shown). Based on PLK1 knockdown efficacy, as determined 
by Western blot against two scramble control viruses (Figure 2.6 left [106]), PLK1 
silencing using the virus expressing PLK1 shRNA 6247 (denoted “PLK1 KO”) clearly 
reduced PLK1 expression, as reported previously [101]. We therefore chose this virus for 
knocking down PLK1 in our subsequent experiments.  
PLK1 knockdown led to a modest increase in 1,4C-1,4Bis mediated transgene 
expression, (Figure 2.6 right [106]) although interestingly this phenomenon was not 
observed when using PEI as the delivery vector (data not shown).  Surprisingly, the 
Figure 2.6 Left – PC3-PSMA cells were infected with a lentivirus expressing scrambled sequence shRNA 
or lentivirus expressing shRNA construct 6247 against the mRNA of PLK1 (denoted PLK1 KO). Cell 
lysates, prepared 72 hours after infection, were immunoblotted using a PLK1 antibody probe. Right – 
Polymer-mediated transfections with polyplexes formed at a 10:1 1,4C-1,4bis : pGL3 plasmid weight ratio, 
in PC3-PSMA cells, beginning 48 hours after infection with the lentivirus, and proceeding for 48 
additional hours to allow for determination of luciferase expression. Transgene expression is reported in 
relative luminescence units normalized to protein content, and normalized to cell viability (RLUV / mg). 
* p-value =0.02, Student’s T-test, compared to scrambled control 
 
38 
 
scramble control virus increased transgene expression relative to treatment without any 
virus when using 1,4C-1,4bis as the polymer carrier (data not shown). Given that viruses 
have evolved to be extremely efficient gene delivery vehicles, in part due to their enhanced 
ability to enter target cell nuclei, it is possible that both scramble control and anti-PLK1 
shRNA expressing viruses were able to assist the plasmid in overcoming particular gene 
delivery barriers faced by polymer-mediated plasmid DNA delivery. This could be due to 
direct virus-plasmid or virus-polymer binding [108, 109], or indirectly by viral-induced 
interruption of the target cell’s natural defense(s) against foreign DNA. It is possible that 
the virus itself was able to assist the plasmid in circumventing particular gene delivery 
barriers overcome by PLK1 silencing, thus dampening the increase in observed transgene 
expression enhancement using our method of PLK1 silencing. Interestingly, PEI-mediated 
gene delivery did not significantly increase in the presence of either virus (data not shown) 
suggesting that PEI and the lentiviral vectors used may assist foreign DNA in overcoming 
similar gene delivery barriers.  However, silencing of PLK1 resulted in enhancement of 
transgene expression with 1,4C-1,4Bis, further providing evidence of PLK1 as a transgene 
expression enhancement target. 
2.3.5 Effect of PLK1 Inhibitors on Cell Cycle Distribution  
PLK1 plays a significant role in cell cycle regulation, mainly in promoting cell 
entry into mitosis. PLK1 localizes the two protein components of the mitosis promoting 
factor (cyclin B1 and CDC2) to the nucleus and phosphorylates the former [110], in 
addition to phosphorylating CDC25 [111], a phosphatase which also promotes the activity 
of the mitosis promoting factor   Given the established role of PLK1 in cell cycle regulation, 
the effects of HMN-214 and BI 2536 on PC3-PSMA cell cycle progression were 
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investigated. Nuclear DNA was stained with propidium iodide (PI) in order to determine 
the amount of DNA using flow cytometry, which allowed for elucidation of the fractions 
of the cell population in different stages of the cell cycle phase. In all cases, drugs or 
equivalent volume DMSO (vehicle control) were added to cells, in the absence of 
polyplexes. Figure 2.7 and Table 2.4 [106] indicate that vehicle control (i.e. DMSO)-
treated cells were mostly in the G0/G1 phase (63.1 ± 7.6%), with a small fraction of the 
cells in the S (9.6 ± 2.3%) phase, and approximately a quarter of the cell population (26.6 
±7.0%) in the G2 or M phases of the cell cycle. However, inhibition of PLK1 with 3.3 μM 
HMN-214 almost completely arrested cells in the G2/M phase (93.6 ± 1.6%), while PLK1 
Figure 2.7 Cell cycle analysis of PC3-PSMA cells treated with vehicle control (DMSO), 25 nM BI 
2536, or 3.3 μM HMN-214 using flow cytometry and staining with propidium iodide (PI). Results 
from one representative experiment out of N = 3 independent experiments are shown.  The y-axis 
(counts) indicates the number of cells with the specific fluorescence intensity shown on the x-axis 
(BL3-A) 
Table 2.4 - Quantification of PC3-PSMA cell cycle phase in absence and 
presence of small molecule PLK1 inhibitors based on (N=3)  
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inhibition with 25 nM BI 2536 also resulted in strong accumulation of the cell population 
(87.1 ± 5.0%) in the G2/M phase of the cell cycle. These results are consistent with the 
known PLK1 inhibition activity of the drugs in other cell lines [112, 113].   
2.3.6 Effect of PLK1 Inhibitors on Intracellular Trafficking of Plasmid DNA 
Intracellular transport/trafficking of plasmid DNA has been demonstrated to 
significantly influence transgene expression in cells [49, 83, 84, 114-118]. In order to 
determine if trafficking of plasmid is altered in our system with PLK1 inhibition, a 
fluorescently-tagged plasmid was complexed with PEI, delivered to PC3-PSMA cells and 
imaged via confocal microscopy 48 hours later.   The distribution of delivered plasmid for 
each inhibitor treatment case is shown in Figure 2.8 [106]. In the absence of BI 2536 
(Figure 2.8A), plasmid DNA is localized at the Perinuclear Recycling Compartment 
(PNRC, white arrows) which is consistent with previous observations of polyplex and 
nanoparticle transport in these cells [84, 119]. In contrast, treatment with BI 2536 (Figure 
2.8B) disrupts PNRC localization and disperses plasmid DNA throughout the cytoplasm 
(red arrows).  Images of BI 2536 treated cells (Figure 2.8B) and cells simultaneously 
treated with DMSO vehicle control (Figure 2.8A) were acquired 48 hours following 
transfection, corresponding temporally to the transgene expression data above. Treatment 
of cells with HMN-214 (3.3 M), however, resulted in significant detachment and 
difficulty in imaging beyond 24 hours; thus cells treated with HMN-214 (Figure 2.8D) and 
vehicle control (Figure 2.8C) were imaged 24 hours following transfection. Even though 
images displayed for HMN-214 treated cells represent a time 24 hours prior to optimal 
transgene expression, it is still clear that HMN-214 treatment alters intracellular trafficking 
of the delivered plasmid (Figure 2.8D), resulting in a similar release from the PNRC as 
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observed with BI 2536 treatment (red arrows). Both drugs appear to disrupt sequestration 
of the plasmid at the PNRC, and favor the distribution of the plasmid throughout the 
cytoplasm. 
 
Figure 2.8 Intracellular trafficking of plasmid DNA in presence and absence of PLK1 inhibitors. PC3-
PSMA cells were transfected with polyplexes of PEI:fluorescein (green)-labeled plasmid DNA at a 
weight ratio of 1:4. Cells treated with A) vehicle control (DMSO) and B) 25 nM BI 2536 are shown 48 
hours after co-treatment with polyplexes.  Cells treated with C) vehicle control (DMSO) and D) HMN-
214 are shown 24 hours after co-treatment with polyplexes.  Scale bar = 20 μm. Blue signal indicates 
DAPI-stained nuclei, and white arrows indicate sequestration of plasmid DNA in the perinuclear 
recycling compartment (PNRC). Red arrows indicate altered plasmid DNA localization following 
treatment with PLK1 inhibitors. Images are representative of three independent experiments (N=3) 
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2.4 DISCUSSION AND CONCLUSIONS 
These experiments discussed above have led to the identification of several kinase 
targets for enhancing polymer-mediated transgene expression, but most prominently, 
PLK1.   The results clearly show that the kinase inhibitors HMN-214 and BI 2536 
significantly enhance transgene expression using different carriers, plasmids, and target 
cell lines.  When coupling these findings with the application of PLK1 silencing, PLK1 has 
been strongly established as a target for transgene expression enhancement. Excitingly, our 
and expression in cancer cell lines. These results are significant since Polo-like kinases are 
an emerging target for anti-cancer therapies, and the PLK1 inhibitor BI 2536 is currently 
in clinical trials for cancer treatments [120, 121], presenting an exciting future opportunity 
to interface this newly found gene therapeutic ability and existing chemotherapeutic 
strategy of PLK1 inhibition for synergistic treatments.  
The exact mechanism by which PLK1 enhances transgene expression is not clear, 
but it is very likely related to the accumulation of cells in the G2/M phase of the cell cycle.  
It is generally accepted that dividing cells, especially cells that are at or near the G2/M 
transition, are more amenable to transgene expression [81, 122], and many targets 
identified in the kinase screen for enhancing transgene expression (including many of those 
targeted by the top 15 inhibitors in Table 2.1) are regarded as cell cycle kinases. The most 
common explanation for enhancement of transgene expression just prior to mitosis (i.e. 
G2/M transition) is the increased permeability of the nuclear membrane prior to nuclear 
envelope breakdown.  However, preliminary qPCR experiments were carried out to detect 
plasmid levels in extracted nuclei, and no increase was detected with PLK1 inhibition in 
our system (data not shown).  Another model that has been proposed is increased protein 
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production associated with the increase in cell diameter which commonly occurs with 
G2/M arrest [82].  Additionally, inhibition of the cell cycle related kinases polo-like kinase 
3 and MEK1 have been identified through a silencing-screening approach to affect 
endocytosis, particularly re-directing transferrin-containing endosomes to the plasma 
membrane [123], illuminating the possibility that cell cycle kinases can affect trafficking 
of endosomally trafficked transgene cargo.  
 The experiments carried out in chapter 2 were motivated by a curiosity to 
understand what kinase targets regulate transgene expression and how they do so.  While 
a complete mechanistic explanation of how PLK1 inhibition enhances transgene 
expression was not obtained, clearly cytoplasmic trafficking of transgene cargo was 
altered, which could very well play a role in the observed enhancement.  Gene delivery 
obstacles such as cellular uptake, endosomal escape, cytoplasmic trafficking, and nuclear 
entry are commonly acknowledged and studied.  However, factors that may regulate 
transgene expression after the transgene has entered the nucleus are rarely addressed.  In 
the next chapter, inhibition a nuclear histone deacetylase and resulting enhancement in 
plasmid transgene expression will be discussed. 
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CHAPTER 3 - INHIBITION OF NUCLEAR HISTONE DEACETYLASE FOR 
ENHANCEMENT OF TRANSGENE EXPRESSION IN CANCER CELLS 
3.1 INTRODUCTION 
The chromosomal DNA inside of a single human cell would extend to nearly two 
meters in length if stretched out [124], a certainly infeasible method for storing DNA inside 
of a cell nucleus.  However, this immense amount of DNA is wrapped up in a mixture of 
RNA and proteins called histones in a surprisingly organized and regulated structure 
referred to as chromatin.  The sub-structure of chromatin is organized into octameric 
histone/DNA structures, nucleosomes (Figure 3.1A), consisting of duplicates of four core 
histone molecules; H2A, H2B, H3, and H4, as well as a linker histone H1 which binds 
DNA on both ends of the nucleosome [125], and assists in condensing chromatin into 
chromosomes during mitosis [126].   
Histones which act as a condensing factor for chromosomal DNA can actually 
decrease gene expression through tight binding, preventing DNA accessibility to 
transcriptional machinery.  The extent to which DNA and histones interact and, by 
extension, local gene expression, is regulated by a number of posttranslational 
modifications to histones, including phosphorylation, methylation, acetylation (Figure 
3.1), among others. These modifications are carried out by a number of enzymes [127] 
[128] [129] [130], which will be discussed in more detail in Chapter 4. These modifications 
can be classified as “epigenetic”, meaning they induce changes in gene expression without 
changing the sequence of the gene itself. 
Two examples of epigenetic modifying enzymes are histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) (Figure 3.1B), which have opposing effects on 
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chromatin structure and local gene expression.  HATs use acetyl CoA to acetylate and 
neutralize the charge of ε-amino groups on lysine residues, thereby releasing DNA for 
transcription. In contrast, histone acetylation may be reversed by HDACs, which remove 
acetyl groups to restore the positive charge and DNA binding activity of histones [131, 
132].  HATs and HDACs are generally non-specific [133], but HDACs have been shown 
to form complexes with other proteins that target deacetylase activity to specific DNA 
sequences, for example a DNA sequence that binds the zinc finger motif of a complex 
containing HDAC2  [134, 135].  
 
The name “HDAC” can be slightly misleading, as these enzymes also have the 
ability to remove acetyl groups from non-histone proteins, such as NF-κB and other 
Figure 3.1 A) Chromosomal DNA is organized in the nuclei of mammalian cells by 
winding around core histone proteins.  Structures containing two copies each of four core 
histones (octamer) combined with interacting DNA is referred to as a nucleosome.  
Histones contain amino acid groups which can be (de)phosphorylated, (de)acetylated, and 
(de)methylated (among other modifications), which result in reorganiziation of 
chromosomal structure and consequently, local gene expression.  B) Experiments in 
chapter 3 focus on inhibiting histone deacetylase (HDAC) 1 and 3.  While inhibition of 
HDAC enzymes is known to enhance local gene expression through minimizing local 
histone-chromsomal DNA interactions, this will be applied to enhance transgene (plasmid) 
expression. Histone acteyltransferaes (HATs) carry out the opposite process of HDACs, 
adding acetyl groups to histone lysines and increasing local gene expression (image 
modified from dev.biologists.org) 
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transcription factors [136, 137]. Consequently, aberrations in HAT/HDAC activity have 
been implicated in several neurodegenerative diseases [138] and cancer [139].  
Interestingly, in addition to chromosomal DNA, histone acetylation can affect 
expression of exogenous or invading DNA.  For example, Bishop et al demonstrated that 
viral DNA, which efficiently enters the nucleus is bound and silenced by histones, with 
expression eventually restored by inhibition of HDAC using trichostatin A [140, 141].  
Also, bacterial plasmid DNA has been shown to bind histones and form nucleosomes in 
cell free assays [142], with evidence also pointing to nucleosome formation of local 
histones with exogenous plasmid DNA in vitro [143].  Applications of histone-DNA 
binding have actually been directly applied to gene delivery, using cationic histone tail 
sequences to carry out non-viral gene delivery [144, 145], a process referred to as 
“histonefection”. Given the existing evidence exogenous DNA/local histone binding, it 
was hypothesized that HDAC inhibition could potentially enhance non-viral polymer-
mediated transgene expression, the focus of the remainder of chapter 3.  
Previously work by Rege et al indicated that inhibition of the cytoplasmic HDAC6 
with tubacin increases polymer-mediated transgene expression likely by influencing 
intracellular plasmid trafficking on stabilized microtubules [84]. In the experiments 
highlighted in chapter 3, the effects of Entinostat, a selective inhibitor of class 1 HDACs 1 
and 3 [146] on polymer-mediated transgene expression are studied in cancer cell lines. It 
is hypothesized that inhibition of nuclear HDACs 1 and 3 (the latter which also has 
cytoplasmic activity) will enhance polymer-mediated transgene expression due to 
increased plasmid DNA availability to transcriptional machinery brought about by histone 
acetylation 
47 
 
3.2 METHODS 
 
3.2.1 Polymer Synthesis  
The 1,4C-1,4Bis and PA8 polymers were synthesized using methods similar to our 
previously published protocols [29, 30, 147]. Briefly, the epoxide groups of diglycidyl 
ether (DGE) monomers 1,4 cyclohexanedimethanol DGE or ethylene glycol DGE, 
respectively, were reacted with polyamine monomers 1,4 bis(3-aminopropyl)piperazine 
and paromomycin, respectively, resulting in the formation of cationic polymers with 
molecular weights (MWs) > 5,000 g/mol. Branched polyethyleneimine (PEI, MW = 25,000 
g/mol) was purchased from Sigma (St. Louis, MO), and fresh stocks (50 ng/μL in HEPES 
buffer, pH 7.4) were prepared before every experiment in order to obviate any effects due 
to storage. Monomer structures used to synthesize 1,4C-1,4Bis and PA8 are shown in 
Appendix III, Figures A2 and A3.  
3.2.2 Transfections in the Presence of Entinostat  
Entinostat was kindly provided by Syndax Pharmaceuticals of Waltham, MA 
through an agreement with the Cancer Therapeutics Evaluation Program (CTEP) at NIH. 
Stocks were prepared in DMSO at concentrations ranging from 60 μM–20 mM and frozen 
at -80oC until needed. Human prostate (PC3 and PC3-PSMA) and murine bladder (MB49) 
cancer cells were seeded onto 24-well plates at a density of 50,000 cells per well with 500 
μL RPMI (PC3 and PC3-PSMA) or DMEM (MB49) containing 10% heat-inactivated fetal 
bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin.  All cell lines 
were incubated overnight (~18-20 hrs) at 37oC, and the serum-containing media (SCM) 
was replaced with serum-free media (SFM) immediately prior to transfection  Polyplexes 
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were prepared by incubating cationic polymers (1,4C-1,4Bis, PEI, or PA8) with pGL3-
Control (luciferase reporter gene, Promega, Madison, WI) or pEGFP-C1 (enhanced green 
fluorescent protein or EGFP reporter gene, Clontech, Mountain View, CA) plasmid DNA.  
The concentration of plasmid DNA was kept constant at 200 ng/well, while the 
polymer:pDNA mass ratio varied for each polymer (PEI = 1:1, 1,4C-1,4bis = 10:1, PA8 = 
50:1), depending on their previously determined optimal concentrations [29]. Polyplexes 
and different doses (0, 0.33, 1, 3.3, 10, 33, and 100 μM) of the HDAC inhibitor Entinostat 
were simultaneously added to the cells; a constant DMSO (for solubilizing the drug) 
concentration of 0.5% (v/v) was employed in all cases. Following six hours of incubation 
at 37oC with the polyplex and drug, serum-free media was exchanged with serum-
containing media containing corresponding Entinostat concentrations. The cells were then 
incubated at 37oC for an additional 48 hours to allow for transgene expression. 
Transfections with 0 μM Entinostat with or without 0.5% DMSO were also performed as 
controls, and 0.5% DMSO was found to not have any significant effects on transgene 
expression efficacy (data not shown). 
3.2.3 Luminescence Assay and Fluorescence Microscopy  
Luciferase assay was carried out in a similar manner as was done for the kinase 
screening in chapter 2.  Following transfections with the pEGFP-C1 plasmid, cells were 
examined with a Zeiss fluorescence microscope to visualize EGFP expression. All images 
were acquired within areas of 90-100% confluence near the center of each well. 
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3.2.4 Quantification of DNase Accessibility and Plasmid DNA in Target Cell Nuclear 
Fraction 
The relative presence and availability of plasmid DNA in the nuclear fraction of 
cells following Entinostat treatment was measured and quantified using methods 
described below. 
3.2.4A Genomic DNA Extraction -  
Genomic DNA (gDNA) was extracted from PC3-PSMA cells to test primer 
specificity against pGL3 plasmid DNA, in the presence of target cell genomic DNA. 
Extraction was carried out using a phenol:chloroform:isoamyl alcohol (iaa) technique. 
Briefly, cells were trypsinized, washed and lysed. Cell content was then isolated via 
extraction with a 25:24:1 phenol-chloroform-iaa buffer (Sigma). A second extraction was 
carried out with chloroform, and trace amounts of chloroform were subsequently 
evaporated at 55oC. DNA was precipitated overnight using a sodium acetate/EtOH 
mixture, and resuspended in TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA).   
All primers, designed against the promoter or luciferase (luc+) gene region of the 
pGL3 plasmid, were purchased from Integrated DNA Technologies (Coralville, IA).  The 
sequences of the forward and reverse primers for the four regions on the plasmid, denoted 
1-4, are as follows (5’-3’):  
Forward 1 – GGTACCGAGCTCTTACGCGTGC 
Reverse 1 – CGGGATGGGCGGAGTTAGGG  
Forward 2 – CAGAAGTAGTGAGGAGGCTTTTTTGGAC 
Reverse 2 – TATGTTTTTGGCGTCTTCCATGGTGGC  
Forward 3 – GCTTTTACAGATGCACATATCGAGGTGG 
Reverse 3 – GTATTCAGCCCATATCGTTTCATAGCTTC  
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Forward 4 – CGAAATGTCCGTTCGGTTGGCAGAAG  
Reverse 4 – GCATAAAGAATTGAAGAGAGTTTTCACTGCATAC.  
 
Region 1 mostly consists of the upstream portion of the SV40 promoter, region 2 
bridges the promoter region as well as the upstream region of the luc+ gene, covering 
portions of both, and regions 3 and 4 are located entirely on the luc+ gene. Endpoint PCR 
was carried out against both the pure pGL3 plasmid template as well as against PC3-PSMA 
gDNA using all pGL3 primer pairs. Agarose gel electrophoresis analyses were carried out 
on PCR products in order to validate the efficacy and specificity of the pGL3 primers. 
3.2.4B Nucleosomal DNA Purification -  
PC3-PSMA and PC3 cell nuclei were extracted using the EZ Nucleosomal DNA 
Prep Kit (Zymo), and purified nuclear DNA was treated with DNase following 48 hours 
of transfection (process summarized in Figure 3.1.  Transfections were carried out with 
the pGL3 plasmid complexed with 1,4C-1,4Bis polymer, in the presence or absence of 33 
μM Entinostat, as described above. Isolated nuclei were then either treated with Atlantis 
dsDNase (0.4 Units/100 μL, per kit instructions, resulting in cut DNA), or equivalent 
volume 1X PBS (resulting in uncut DNA). Nucleosomal DNA (cut and uncut) were then 
isolated using spin columns, supplied with the EZ Nucleosomal DNA Prep kit. The spin 
columns efficiently (70-90%) capture DNA 75 bp to 10 kb, which is a relevant size range 
for the pGL3 plasmid.     
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3.2.4C qPCR Experiments and Analysis - 
Quantitative PCR (qPCR) experiments were carried out on DNA isolated from the 
nuclear fraction of PC3-PSMA or PC3 cells (above), using the primers described above. 
Detection of fluorescence accumulated by amplified, double stranded DNA was carried out 
using SYBR® Green Master Mix (Life Technologies). PCR reactions (15 μL volumes) 
were prepared in triplicate for each independent experiment as follows: 2 μL template DNA 
Figure 3.1 Illustration of the process of nucleosomal DNA purification for normalized 
DNase accessibility and plasmid nuclear presence quantification 
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(1/75 total cellular nucleosomal DNA extraction, or roughly 3.8X104 nuclei for vehicle-
control treated PC3-PSMA cells and 1.0X104 nuclei for Entinostat-treated PC3-PSMA 
cells; PC3 cell counts were not quantified), 7.5 μL 2X SYBR Green Master Mix, 1.5 μL 
forward primer (0.57 pmol), 1.5 μL reverse primer (0.57 pmol), and 2.5 μL ddH2O. 
Reactions were carried out in opaque white 96-well plates (Roche 04 729 692 001), and 
thermal cycling was conducted in a Light Cycler® 480 PCR instrument (Roche). A pre-
incubation step was carried out for 5 min. at 95oC. Next, 45 amplification cycles were run: 
denaturation at 95oC for 10 sec., annealing at 58oC for 10 sec., extension at 72oC for 10 
sec. Fluorescence was recorded after each extension step. Melting analysis (95oC for 60 
sec., 40oC for 120 sec., 95oC at 0.19oC (sec-1) with fluorescence readings at 3(sec-1)) of 
reactions with and without DNA templates confirmed that 95-100% of the fluorescence 
signal was associated with PCR amplicons rather than primer dimers. The Roche Light 
Cycler® 480 software was used for subsequent calculations of DNase accessibility and 
relative plasmid content in the nuclear fraction. 
Cp values (maximum y-value of the second derivative of fluorescence = y / cycle 
number = x) for cells treated with Entinostat (E) or 0.2% DMSO (D) were used in DNase 
accessibility calculations. Calculations were performed separately for every PCR-
amplified region (Figure 3.5). Cp (crossing point) values indicate the PCR cycle number 
at which fluorescence due to amplification exceeds background fluorescence; thus, a lower 
Cp value indicates a greater amount of target DNA template since fewer numbers of cycles 
are required to produce a detectable fluorescence signal. The effect of DNase treatment on 
the purified nuclear DNA was quantified for cases with vehicle control (DMSO) and 
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Entinostat treatment, simply as the difference in Cp for DNA treated with DNase (C = cut) 
and without (UC = uncut):  
DMSO: 𝛥𝐶𝑃,𝐷 = 𝐶𝑃,𝐷,𝐶 − 𝐶𝑃,𝐷,𝑈𝐶 
Entinostat: 𝛥𝐶𝑃,𝐸 = 𝐶𝑃,𝐸,𝐶 − 𝐶𝑃,𝐸,𝑈𝐶 
where each delta value represents the difference in intact DNA before and after 
DNase treatment. A larger delta value indicates greater sensitivity to DNase, and thus 
indicates greater accessibility. All delta values were normalized using the average DMSO 
control value to test the hypothesis that relative to the DMSO control, Entinostat treatment 
increases DNA accessibility:  
DMSO: 𝛥𝛥𝐶𝑃,𝐷 =  𝛥𝐶𝑃,𝐷 − 𝛥𝐶𝑃,𝐷_𝑎𝑣𝑔  
Entinostat: 𝛥𝛥𝐶𝑃,𝐸 =  𝛥𝐶𝑃,𝐸 − 𝛥𝐶𝑃,𝐷_𝑎𝑣𝑔 
where 𝛥𝐶𝑃,𝐷_𝑎𝑣𝑔 is an average of 𝛥𝐶𝑃,𝐷 across all replicates.  DNase accessibility 
can be expressed as a fold-difference in the template DNA that remains after cutting by 
DNase for all samples, relative to the DMSO control 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝐷𝑁𝑎𝑠𝑒 𝐴𝑐𝑐𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦, 𝐷𝑀𝑆𝑂 =  2𝛥𝛥𝐶𝑃,𝐷  
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝐷𝑁𝑎𝑠𝑒 𝐴𝑐𝑐𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦, 𝐸𝑛𝑡𝑖𝑛𝑜𝑠𝑡𝑎𝑡 =  2𝛥𝛥𝐶𝑃,𝐸  
“Normalized DNase accessibility, DMSO” has an average value close to 1, since it 
is normalized by its own average value (Figure 3.5). “Normalized DNase accessibility, 
Entinostat” values greater than 1 support the hypothesis that an increase in DNase 
accessibility is associated with Entinostat treatment, while other values reject the 
hypothesis (Figure 3.5). 
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Next, we used Cp values from the uncut DNA samples to compare the amount of 
plasmid DNA in the nuclear fraction of Entinostat-treated versus untreated (DMSO) cells. 
All values were normalized using the average Cp value for the DMSO control sample  
DMSO: 𝛥𝐶𝑃,𝐷,𝑈𝐶 = 𝐶𝑃,𝐷_𝑎𝑣𝑔,𝑈𝐶 − 𝐶𝑃,𝐷,𝑈𝐶  
Entinostat: 𝛥𝐶𝑃,𝐸,𝑈𝐶 = 𝐶𝑃,𝐷_𝑎𝑣𝑔,𝑈𝐶 − 𝐶𝑃,𝐸,𝑈𝐶  
with fold-increase of plasmid in the nuclear fraction calculated as 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑃𝑙𝑎𝑠𝑚𝑖𝑑 𝑖𝑛 𝑁𝑢𝑐𝑙𝑒𝑎𝑟 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛, 𝐷𝑀𝑆𝑂 = 2𝛥𝐶𝑃,𝐷,𝑈𝐶  
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑃𝑙𝑎𝑠𝑚𝑖𝑑 𝑖𝑛 𝑁𝑢𝑐𝑙𝑒𝑎𝑟 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛, 𝐸𝑛𝑡𝑖𝑛𝑜𝑠𝑡𝑎𝑡 = 2𝛥𝐶𝑃,𝐸,𝑈𝐶  
“Normalized plasmid in nuclear fraction, Entinostat” values greater than 1 support 
the hypothesis that greater plasmid uptake is associated with Entinostat treatment, while 
other values reject the hypothesis (Figure 3.6). 
 
3.3 RESULTS 
 
3.3.1 Enhancement of Luciferase and EGFP Transgene Expression by Entinostat  
The effects of Entinostat on transgene expression were evaluated in three cell lines: 
two human prostate cancer cell lines (PC3 and PC3-PSMA) and a murine bladder cancer 
cell line (MB49) (Figure 3.2) [148].  The left side of Figure 3.2 represents enhancement 
in luciferase expression relative to polyplex + vehicle (DMSO) control for Entinostat dose 
responses using three different polymers to deliver the pGL3 plasmid, which encodes for 
the firefly luciferase gene, controlled by the SV40 promoter.  Regardless of the polymer 
used, enhancement of transgene expression seems to be a generalizable phenomenon in all 
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three cell lines tested.  However, there are notable differences between the evaluated 
systems.  For instance, in PC3 cells, PEI mediated transfection was enhanced about 24-
fold when treated with 33 μM Entinostat.  However, PA8 and 1,4C-1,4Bis mediated 
delivery was enhanced to a much lesser extent.  In PC3-PSMA cells, Entinostat again 
drastically enhanced PEI-mediated transfection levels, but PA8 transgene expression 
enhancement was greatly increased with Entinostatin this cell line when compared to PC3.  
Interestingly, in MB49 cells, Entinostat treatment similarly affected transfection with each 
of the three polymers tested.  Taken together, these results point to HDAC 1/3 inhibition 
with Entinostat treatment as a reliable strategy for enhancing polymer-mediated transgene 
expression.  However, polycations do affect the level to which enhancement may occur.  It 
should be noted that in PC3 and PC3-PSMA cells, 1,4C-1,4Bis baseline transfection 
efficacy was 5-10 times lower than observed with PA8 or PEI as a delivery vehicle.  
However, in MB49 cells, basal levels of transgene expression were similar using all three 
polymer carriers. In addition to the pGL3 plasmid, transfection experiments were carried 
out using PEI-(pEGFP-C1) polyplexes (Figure 3.2, right side) in PC3 and PC3-PSMA 
cells.  At Entinostat doses correlating to optimal enhancement in transgene expression 
observed with the pGL3 vector, clear visual enhancement in recombinant EGFP expression 
can be observed.  Given that the pEGFP-C1 plasmid uses the CMV promoter to drive 
reporter expression, these results indicate that Entinostat can enhance polymer-mediated 
transgene expression with a variety of different polymers in multiple cancer cell lines, and 
is likely not promoter-specific.  
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3.3.2 Enhancement of Transgene Expression Relative to Change in Global Protein 
Expression  
Due to the effects of Entinostat on HDAC and, consequently, chromatin structure, 
it is possible that Entinostat treatment increases global protein production. This 
Figure 3.2 Left - Relative luciferase expression (pGL3 plasmid, SV40 promoter) in PC3 
human prostate cancer, PC3-PSMA human prostate cancer, and MB49 murine bladder cancer 
cells. Asterisks (*) denote statistically significant (p< 0.05) enhancement of luciferase 
expression relative to the corresponding polyplex controls. Data shown indicate mean values 
± one standard deviation. Right - Enhancement of EGFP expression by Entinostat at the 
indicated dose in PC3 and PC3-PSMA human prostate cancer cells post-transfection with PEI 
(polymer : plasmid DNA mass ratio of 1:1). These representative images are consistent with n 
= 3 independent experiments 
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necessitates an investigation into how increases in transgene expression might vary 
corresponding to any changes in global protein expression levels.  Interestingly, the total 
protein content in PC3-PSMA cells transfected with 1,4C-1,4Bis:pGL3 polyplexes did 
not change significantly with optimal Entinostat treatment (33 μM) compared to DMSO 
(vehicle)-treated cells (i.e. absence of Entinostat) [148]. However, it is important to note 
that with fewer cells present following 33 μM Entinostat treatment, the total protein 
content per cell escalated as shown in Figure 3.3. This could be due to increased 
acetylation of chromatin or possibly reduced cell growth rate and a concomitant alteration 
in cell metabolism. However, the fold-increase in protein content per cell (approximately 
2.8-fold) with 33 μM Entinostat treatment did not nearly account for the fold-
enhancement in transgene expression observed per cell with inhibitor treatment 
(approximately 28-fold; cell counts, RLU values, and protein content in Appendix II) 
(Figure 3.3). This result indicates that mechanisms in addition to changes in total protein 
Figure 3.3 Effect of Entinostat on global protein expression (as measured via BCA 
assay) and transgene (luciferase) expression in PC3-PSMA cells transfected with 10:1 
(w/w) 1,4C-1,4Bis pGL3 polyplexes in serum free-media i.e. SFM (n=3).  The 
protein/cell and RLU/cell reported for Entinostat in this graph are normalized with those 
observed for the DMSO (i.e. vehicle control in absence of Entinostat). Data shown 
indicate mean values ± one standard deviation. Asterisks (*) denote significant increase 
in RLU/cell relative to protein/cell with 33 μM Entinostat treatment. 
2.8±0.3 
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content are likely responsible for enhancement in transgene expression with 33 μM 
Entinostat treatment. 
3.3.3 Effect of Entinostat Treatment on Cell Cycle Distribution 
Given the known importance of cell cycle phase in transgene expression, we 
examined the effects of Entinostat on cell cycle progression in PC3-PSMA cells (Figure 
3.4 and Table 3.1) [148]. The majority of the control cells (treated with only 0.5% DMSO) 
were found to be in the G0/G1 phase of the cell cycle (62%), while 28% of the cells were 
in the G2/M phase and 10% were in the S phase. Treatment with 3.3 µM Entinostat resulted 
in significant accumulation (86%) of PC3-PSMA cells in the G0/G1 phase, with a 
concomitant decline in both S and G2/M cells. Treatment with 33 μM Entinostat (the 
optimal tested dose for transgene expression in PC3-PSMA cells) showed no significant 
G0/G1 arrest, although a modest (6.2%) increase in the apoptotic cell population was 
observed. These results have some similarity to a previous study in which 1 µM Entinostat 
resulted in G0/G1 arrest of U397 human leukemic monocyte lymphoma cells, while a higher 
dose (5 µM) failed to induce G0/G1 arrest, but did lead to a significant increase in apoptotic 
cell population [149].  However, these results differ from a study in closely related PC-3 
cells, in which, G2/M arrest was reported with Entinostat treatment [150]. These cell cycle 
distribution results indicate that the observed increase in transgene expression observed 
with 33 µM Entinostat treatment is unlikely to be explained by cell cycle effects alone, but 
the G0/G1 arrest observed at 3.3 μM and the modest increase in apoptotic cells at 33 μM 
correlate with the observed decreases in cell viability at these concentrations, (64.6 ± 6.9 
and 71.1 ± 6.0 % viability respectively) with PEI compared to PEI + 0.5% DMSO at 88.0 
± 6.5 % viability.  While drug treatments prior to cell cycle staining were not accompanied 
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by polyplexes, viability experiments were not carried out in the absence of polyplexes, so 
the aforementioned statements regarding cell cycle and viability assume that PEI and 
Entinostat do not synergistically kill cells.  
 
 
Table 3.1 - Fractions of PC3-PSMA cells in each phase of the cell cycle following 
treatment with Entinostat. Asterisks (*) indicate significant change from vehicle 
control (DMSO control) treatment (Student’s T-Test, p<0.05) 
 
3.3.4 DNase Accessibility with Entinostat Treatment 
Positively charged deacetylated histones are tightly wrapped with negatively 
charged DNA, while acetylation of histones removes the positive charge, disrupts DNA-
histone binding, and facilitates increased DNA availability for transcription. Given these 
Figure 3.4 Cell cycle analysis of PC3-PSMA cells treated with 0.5% DMSO, 3.3 μM Entinostat, and 
33 μM Entinostat (n = 3); results from one representative experiment are shown. The y-axis indicates 
the number of cells with the specific fluorescence intensity shown on the x-axis 
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known mechanisms between histone (de)acetylation and chromosomal DNA, it was 
hypothesized that treatment of plasmid-transfected cells with Entinostat would, in part, 
increase transgene expression by reducing the binding of plasmid DNA to histones, thereby 
increasing the availability for transcription.  
One way to indirectly measure the availability of a region of DNA is by treatment 
with DNase, which cuts “unprotected” or transcriptionally “accessible” DNA. This 
includes portions of the plasmid that do not interact with histones in the nucleus. Thus, 
determination of amount / extent of ‘cut’ portions, e.g. using qPCR, is an indication of how 
accessible the plasmid is for transcription inside host cell nuclei. This approach has been 
previously applied to elucidate the availability of promoter and other regions of 
chromosomal DNA [151-153]. In our case, we applied this same principle, but to 
exogenously delivered plasmid DNA, as opposed to host cell chromosomal DNA assayed 
in these previous investigations. As stated previously, evidence suggests that plasmids do 
form nucleosomes extracellularly and possibly in vitro, which motivated the use of this 
strategy for elucidation of DNase accessibility in vitro. 
qPCR analyses were performed on purified PC3-PSMA nuclear DNA fractions 
with  primer pairs amplifying different regions around the luc+ and SV40 promoters gene 
on the pGL3 plasmid; control experiments with nuclei from untransfected cells were 
carried out in order to verify that the PCR signal was exclusively from pGL3 plasmid DNA. 
The regions amplified using qPCR include: a region on the SV40 promoter (primer pair 1), 
a region bridging the SV40 promoter and luc+ gene (primer pair 2), and regions on the 
luc+ gene (primer pairs 3 and 4) (Figure 3.5). Normalized DNase accessibility for each of 
the four explored regions in the promoter and gene area are shown in Figure 3.5 [148]. 
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The results are similar for each of the four regions assayed in that no statistically significant 
change in DNase accessibility was observed due to Entinostat treatment.   
 
It is possible that plasmid DNA forms nucleosomes inside cells, and that Entinostat 
does not strongly influence the transcriptional availability in the luc+ promoter/gene region 
in our particular system. It is also possible that nucleosomes did not form with the delivered 
plasmid, and the increase in transgene expression observed with Entinostat treatment is due 
to changes in chromosomal availability (discussed below). Additionally, there may be 
regions, upstream of the promoter or elsewhere on the promoter that were not included in 
the qPCR analyses, but may play a role in transcription factor binding. 
3.3.5 Evaluation of Plasmid DNA Content in the Nucleus 
While a change in DNase accessibility to exogenously delivered plasmid with 
Entinostat treatment was not detected, qPCR experiments revealed a very interesting result.  
Figure 3.5 DNase accessibility data normalized to DMSO treatment (n = 3) in PC3-PSMA cells. 
The y-axis indicates fractional DNase accessibility relative to DMSO-treated cells.  Data shown 
indicate mean values ± one standard deviation. For all four regions, as indicated by primer pairs 
1-4 in the promoter/gene map, the difference in DNase accessibility between DNA harvested 
from DMSO and Entinostat (33 μM) treated cells was not found to be statistically significant 
(p<0.05 threshold, Student’s t-test) 
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In two cancer cell lines, PC3-PSMA and PC3, Entinostat treatment at the optimal 
concentration for enhancing transgene expression increased detected intact (i.e. not treated 
with DNase) pGL3 in the nucleus (Figure 3.6) [148].  In PC3-PSMA cells treated with 33 
μM Entinostat (Figure 3.6A), normalized plasmid in nuclear fraction values of 2.8 ± 0.6 
and 2.5 ± 0.4 were observed with primer pair 1 and primer pair 2 for the plasmid in the 
nuclear fraction; both primer pairs amplify regions containing part of the SV40 promoter, 
with the latter including a portion of the luc+ gene.  qPCR using primer pair 3 for 
amplification indicated the normalized plasmid levels to be 3.0 ± 0.7, while primer pair 4 
yielded a value of 3.9 ± 2.0 compared to the control; both of these primer pairs amplify 
portions of the luc+ gene. In PC3 cells treated with 10 μM Entinostat, a modest increase 
in pGL3 in the nuclear fraction was observed (Figure 3.6B) [148].  As shown through PCR 
amplification of several portions close to / of the pGL3 SV40-luc+ region, the presence of 
Figure 3.6 Normalized plasmid content in the nuclear fraction (FI = fold increase) indicating the 
relative amount of exogenously delivered plasmid DNA present in the nucleus following A) 33 μM 
Entinostat treatment in PC3-PSMA cells or B) 10 μM Entinostat treatment in PC3 cells.  Data 
represented as mean ± one standard deviation. Asterisks (*) denote p<0.05 (Student’s T-test) 
comparing pGL3 levels in nuclear fraction of Entinostat + polyplex treated cells relative to DMSO + 
polyplex treated cells. The base pairs are labeled such that position 1 is the first base pair amplified 
by our primers. The numbering system was defined for convenience, and is not relate to that 
provided by the vendor (Promega) 
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the exogenous plasmid DNA in the nucleus is significantly enhanced by Entinostat 
treatment in two different cell lines. These results indicate that the modest increase in 
plasmid present in cell nuclei (~3.1-fold in PC3-PSMA cells and ~1.7 in PC3 cells, from 
the average value for all primer pairs) likely contributes to the enhancement in transgene 
expression observed with Entinostat.  
 
3.4 DISCUSSION AND CONCLUSIONS 
The experiments carried out in chapter 3 have clearly identified inhibition of 
HDAC1/3 using the small molecule inhibitor Entinostat as a target for enhancing polymer-
mediated plasmid transient expression in cancer cell lines.  This phenomenon appears to 
be very general, as it was shown to be active in three cancer cell lines using three 
polycations delivery vehicles.  Additionally, expression of a second plasmid driven by 
another promoter (CMV-EGFP) was shown to be improved with Entinostat treatment in 
two of the cancer cell lines.  These results agree with previous findings that the pan-HDAC 
(HDAC 1, 3, 4, 6, and 10) inhibitor Trichostatin A significantly enhances expression from 
a variety of viral promoters, including the SV40 and CMV promoters used in this study 
[84, 154]. 
Treatment of PC3-PSMA cells with a low micromolar dose (3.3 μM) of Entinostat 
resulted in accumulation of cells in the G0/G1 phase, while addition of a higher dose (33 
μM) yielded no significant alteration in cell cycle distribution.  Given that both of these 
doses are correlated with high transgene expression, it is unlikely that the cell cycle plays 
a major role in the observed enhancement in transgene expression. It is interesting to note 
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that the optimum concentration of Entinostat observed in our experiments (3.3-33 μM) is 
much higher than the previously published submicromolar (< 1 μM) IC50 values for the 
anti-proliferative effects of Entinostat [149]. However, these concentrations are consistent 
with other studies showing enhancement of viral gene therapy at 3.3-10 μM [155, 156].  
This optimum concentration range corresponds well with inhibition of HDAC 3 (IC50 = 8 
μM) but is much higher than that required for inhibiting HDAC 1 (IC50 = 0.3 μM) [146], 
although IC50 values are often underestimated for in vitro applications, as they are often 
estimated in cell free assays. It is possible that inhibition of this second target at higher 
concentrations plays a role in the reversal of the cell cycle distribution. Given IC50 values, 
it appears that inhibition of HDAC3 may be at least partly responsible for the observed 
enhancement of transgene expression, although more studies are required to elucidate this. 
DNase accessibility was not found to be altered by Entinostat treatment in these 
experiments.  As addressed above, it is possible that the region(s) tested on the promoter 
and gene lie outside of an affected locus.  It is also quite possible that Entinostat, by 
affecting chromatin structure of the target cell results in increased expression of a gene that 
itself directly or indirectly improves nuclear entry of our delivered plasmid.  It is important 
to note DNase accessibility is not always positively correlated to high local gene 
expression.  There is recent evidence that indicates a more complex relationship between 
these factors. For example, high rates of DNase I hypersensitivity were detected on cis-
elements associated with low-expression genes in HeLa cells, suggesting DNase 
accessibility alone does not indicate high expression. Counter-intuitively, a positive 
correlation between silenced genes and chromatin relaxation was observed in one case 
[157].  To really understand if HDACs interact with delivered plasmids, more involved 
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assays, such as chromatin immunoprecipitation (ChIP) may be necessary (discussed in 
chapter 5). These experiments, however, did identify that Entinostat treatment improves 
nuclear entry of a delivered plasmid, or the gene delivery barrier that is generally 
considered the least efficient (or most difficult) for a transgene to overcome. The 
mechanism behind improved plasmid nuclear entry is not clear, but it is very likely an off-
target effect, involving overexpression of a target cell gene through chromatin 
hyperacetylation, assisting in nuclear entry. 
In chapters 2 and 3, certain kinase classes and HDAC1 (and/or HDAC3) have been 
identified as targets for enhancing transgene expression. Inhibition of PLK1 was clearly 
shown to affect trafficking of delivered plasmids in the cytosol, while the HDACs inhibited 
by Entinostat both have activity in the nucleus.  The mechanism by which the signal 
transduction – transcription responsive JAK-STAT pathway enhances transgene 
expression is unknown.  However, it is likely that all of these pathways act independently 
in certain facets of their functions, but may have overlapping functions as well.  
Experiments were carried out inhibiting the lead inhibitor of each of these three targets and 
in combination while delivering plasmid, ultimately observing how these inhibitors affect 
transgene expression individually and in combination (Figure 3.7) [106].      
Simultaneous inhibition of PLK1 (H=HMN-214), histone deacetylase 1/3 (E = 
Entinostat), and JAK2-STAT (A=AG490) resulted in further enhancement of transgene 
expression relative to inhibition of each individual target. Each pairwise inhibition led to 
significant transgene expression enhancement compared to either individual component 
with at least one polymer, and the triple (HAE) combination significantly enhanced 
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expression relative to each dual-combination with 1,4C-1,4Bis as the carrier, and led to 
enhancement relative to all three single agent treatments with PEI as the gene carrier.   
These results demonstrate that inhibition of key intracellular kinase targets using small-
molecule inhibitors can enhance transgene expression and potentially improve gene 
therapy efficacy. Interestingly, each of the three inhibitors tested have been shown to have 
anticancer activity, potentiating enzyme inhibition combinations for cancer gene 
therapeutic applications [158] [112, 159].  
 
 
 
 
 
 
 
 
Figure 3.7  Effects of inhibitor drug combinations on relative luciferase expression (RLUV, left) 
and cell proliferation (right) in PC3-PSMA cells following transfections with 1,4C-1,4Bis and 
pGL3.0 plasmid DNA polyplexes.  † indicates combinations with RLUV significantly higher than 
the corresponding individual treatments (e.g. HE compared to H or E), ‡ indicates triple 
combinations (HAE) with RLUV significantly higher than any pair-wise treatment (e.g. HAE 
compared to HE, AH, and EA). Asterisks indicate combination treatments containing HMN-214 
with significant increases in proliferation compared to HMN-214 alone. In all cases, statistical 
significance was determined using the Student’s t-test, and a p-value < 0.05 was considered 
significant. H = 3.3 μM HMN-214 (PLK1 inhibitor), A = 3.3 μM AG-490 (JAK/STAT/EGFR 
inhibitor), and E = 33 μM Entinostat (HDAC1 inhibitor, N = 3 independent experiments). Error 
bars indicate standard deviations 
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CHAPTER 4 – IDENTIFICATION OF EPIGENETIC ENZYMATIC TARGETS 
AFFECTING TRANSGENE EXPRESSION 
4.1 INTRODUCTION 
The studies discussed in chapter 2 were focused on phenomenological discovery 
of kinase targets for enhancing non-viral (polymer)-mediated transgene expression, as 
well as basic mechanistic evaluation of how inhibition of the lead kinase target (PLK1) 
enhances transgene expression.  The kinase screening study was proposed based on the 
idea that several kinases have been established to play a role in transgene expression 
through affecting cargo endocytosis and trafficking, as well as many more which have 
potential, given their effects on known barriers of endocytosis and trafficking outside of 
the context of gene delivery (examples of both given in section 2.1). Experiments carried 
out in chapter 3 then focused on a downstream barrier to gene delivery, inhibiting an 
epigenetic modifying enzyme with known nuclear histone deacetylation activity.  Given 
the lack of research efforts that have been focused on how events inside the nucleus 
affect transgene expression, the work carried out in chapter 4 focused on identification 
and mechanistic evaluation of epigenetic modifying enzymes for enhancing transgene 
expression.   
Epigenetics is a vast field studying the effects on gene expression of factors that 
do not change the nucleic acid sequence of DNA. Different epigenetic states, resulting in 
expression activation or repression of particular genes are generally heritable, and can be 
activated by environmental changes [160].  Epigenetic modifications are involved in a 
number of cellular processes, such as development [161], metabolic regulation [162], and 
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aging [163], and improper epigenetic regulation can lead to diseases such as cancer [164] 
and neurodegenerative disorders [165]. 
As discussed in chapter 3, chromosomal DNA is organized in a collective structure 
with histone proteins referred to as chromatin, and these DNA-histone interactions play a 
pivotal role in regulation of gene expression. In addition to DNA methyltransferases, which 
facilitate methylation of promoter DNA and generally have an inhibitory effect on gene 
expression [166], there are a number of enzymes which post-translationally functionalize 
histones, affecting chromatin structure and, ultimately, gene expression.  A common theory 
used to describe the interplay between these enzymatic processes is the histone code theory, 
which classifies enzymes as writers (enzymes that carry out histone modifications), erasers 
(those that remove functional modifications), and readers (those that recognize the 
“epigenetic mark” of these modifications and recruit other proteins for chromatin 
remodeling) [167, 168].  These enzymes, which carry out modifications such as histone 
(de)acetylation, (de)phosphorylation, and (de)methylation mark histones for reader 
enzymes to enable a change in chromatin structure and gene expression; many of these 
marks and their effects on gene expression are well understood.  The acetylation mark on 
many different lysine groups on core histones, as well as phosphorylation of histone H3 
serine 10 are known to be activators of gene expression [165].  Histone methylation, on the 
other hand, can have activating or repressing effects on local gene expression; for instance, 
di- or tri- methylation of Histone H3 lysine 4 (H3K4me2 or H3K4me3, respectively) 
activates transcription, while trimethylation of H3K9 (H3K9me3) and H3K27me3 promote 
repression of transcription [165]. 
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While many epigenetic modifications are well understood in the context of 
chromatin involving chromosomal DNA, a thorough understanding of how native gene 
expression machinery articulates with exogenously delivered DNA (eg. plasmid DNA), 
especially non-viral DNA, is severely lacking. However, the literature is not completely 
devoid of examples of epigenetic enzyme inhibition for enhancing non-viral transgene 
expression.  The Pan-HDAC inhibitor sodium butyrate [169], and now the class I HDAC 
inhibitor Entinostat (chapter 3) have been demonstrated to enhance non-viral transient 
expression.  Additionally, DNA methyltransferase inhibition with 5-Azacytidine has been 
shown to enhance transgene expression [170].  While these targets have been identified, 
there are likely many more to be discovered. 
The major goal of this chapter is to identify epigenetic enzyme targets that can be 
inhibited (or conversely, overexpressed) to enhance transgene expression, and begin to 
understand why they do.  Using a commercially available library consisting of 89 small 
molecule epigenetic enzyme inhibitors targeting writer, eraser, and reader enzymes of the 
epigenetic code, a screen has been carried out to determine the effects of inhibiting 
epigenetic modifiers on polymer-mediated transgene (plasmid) expression in two cell lines: 
UMUC3 bladder cancer cells, commonly used in modeling bladder malignancies and 
Chinese Hamster Ovary (CHO-K1) cells, a cell line commonly used in both stable and 
transient protein production biotechnology.   
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4.2 METHODS 
4.2.1 Small Molecule Epigenetics Screening Library and Stock Solution Preparation  
A library of 89 small molecule epigenetic enzyme inhibitors from Cayman 
Chemicals (Item number 11076, 10 mM in DMSO) was purchased. Based on a 
combination of published IC50 values and literature search for concentration ranges 
typically used, all inhibitors were categorized either as high dose candidates (screened at 
500 nM, 5 μM, and 50 μM) or low dose candidates (screened at 50 nM, 500 nM, and 5 
μM). Stock solutions were prepared in DMSO at 100X the highest concentration to be 
assayed (5 mM for high dose candidates, 0.5 mM for low dose candidates).  
4.2.2 Epigenetic Inhibitor Transgene Expression Screen  
On the evening prior to screening, 10,000 cells were plated per well in 96 well 
plates in RPMI 1640 media (10% fetal bovine serum and penicillin (100 units/mL) – 
streptomycin (100 μg/mL).  On the following morning, neomycin resorcinol diglycidyl 
ether (N-RDGE) polymer solution [66]  was prepared at 0.375 mg/mL in 1X PBS and 
filtered through a 0.2 μm regenerated cellulose syringe filter.  pEF-Luc plasmid DNA 
was prepared at 15 ng/μL in EB buffer (Qiagen).  In a sterile deep well 96-well block, 
small-molecule library inhibitors were added corresponding to experimental plate 
position.  Cell-containing plates and the deep well inhibitor-containing block were then 
placed inside of a Biomek FXp liquid handing system (LHS) and, using an optimized 
protocol, serum-containing RPMI media was added to the 100X concentrated inhibitors, 
diluting them to the highest working concentration to be tested, and mixed using an 
orbital shaker.  Old media was removed from cells and replenished with drug-containing 
media by the LHS.  The LHS carried out 10X dilutions of the original inhibitor solution 
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to prepare media at the two lower working inhibitor concentrations to be tested.  A 
reservoir of polymer-DNA complexes (polyplexes) was prepared manually in a laminar 
flow biohood at a 25:1 (w/w) ratio and allowed to form for 20 minutes at room 
temperature.  Polyplexes containing 75 ng DNA/well were then distributed to all cells (10 
μL/well) by the LHS, and transfection was allowed to proceed for 48 hours at 37oC/5% 
CO2 
4.2.3 Transgene Expression Quantification 
48 hours after transfection, cells were assayed for transgene expression.  Cell lysis 
was carried out using cell culture lysis reagent (Promega) and luminescence was detected 
using a Synergy 2 plate reader (Biotek, Winooski, VT).  Protein content was assayed for 
each well using the BCA assay (ThermoFisher); to account for any well-to-well variation 
in cell plating, luminescence values were normalized to protein content. Additionally, 
MTT viability assays (ATCC) were carried out in parallel plates, and luminescence 
values were also normalized to viability.  For dose-response optimization and 
combination transfections, protein content and viability were not assayed, thus 
luminescence values for these transfections are representative of total well luminescence.   
4.2.4 Dose Response Optimization Transfections 
Select lead inhibitors from the epigenetic screen were chosen for dose 
optimization with the pEF-Luc plasmid, driven by the EF1α promoter as well as the 
pGL3 plasmid, also expressing luciferase, but under control of the Simian Virus 40 
(SV40) promoter.  These transfection experiments were carried out by hand, using the 
same polymer and plasmid conditions as used in the screen.  Inhibitors were purchased 
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from Cayman Chemical in solid form and dissolved in DMSO to 500x working 
concentration for each dose to be tested.  Doses were chosen to test at and above (where 
possible) and below the optimal of three doses tested in the screen, based on screening 
results.  Luciferase assay was employed in a similar manner as the screen, with the 
exception of viability and protein content normalization.   
 
4.2.5 Plasmid Nuclear Localization  
            As in chapter 3, pGL3 transfections were carried out and 48 hours later, cell 
nuclei were isolated.  Using the same primer pairs discussed for pGL3 detection in 
chapter 3, a qPCR routine was performed and relative nuclear plasmid levels were 
quantified. 
 
4.3 RESULTS 
4.3.1 Small Molecule Epigenetic Inhibitor Screening for Effects on Plasmid Expression 
An epigenetics screening library, consisting of 89 small molecule inhibitors of 
many epigenetic effector enzymes, was screened for enhancement of transgene 
expression in CHO-K1 and UMUC3 cells.  Each inhibitor was tested at three different 
concentrations, as described in section 4.2, with the dose yielding the greatest 
enhancement in transgene expression shown for CHO-K1 in Figure 4.1A and 4.1B, and 
for UMUC3 in Figure 4.2A and 4.2B.  The actual doses with which these reported data 
correspond for each inhibitor can be found in Appendix IV, Table A4. 
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Figure 4.1 Epigenetics screening library inhibitors were assayed for enhancement of transgene 
expression in CHO-K1 cells.  The concentration of each drug leading to the greatest enhancement in 
transgene expression is included.  Polyplexes were formed by adding N-RDGE polymer to 75 ng EF-
Luc plasmid DNA at a 25:1 (wt/wt) ratio. Inhibitors are organized by target, with targets organized 
alphabetically in figure A, continued in figure B.  * = Student’s T-test p<0.05 for enhancement in 
transgene expression; v = Student’s T-test p<0.05 for reduction in transgene expression.  Chaetocin 
and GSK-J4 were not considered statistically significant reducers of transgene expression because 
viability was very low for cells treated with these inhibitors 
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Figure 4.3 Identified epigenetic targets for enhancing transgene expression in the two cells lines 
included in the screen. Targets are defined as enzymes for which multiple small molecule 
inhibitors led to enhancement in transgene expression if multiple inhibitors were provided in the 
library.  If only one inhibitor was provided for a target and it resulted in transgene expression 
enhancement, it is included here. The latter is the case for WDR5, LSD1, and Aurora kinase 
Figure 4.2 Epigenetics screening library inhibitors were assayed for enhancement of transgene 
expression in UMUC3 cells.  The concentration of each drug leading to the greatest enhancement in 
transgene expression is included.  Polyplexes were formed by adding N-RDGE polymer to 75 ng EF-
Luc plasmid DNA at a 25:1 (wt/wt) ratio. Inhibitors are organized by target, with targets organized 
alphabetically in figure A, continued in figure B.  * = Student’s T-test p<0.05 for enhancement in 
transgene expression; v = Student’s T-test p<0.05 for reduction in transgene expression.  Chaetocin 
and GSK-J4 were not considered statistically significant reducers of transgene expression because 
viability was very low for cells treated with these inhibitors 
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The screening revealed inhibition of several enzyme candidates for enhancing polymer-
mediated transgene expression in both CHO-K1 and UMUC3 cells, as well as some that 
show promise in only one cell line or the other (Figure 4.3).  They are discussed 
subsequently by enzyme class. 
4.3.1A Histone Deacetylase (HDACs, classes I and II) -  
The HDAC family of enzymes was highly represented in the epigenetic screening 
library.  HDACs catalyze the removal of acetyl groups from lysine residues of histones, 
generally leading to a decrease in local gene expression.  HDAC inhibitors (HDACis) 
have been used extensively for treatment of diseases, especially cancer, in which aberrant 
expression of HDAC enzymes is common [171].  While HDACis have been used for 
altering endogenous gene expression, they have also been applied for the enhancement of 
transient gene expression, using a variety of gene delivery vehicles including baculovirus 
vector [172], cationic polymers [84, 148, 173], and calcium phosphate [169].  The screen 
in both CHO-K1 and UMUC3 cells identified several Class I/II HDACis as enhancers of 
transient transgene expression (Figure 4.1A and 4.2A), in general leading to greater 
enhancement in UMUC3 cells than CHO-K1.  (S)-HDAC-42 is a structurally optimized 
derivative of phenylbutyrate [174], which is a very weak HDACi. Vorinostat, also known 
as suberoylanilide hydroxamic acid (SAHA) and its more potent [175] hydrophobic 
derivative 4-iodo-SAHA both demonstrated enhancement in transgene expression. SAHA 
and 4-iodo-SAHA have been shown to inhibit HDAC1 and HDAC6, which are nuclear 
class I and cytoplasmic class II HDACs, respectively. Oxamflatin is a class I HDACi that 
belongs to the same biochemical class as SAHA [176].    CBHA is an inhibitor of 
HDAC1 and HDAC3 [177], while Chidamide inhibits these HDACs as well as HDACs 2 
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and 10, the latter which is a mostly cytoplasmic class II HDAC [178]. Finally, among 
inhibitors resulting in transgene enhancement in both cell line tested, SB939 is a pan-
HDACi, inhibiting all HDAC enzymes with the exception of HDACs 6 and 7 [179].  
Several Class I/II HDACis which were not found to consistently enhance transgene 
expression in CHO-K1 cells clearly improved expression in UMUC3 cells: apicidin, 
CAY10433, CAY10603, ITF2357, M 344, MS-275, pimelic diphenylamide 106, 
pyroxamide, scriptaid, suberohydroxamic acid (SBHA), and Trichostatin A.  Interestingly 
among this group is CAY10603 which potently and exclusively inhibits HDAC6, a 
primarily cytoplasmic HDACi that is known to deacetylate tubulin, affecting intracellular 
trafficking.  HDAC6is have previously been found to enhance transgene expression by 
modifying intracellular trafficking [84, 180]. 
Others have already demonstrated class I/II HDACis to enhance transgene 
expression in certain systems.  Entinostat (MS-275), trichostatin A, sodium butyrate, and 
valproic acid are known enhancers of transgene expression, and we have previously 
demonstrated Entinostat’s ability to enhance transgene expression in cancer cells [148].  
It is important to note that due to constraints introduced by manufacturer-provided 
inhibitor concentrations in the screening library, valproic acid and sodium butyrate were 
tested well below their IC50 values in the above screen.   
4.3.1B Sirtuins (HDACs, Class III) – 
In addition to the classical HDAC classes I, II, and IV (those discussed above fall 
under class I and II), class III HDACs are a group of NAD+ dependent protein 
functionalizing enyzmes known as sirtuins.  While several class I and II HDACis were 
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identified as enhancers of transgene expression, sirtuins were shown to be a potential 
target for transgene expression enhancement in both cell lines (Figure 4.1B and 4.2B), 
although a more promising target in CHO-K1 than UMUC3 cells.  Tenovin 1 and its 
improved analog Tenovin 6, both identified as enhancers of transgene expression in both 
cell lines, are inhibitors of sirtuins SIRT1 and SIRT2 [181], which are responsible for 
carrying out histone deacetylation on H3K9 and H4K16 (SIRT1) or just H4K16 (SIRT2) 
[182], in addition to many other non-histone protein targets.  Tenovin 6 has been shown 
to have anti-cancer activity by attenuating the effects of SIRT1 overexpression common 
in cancers, through increased expression of death receptor 5 for apoptosis induction [183, 
184] as well as interference with protective autophagy [185].  In addition to histone 
deacetylation and its downstream effects, SIRT1 regulates the activity of transcription 
factors such as p53 through direct deacetylation. Also identified as enhancers of 
transgene expression in CHO-K1 cells were sirtinol, a SIRT1/2 inhibitor [186] and its 
derivative naphthoic acid [187].   Also, JGB1741, an inhibitor of SIRT1 and weak 
inhibitor of SIRT2 led to moderate transgene expression enhancement.  AGK2 a SIRT2 
inhibitor enhanced transgene expression in both cell lines and salermide (SIRT1/2 
inhibitor) also showed promise in enhancing transgene expression in CHO-K1 cells.  In 
general, sirtuin inhibitors appear to be more promising for enhancing transgene 
expression in CHO-K1 cells than in UMUC3; interestingly, Piceatannol, which has been 
shown to activate SIRT1 expression in human monocytes [188],  enhanced transgene 
expression in UMUC3, but not in CHO-K1 cells.  This further indicates that the sirtuins 
may not be a strong inhibition target for enhancing transgene expression in UMUC3 
cells.   
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4.3.1C Histone Acetyltransferase (HAT) -  
HAT enzymes catalyze the addition of acetyl groups to the ε-amino groups of 
lysine residues present on core histones, carrying out the opposite activity of HDACs, 
with which they work to regulate gene transcription. Addition of these acetyl groups at 
nucleosomes lead to a general increase in chromatin accessibility [189], allowing 
interaction with necessary transcriptional machinery.  The screen identified CPTH2 
hydrochloride as a strong enhancer of transgene expression in both cell lines (Figure 
4.1A and 4.1B). CPTH2 hydrochloride specifically inhibits the HAT enzyme Gcn5, 
which has known acetyltransferase activity at Histone H3K9 [190] and H3K14[191].  A 
similar protein with HAT activity, PCAF, was represented in the screening by the 
inhibitor CAY10669 which moderately enhanced transgene expression in CHO-K1 cells.  
In addition to the Gcn5/PCAF family of HATs, there were several inhibitors represented 
from the CBP/p300 family of HATs. Anacardic acid inhibits both PCAF and p300, while 
C646 inhibits p300 only; neither of these inhibitors enhanced transgene expression in 
either cell line.  While the inhibitor of CBP, I-CBP 112 Hydrochloride, very moderately 
enhanced transgene expression in UMUC3 cells, delphinidin (chloride), a CBP/p300 
HAT inhibitor, significantly decreased transgene expression in both cell lines, one of 
only three inhibitors in the library to do so. Taken together, while there are exceptions, 
inhibitors of HAT enzymes in the Gcn5/PCAF family appear to have the potential to 
enhance transgene expression while inhibitors of CBP/p300 HAT enzymes do not 
enhance transgene expression and, in one case, decreases, transgene expression, which is 
more in line with the function of HATs and chromosomal transcription regulation.  
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4.3.1D Histone Methyltransferase (HMT) -  
Methylation of core histone tails by HMT enzymes plays a major role in the 
regulation of gene expression. Inhibitors of several HMT or HMT-complex associated 
enzymes were identified in the screen to affect transgene expression.   
WDR5 is a WD-repeat family protein that is a non-catalytic subunit of trithorax 
(TRX) methyltransferase complexes, including the mixed myeloid leukemia (MLL) 
complex, catalyzing H3K4 methylation [192].  The small molecule inhibitor WDR5-
0103, an inhibitor identified for enhancing transgene expression in both cell lines, has 
been demonstrated to bind with WDR5 and inhibit MLL methyltransferase activity in 
vitro [193].  Interestingly, the H3K4 methylation is a transcriptional activation mark, so it 
is assumed that there may be an off-target effect leading to enhanced transgene 
expression in both CHO-K1 and UMUC3 cells.  WDR5 is overexpressed in bladder 
tissue, and is associated with poor prognosis [194], potentiating a synergistic gene 
therapeutic strategy involving the inhibition of this target.  Another target that has been 
shown to bind with the MLL complex (Menin) is inhibited by MI-2 (under “other”, 
Figure 4.1B and 4.2B); MI-2 demonstrated moderate enhancement in transgene 
expression.  MI-2 has been found to reduce H3K4me3 and H3K79me2 in MLL leukemia 
cells [195]. 
G9a is a HMT that is capable of carrying out monomethyl and dimethyl histone 
transfer at H3K9; these are transcriptional activation or repression marks, respectively.  
BIX01294 hydrochloride and UNC0638 are G9a HMT inhibitors and both resulted in 
moderate transgene expression enhancement in CHO-K1 cells, while imposing no effect 
on UMUC3 cell transgene expression.  Interestingly, other G9a inhibitors UNC0224, 
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UNC0321 trifluoroacetate salt, and UNC0638 did not show up in the screen as enhancers 
in either cell line.    
Enhancer of Zeste Homolog 2 (EZH2) is a specific histone methyltransferase that 
functions as the catalytic unit of the polycomb repressive complex 2 (PRC2).  Within the 
context of PRC2, EZH2 facilitates trimethylation of histone H3, lysine 27 (H3K27me3), 
generally resulting in transcriptional repression [196].  The EZH2 inhibitors GSK343 and 
UNC1999 displayed moderate promise as transgene expression enhancers in CHO-K1 
cells, while they did not have this effect in UMUC3 cells. 
Each of the HMT targets discussed so far in this subsection catalyze methylation 
at lysine sites on histone H3.  Conversely, the enzyme coactivator-associated arginine 
methyltransferase 1 (CARM1) facilitates methylation at an arginine site (H3R17). 
Additionally, CARM1 methylates the p300/CBP HAT, contributing to gene activation 
activity of this HAT [197].  CARM1 was represented by a single inhibitor in the screen, 
Ellagic acid, which resulted in a drastic decline in transgene expression; this behavior is 
consistent with the known gene activation activity of CARM1. 
4.3.1E Histone Demethylase -  
Only one histone demethylase was detected as a promising target in the screen; 
lysine specific demethylase 1 (LSD1) is a demethylase that specifically removes methyl 
groups from lysines H3K4 and in some cases, H3K9.  While only one inhibitor of LSD1, 
2-PCPA hydrochloride, was available in the enzyme library, it led to transgene 
expression enhancement in both cell lines (Figure 4.1B and 4.2B under “histone 
demethylases”).  Another LSD1 inhibitor was purchased from Cayman Chemicals to 
validate LSD1 as a target (Figure 4.5). Demethylation at H3K4 is a repression mark of 
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the histone code, and LSD1 participates as part of the CoREST complex with HDAC1/2 
[198], linking demethylation and deacetylation.  Additionally, LSD1 can demethylate 
H3K9, which can have either a repressive (H3K9me  H3K9) or enhancing (H3K9me2 
 H3K9me) effect on transcription. Both of these lysine sites can also be trimethylated, 
but LSD1 is not capable of demethylating H3K4me3 or H3K9me3.  Interestingly, IOX-1 
and N-Oxalylglycine, which both inhibit jumonji domain histone demethylases, 
responsible for demethylating H3K9me3, did not show promise in enhancing transgene 
expression in the screen. This indicates that the extent of methylation at one or both of 
these sites may play a role in the ability to enhance transgene expression.   
4.3.1F DNA (De)Methylation -  
RSC-133 strongly enhanced transgene expression in both CHO-K1 and UMUC3 
cells.  RSC-133 is a unique inhibitor, in that it has been shown to inhibit both HDAC1 
and DNA Methyltransferase 1 (DNMT1).  Cytosine methylation at promoter sites, carried 
out by DNMT1 as well as deacetylation of histone lysines are generally repressive marks 
on gene expression, and a coordination between these two functionalities is well 
established. Specifically, methylated CpG sites recruit HDACs to repress transcription 
[199] and physical binding between these two enzymes has even been observed [200].  
RSC-133 was found to be more efficient than individual DNMT or HDAC inhibitors in 
reprogramming human somatic cells into pluripotent stem cells [201], a process that is 
carried out by epigenetically forcing expression of several transcription factors.  
Therefore, it is conceivable that the strategy of simultaneously inhibiting class I HDACs 
and DNMT1 could synergistically enhance transgene expression in cases when promoter 
DNA methylation is high, if the same epigenetic mechanisms apply to both chromosomal 
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and transient transgene expression.  Interestingly, synergistic enhancement in transgene 
expression with simultaneous inhibition of RSC-133 appeared to occur in CHO-K1 cells 
(Figure 4.1A), while it did not occur in UMUC3 (Figure 4.2A). In CHO-K1 cells, 
neither HDAC nor DNMT inhibitors drastically enhanced transgene expression, while 
simultaneous inhibition with RSC-133 greatly enhanced transgene expression.  It is 
possible that the cytosine methylation levels of the EF1α promoter driving plasmid 
luciferase expression differs in the nuclei of these two cell lines, although this has not 
been tested.     
Gemcitabine, an inhibitor of Growth arrest and DNA-damage-inducible protein a 
(Gadd45a) [202] drastically reduced transgene expression in both cell lines (Figure. 4.1A 
and Figure 4.2A). As discussed in chapter 1, Gadd45 is expressed in response to DNA 
damage, leading to G2/M arrest, and Kim et al produced a CHO cell line that inducibly 
over-expressed Gadd45, leading simultaneously to G2/M cell cycle arrest and enhanced 
PEI-mediated transgene expression [82].  The use of gemcitabine conversely inhibits this 
protein rather than increasing its expression. The observed decrease in transgene 
expression is in agreement with this study. Epigenetically, Gadd45 overexpression 
increases global DNA demethylation [203], a known activating mechanism for gene 
expression. The observed decrease in transgene expression may be attributable to 
increased plasmid promoter methylation, increased progression through the G2/M 
checkpoint (the opposite effect of transgene expression enhancers such as inhibitors of 
PLK1 and Aurora kinase discussed in chapter 1, which arrest cells in G2/M), or a 
combination of these effects.  
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Sinefungin is a nucleoside which is isolated from Streptomyces griseolus [204], 
and has known inhibitory activity against lysine methyltransferases [205], but also has 
shown activity against DNA methyltransferases [206]. Sinefungin (Figure 4.1B and 
4.2B under “M’transferases (general)”) led to moderate transgene expression 
enhancement in both cell lines.  Despite the leads discussed in this section, the majority 
of DNA methyltransferase inhibitors included in the screen did not increase transgene 
expression, suggesting that this modification in isolation may not be a strong candidate 
for enhancing transient plasmid expression in the cell lines used. 
4.3.1G Other Interesting Inhibitors –  
 Inhibitors of two other targets, hypoxia-inducible factor 1-alpha prolyl 
hydroxylase (HIF-PH) and aurora kinase A, surfaced as interesting candidates from the 
screening (Figures 4.1A and 4.2A).  These targets differ from the above targets because 
they do not carry out functional histone addition or removals with well-characterized 
effects on transcriptional regulation.  HIF1α is a transcription factor that is activated in 
the presence of hypoxia and other stresses, resulting in the expression of certain genes in 
response to these stresses; it is regulated by the oxygen-sensing enzyme, HIF-PH, which 
hydroxylates a proline residue, marking HIF1α for degradation. Inhibition of HIF-PH 
using 2,4-DPD and DMOG drastically enhanced transgene expression in UMUC3 cells, 
while it did not improve transfection in CHO-K1 cells. Because HIF-PH facilitates 
degradation of HIF1α at normoxic conditions, inhibition of HIF-PH is expected to 
maintain relatively high levels of HIF1α.  HIF1α has been found to interact with jumonji-
domain containing histone demethylase proteins (JMJD1A and JMJD2A) which are 
responsible for the removal of tri-methyl groups from Histone H3K9 [207]; it should be 
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reiterated from section 4.3.1E that inhibitors of jumonji-domain containing demethylases, 
however, did not affect transgene expression in the screen.  Also, HIF1α has been 
demonstrated to transcriptionally reduce levels of the class I HDAC, HDAC2, in 
epithelial lung and macrophage cells [208].  As discussed above, HDACs generally 
promote transcriptional repression. The putative repression of HDAC expression due to 
inhibition of HIF-PH with 2,4-DPD and DMOG (and consequently maintenance of 
HIF1α) is consistent with the screening observations, in that HDAC as well as HIF-PH 
inhibitors led to drastic enhancement in UMUC3 transgene expression, but failed to do so 
in CHO-K1 cells, suggesting that the observed enhancement in transgene expression with 
HIF-PH inhibitors may be explained by the same mechanisms driving transgene 
expression enhancement in the presence of HDAC inhibitors.   
Finally, the only inhibitor of Aurora Kinase A (AKA) in the screening, 
phthalazinone pyrazole, resulted in strong enhancement of transgene expression in 
UMUC3 cells.  AKA and the closely related Aurora Kinase B (AKB) have been 
demonstrated to capably catalyze phosphorylation of Histone 3 Serine 10 (H3S10) at the 
onset of mitosis [209], playing a major role in chromosomal segregation. While the 
capability to carry out epigenetic modifications generally corresponding to transcriptional 
regulation such as (de)methylation and (de)acetylation are lacking in the literature for 
AKA, AKB has been demonstrated to facilitate the double histone modification H3K9 
trimethylation and H3S10 phosphorylation both in cells undergoing mitosis, but also in 
post-mitotic cells; this modification is localized at repressed genes in differentiated cells, 
but at both active and silent genes in dividing cells [210], which are representative of the 
cells in the screen. While phthalazinone pyrazole is known to inhibit AKA and not AKB 
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at the concentrations used in the screen, the AKB-specific inhibitor ZM-447439, as well 
as a number of pan-Aurora inhibitors showed up as leads in the screen discussed in 
chapter 2 [106]. This suggests that Aurora Kinase enyzmes (A-C) may all be targets for 
enhancing transgene expression.  While there may be an epigenetic role in this 
phenomenon, inhibition or Aurora Kinase enzymes generally results in cell cycle arrest at 
the G2/M transition, likely playing a major role in the transgene expression enhancement.  
4.3.1H Similarities and Differences Between Epigenetic Regulation of Chromosomal and 
Plasmid Expression 
The findings discussed in the previous subsections of section 4.3 highlight some 
key similarities between endogenous and transgene expression, as well as cases where 
plasmid and chromosomal gene expression may be regulated very differently (Table 4.1).   
Table 4.1 – Epigenetic Enzyme Targets Affect Chromosomal Gene Expression and 
Transgene Expression Similarly in Some Cases and Differently in Others 
Same Effect on 
Endogenous and 
Transgene Expression 
Opposite Effect on 
Endogenous and 
Transgene Expression 
HDAC/Sirtuin HAT (Gcn5/PCAF) 
EZH2 WDR5 
LSD1  
Gadd45  
HAT (CBP/p300)  
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Class I/II HDAC enzymes generally resulted in drastic transgene expression 
enhancement in UMUC3 cells and, with some inhibitors, moderate enhancement in 
CHO-K1 cells.  Several inhibitors of class III HDACs, sirtuins, resulted in transgene 
expression enhancement in CHO-K1 cells and to a lesser extent in UMUC3 cells.  The 
removal of acetyl groups from core histone lysines is generally associated with low 
chromosomal gene expression, and this phenomenon seems to occur with plasmid 
transgene expression.  Inhibition of EZH2 led to moderate enhancement in plasmid 
expression in CHO-K1 cells.  EZH2 is the catalytic unit of the Polycomb repressive 
complex (PRC2), tri-methylating a specific lysine residue on histone H3 at the promoters 
of silenced genes; EZH2 has a known inhibitory effect on chromosomal transcription and 
the screen points to a potentially similar phenomenon for transgene expression.  LSD1 is 
most commonly known to remove mono- and di- methyl groups from histone H3K4, 
leading to transcriptional repression of target genes.  Transgene expression enhancement 
observed with the LSD1 inhibitors 2-PCPA hydrochloride and, to a lesser extent, OG-
L002 (next section) suggest that LSD1 may similarly regulate chromosomal and transient 
gene expression.  Gadd45 inhibition with gemcitabine significantly decreased transgene 
expression.  Gadd45 overexpression promotes DNA demethylation, a known activator of 
transcription.  Also, Gadd45 overexpression promotes cell cycle arrest at the G2/M 
phase, known to be a prime point in the cell cycle for transient gene expression.  Finally, 
while several inhibitors of HAT enzymes surprisingly increased transgene expression, the 
CBP/p300 HAT inhibitor dephinidin (chloride) drastically reduced transgene expression, 
one of only three inhibitors in the screening library to do so.  
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The inhibition of two epigenetic enzyme targets, HAT and WDR5, led to an effect 
on transgene expression opposing their known roles in chromosomal transcription 
regulation.  While the HAT inhibitor Delphindin (chloride) decreased transgene 
expression, consistent with the expected mechanism of HATs and chromosomal 
transcription, multiple other HAT inhibitors unexpectedly increased transgene 
expression.  In addition to the Gadd45 inhibitor gemcitabine and delphindin (chloride), 
the inhibitor of CARM1, ellagic acid, reduced transgene expression.  As discussed in 
section 4.3.1D, CARM1 methylates the CBP/p300 HAT, leading to its activation.  
Therefore, two of the three molecules in the screen that reduced transgene expression 
(dephinidin (chloride) and ellagic acid) directly or indirectly inhibit the activity of 
CBP/p300 HATs.  Taking into consideration that the lead HAT inhibitor identified in the 
screen for enhancing transgene expression (CPTH2 hyrdochloride) targets only the 
Gcn5/PCAF family of HATs, it seems that the family of HAT inhibited plays a major 
role in whether enhancement or reduction in transgene expression is observed. 
WDR5-0103 inhibits WDR5, which is a subunit of the mixed myeloid leukemia 
(MLL) complex which facilitates H3K4 methylation.  This is generally an activation 
mark for transcription, but WDR5-0103 surprisingly increased transgene expression in 
both CHO-K1 and UMUC3 cells.   The explanation for this phenomenon is unknown.  
4.3.2 Select Lead Inhibitor Dose Optimization with Additional Plasmid 
The results outlined in Section 4.3.1 identified several inhibitors of epigenetic 
related enzymes as candidates for enhancing transgene expression in UMUC3 bladder 
cancer cells and/or CHO-K1 cells.  However, local chromatin structure and 
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transcriptional activity are often dependent on the promoter and gene.  Consequently, a 
subset of the lead inhibitors identified in the screen were dose-optimized for their abilities 
to enhance transgene expression with both the pEF-Luc plasmid as well as a second 
luciferase expressing plasmid driven by a different promoter; the pGL3 plasmid with 
luciferase expression under control of the SV40 promoter.  The experiments were carried 
out using the same polymer carrier as used for the screening (Neomycin resorcinol 
diglycidyl ether), and the vehicle-control normalized luciferase expression are shown for 
CHO-K1 cells in Figure 4.4 and UMUC3 cells in Figure 4.5.  In CHO-K1 cells, the 
combination HDAC/DNMT inhibitor (RSC-133), a sirtuin inhibitor (Tenovin-1), a HAT 
inhibitor (CPTH2 hydrochloride), an LSD1 inhibitor (2-PCPA hydrochloride), and the 
WDR5 inhibitor (WDR5-0103) were dose-optimized for transfection enhancement 
efficiency.  While these dose response experiments served the purpose of finding the 
optimal lead inhibitor concentrations for further mechanistic experimental evaluation, it 
is evident based on two independent trials that transgene expression enhancement is not 
highly dependent on promoter (SV40 or EF1α).  As in CHO-K1 cells, the ability of lead 
inhibitors to enhance transgene expression in UMUC3 cells did not appear to depend on 
promoter identity.  The lead inhibitors chosen for dose-optimization with both DNA 
plasmids in UMUC3 cells were a pan nuclear HDAC inhibitor (SB939), a cytoplasmic 
HDAC6 inhibitor (CAY10603), RSC-133, 2-PCPA hydrochloride, and a second LSD1 
inhibitor that was not included in the initial screen (OG-L002).  
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Figure 4.5 Several lead inhibitors from the screening were assayed for their ability to enhance 
transgene expression in UMUC3 cells at additional doses and with a second plasmid, pGL3, containing 
a luciferase gene with expression driven by the SV40 promoter. The original plasmid (pEF-Luc) was 
also included. Transfection efficiencies (n=2) are reported normalized to the vehicle control (0.2% 
DMSO), and normalization to protein and viability are not taken into account 
Figure 4.4 Several lead inhibitors from the screening were assayed for their ability to enhance 
transgene expression in CHO-K1 cells at additional doses and with a second plasmid, pGL3, 
containing a luciferase gene with expression driven by the SV40 promoter. The original plasmid (pEF-
Luc) was also included. Transfection efficiencies (n=2) are reported normalized to the vehicle control 
(0.2% DMSO), and normalization to protein and viability are not taken into account 
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4.3.3 Effect of Epigenetic Enzyme Inhibitors on Plasmid Nuclear Entry 
With the exception of the cytoplasmic activity of a subset of HDACs, the known 
activity of most of the enzymes found to be leads for enhancing transgene expression 
occurs in the nucleus, affecting histone/DNA interactions.  However, it is possible that 
there are off-target effects of inhibiting some of these targets that alter the amount of 
plasmid entering the nucleus, thus increasing transgene expression irrespective of changes 
in putative histone/plasmid DNA particles.  To elucidate this potential phenomenon in our 
systems, several lead inhibitors at their optimal concentrations for enhancing transgene 
expression were introduced to cells which were then transfected with the pGL3 plasmid.  
Following two days of transfection, nuclei were isolated and using primers described in 
chapter 3, qPCR was carried out to quantify relative amount of plasmid inside the nuclei 
of transfected cells, denoted as “FI (fold increase) plasmid nuclear localization".   In CHO-
K1 cells (Figure 4.6), inhibitors of HDAC/DNMT, sirtuins, LSD1, pan-HDAC, and HAT, 
all of which were leads for enhancing transgene expression, did not appear to affect the 
Figure 4.6 pGL3 plasmid enrichment in CHO-K1 nuclear fraction with lead inhibitor + transfection 
treatment, including the pan-HDAC inhibitor SB939, which was not a strong lead in CHO-K1 cells. 
N=2 independent experiments.  Black = 0.2% DMSO (vehicle control); Orange = 50 μM RSC-133; 
Green = 1 μM Tenovin-1; Purple = 200 μM 2-PCPA hydrochloride; Red = 500 nM SB939; Blue = 5 
μM CPTH2 hydrochloride 
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presence of plasmid inside the nucleus.  This suggests that in CHO-K1 cells, the 
mechanistic explanation for plasmid expression enhancement lies at some point following 
nuclear entry, likely involving epigenetic mechanisms. 
In UMUC3 cells (Figure 4.7), drug treatments included a lead pan-HDAC inhibitor 
(SB939), cytoplasmic HDAC6 inhibitor (CAY10603), and LSD1 inhibitor (OG-L002).  
While the LSD1 inhibitor did not affect plasmid presence in target nuclei, both HDAC 
inhibitors increased detectable intact plasmid inside nuclei, likely playing a role in the 
observed enhancement in transgene expression.  We have previously reported increased 
plasmid uptake in two prostate cancer cell lines treated with the nuclear HDAC1/HDAC3 
inhibitor entinostat (chapter 3, [148]).  The increase in nuclear plasmid levels 
accompanying inhibition of HDAC6 is likely related to increased levels of acetylated 
tubulin, previously demonstrated to improve cargo transport toward the nucleus [84, 180].     
With the observation of increased plasmid inside the nucleus of human bladder 
cancer cells and our previous studies in human prostate cancer cells, it seems evident that 
human cancer cells possess an HDAC-regulated mechanism directly or indirectly 
regulating transport of internalized cargo to the nucleus; this mechanism is lacking in 
Chinese Hamster Ovary cells (Table 4.2).  Given the lack of cell lines tested, however, it 
is unclear if this phenomenon is cancer-specific or species-specific (human vs hamster).  
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Table 4.2 – Effect of HDAC Inhibition on Delivered Plasmid Levels in Nuclei of 
Human Cancer Cells vs Chinese Hamster Ovary Cells 
Increase in pGL3 plasmid Nuclear Entry? Yes or No 
  Cell Line 
Cytoplasmic 
HDAC Inhibitor  
Nuclear HDAC 
Inhibitor Source 
Human 
Prostate Cancer 
Cells 
PC3 N/A Entinostat Elmer, 
Christensen, et al. 
Biotech & Bioeng 
2015 PC3-PSMA N/A Entinostat 
Human Bladder 
Cancer Cells UMUC3 CAY10603 SB939 Chapter 4 Study 
(unpublished) 
Hamster Non-
Cancerous Cells CHO-K1 CAY10603 SB939 
Figure 4.7 pGL3 plasmid enrichment in UMUC3 nuclear fraction with lead inhibitor + transfection 
treatment. N=3 independent experiments (primer pair 4 n=2 for SB939). Black = 0.2% DMSO (vehicle 
control); Red = 500 nM SB939; Grey = 1 μM CAY10603; Blue = 40 μM OG-L002. * indicates p<0.05, 
plasmid presence in nuclear fraction relative to vehicle control condition (Student’s T-test) 
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4.3.4 Inhibitor Combinations for Further Enhancement of Plasmid Expression 
 While inhibiting individual epigenetic enzymes has clearly been demonstrated to 
enhance transgene expression, the strategy of inhibiting multiple enzymes at once in 
parallel with detection of luciferase expression is advantageous in two ways: first, there is 
potential for increased enhancement in transgene expression and, second, the results may 
provide hints regarding which mechanisms are independent, redundant, or synergistic.  
Combinations of several inhibitors at 1-3 optimal concentrations were carried out in 
CHO-K1 cells (Figure 4.8).  When not accounting for changes in viability, there is no 
detectable enhancement in transgene expression with HDAC inhibitor (SB939) treatment.  
However, enhancement of transgene expression observed with inhibition of LSD1 using 
500 μM 2-PCPA hydrochloride is amplified by inhibition of HDAC with SB939.  This 
suggests there is synergy between these two processes affecting transient transgene 
expression.  Additionally, the combination of LSD1 enhancement with 2-PCPA 
hydrochloride and EZH2 inhibition with UNC1999 is at least additive in enhancing 
transgene expression in CHO-K1 cells, and may be synergistic with 500 μM 2-PCPA 
hydrochloride and 5 μM UNC1999; individual treatments enhance transgene expression 
by factors of 4.2-fold and 1.4-fold respectively, and the combination yields 7.7-fold 
enhancement.  
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Figure 4.8 Transfections with the NR polymer complexed with the pEF-Luc plasmid were 
carried out in CHO-K1 cells in the presence of single epigenetic inhibitors (top) or dual 
combinations of inhibitors (bottom) at expressed doses. Dual combinations are represented 
by checkers of the two colors corresponding to the individual treatments in the top plot. 
Transfection efficiency is not normalized to viability, but rather expressed as total 
luminescnece normalized to DMSO control transfection. *Student’s T-test, p<0.05 relative 
to DMSO control treatment (top);  + Student’s T-test, p<0.05 relative to both individual 
inhibitor treatment transfections. S = SB939 (nM); P = 2-PCPA Hydrochloride (μM); T = 
Tenovin-1 (μM); U = UNC1999 (μM) 
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Similar inhibitor combination transfections were carried out in UMUC3 cells (Figure 
4.9). HDAC inhibition and LSD1 inhibition, which both increase transgene expression 
individually, additively increased transgene expression when used in combination.  
Figure 4.9 Transfections with the NR polymer complexed with the pEF-Luc 
plasmid were carried out in UMUC3 cells in the presence of single epigenetic 
inhibitors (top) or dual combinations of inhibitors (bottom) at expressed doses. 
Dual combinations are represented by checkers of the two colors corresponding 
to the individual treatments in the top plot. Transfection efficiency is not 
normalized to viability, but rather expressed as total luminescnece normalized 
to DMSO control transfection. *Student’s T-test, p<0.05 relative to DMSO 
control treatment (top); + Student’s T-test, p<0.05 relative to both individual 
inhibitor treatment transfections. S = SB939 (nM); P = 2-PCPA Hydrochloride 
(μM); U = UNC1999 (μM) 
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Combinations involving HDAC/EZH2 and LSD1/EZH2 were not promising for further 
increase in transgene expression.   
 
4.4 DISCUSSION AND CONCLUSIONS 
 The work explained in chapter 4 has identified a number of epigenetic enzyme 
classes that play an activating or repressive role in transgene expression in two cell lines.  
Histone Deacetylase, Lysine Specific Demethylase, and Enhancer of Zeste Homolog 2 
enzymes have well-established roles in repressing transcription by removing or adding 
functional groups to promoters of target genes.  In agreement with these roles in 
chromosomal transcription regulation, inhibitors of these enzymes enhanced transgene 
expression in one or both cell lines.  Inhibition of WDR5 (an MLL methyltransferase 
component) enhanced transgene expression, contrary to its role of activating target genes 
in the chromosome.  Histone acetyltransferase inhibition led to enhancement, reduction, or 
no effect on transgene expression; however, the effect on transgene expression appeared to 
depend on the family of HAT inhibited. 
 One major limitation of the screening experiments was the inclusion of only one 
plasmid, given that epigenetic modifications are often dependent on the promoter driving 
target gene expression.  To gauge the generality of the phenomena observed in the screen, 
dose-response experiments were carried out with select lead inhibitors in each cell line in 
conjunction with transfections using the original screening plasmid (pEF-Luc) and a 
second luciferase plasmid, pGL3 (driven by a different promoter).  These experiments were 
carried out twice and it was evident that the observed enhancement in transgene expression 
occurred regardless of the plasmid (i.e. promoter) used.   
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 Because epigenetic regulation of transcription occurs in the nucleus, it was 
necessary to determine if there were off-target effects of lead inhibitors altering the amount 
of plasmid delivered to the nucleus, changing transgene expression independent of 
epigenetic effects.  The pGL3 plasmid was chosen for transfections, which were carried 
out for 48 hours as with the screen and dose-optimizations.  Following transfections, cell 
nuclei were isolated, DNA purified, and nuclear plasmid quantified using qPCR.  Lead 
inhibitors in CHO-K1 cells did not yield an increase in the presence of plasmid inside target 
nuclei, indicating that the mechanism(s) responsible for enhanced transgene expression 
occurred following nuclear entry.  In UMUC3 cells, however, HDAC inhibition increased 
the levels of plasmid inside transfected cell nuclei, explaining a large portion (although not 
all) of the enhancement in transgene expression.  This was consistent with the studies 
carried out in chapter 3, in which increased plasmid in target prostate cancer cell nuclei 
transfected in the presence of a different HDAC inhibitor was observed.  These data 
suggested that a currently undetermined mechanism by which HDAC inhibition facilitates 
transfected plasmid to more efficiently enter the nucleus in human cancer cells; this 
mechanism was not observed with HDAC inhibition in CHO-K1 cells, which showed only 
a very moderate enhancement in transgene expression with HDAC inhibition in the screen.  
 Finally, several of the lead inhibitors were added in combinations to determine if 
further transfection enhancement was possible.  In CHO-K1 cells, HDAC inhibition with 
SB939 did not enhance transgene expression when not accounting for viability loss (which 
was accounted for in the screening).  However, LSD1 inhibition with 2-PCPA 
hydrochloride, which strongly enhanced transgene expression individually, was rendered 
even more effective when carried out in combination with HDAC inhibition.  This suggests 
98 
 
synergy in the mechanisms of LSD1 and HDAC related to transgene expression 
(hypothesis discussed in chapter 5).  Additionally, the combination of LSD1 and EZH2 
inhibition led to significant further enhancement of transgene expression, with some 
synergy likely occurring (hypothesis discussed in chapter 5). In UMUC3 cells, 
simultaneous inhibition of LSD1 and HDAC resulted in additive, although probably not 
synergistic, enhancement in transgene expression.  This suggests that the mechanisms by 
which LSD1 and HDAC affect transgene expression in UMUC3 cells are not highly linked, 
but rather likely act independently of each other.        
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CHAPTER 5 – SUMMARY AND FUTURE DIRECTIONS 
 The research carried out in chapters 2-4 identified a number of enzymatic targets 
that positively or negatively affect polymer mediated transgene expression in cancer cells 
as well as a biotechnologically relevant cell line, CHO-K1.  Identified targets included 
kinase enzymes that regulate functions from cell cycle regulation to extracellular-
intracellular signal transduction as well as enzymes that regulate functions such as 
histone modifications and hypoxia response.  Mechanistic evaluation of these inhibitory 
targets has elucidated information regarding cell cycle, visual transgene trafficking within 
the cytoplasm, and qPCR quantification of relative transgene levels in the nuclei.   
Current experimentation is seeking to create a more tangible link between the 
regulation of chromosomal gene expression and transgene expression by: 1) assaying for 
the formation of nucleosomes between plasmid DNA and a core histone as occurs with 
native DNA chromatin and 2) determining if known histone modifications in native 
chromatin interact with plasmid DNA.  These ongoing experiments are discussed in 
Future Direction 1.   
 
5.1 FUTURE DIRECTION 1 – PLASMID-HISTONE INTERACTION 
QUANTIFICATION 
5.1.1 Introduction 
 As discussed in chapters 3 and 4, chromatin structure and transcriptional activity 
are regulated by a number of post-translational modifications, such as acetylation and 
methylation, on core histones. These post-translationally modified histones typically 
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interact with the promoter region of the regulated gene, but can also interact with DNA 
upstream or downstream of the promoter.  While the formation of chromatin with 
endogenous DNA in eukaryotic cell nuclei is well understood, the formation of plasmid 
DNA/histone “chromatin” is not well established within the cell.  There are numerous 
examples of nucleosomal DNA/histone particles composed of foreign DNA forming 
outside of the cell or in cell free assays, but less evidence of exogenous DNA forming such 
particles inside of a transfected cell; however, a study performed by Russev et al in 2009 
suggested that transfected plasmid DNA can form nucleosome-like particles in HEK 293 
cells following double strand break-induced linearization [143].  While this study used 
micrococcal nuclease treatment to form nucleosome-like particles before running a DNA 
gel to compare the DNA fragment size profile with a chromatin ladder, a stronger argument 
for the formation of plasmid/histone particles is to directly assay the interaction using 
chromatin immunoprecipitation (ChIP).    
 ChIP is a procedure using immunoprecipitation to isolate a desired protein with its 
complexed nucleic acid components and either subsequent massive DNA sequencing to 
determine which DNA sequences in a genome interact with this protein (ChIP-seq) [211] 
or subsequent qPCR (ChIP-qPCR) [212] with a specific set of primers to determine if and 
to what extent the protein of interest interacts with specific known DNA sequences (ChIP 
discussion henceforth will refer to ChIP-qPCR).  ChIP can be conducted in two different 
modes. The first mode, termed Native ChIP (N-ChIP) involves immunoprecipitation of 
chromatin in its native state, directly retrieved from cells or tissue, without cross-linking 
chromatin protein and DNA.  Chromatin is then treated with micrococcal nuclease 
(MNase) to cut particles into mono-, di-, tri-, etc nucleosomes (depending on MNase 
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treatment concentration and time).  Following immunoprecipitation of proteins, DNA can 
be isolated from its interacting proteins for final qPCR analyses using phenol:chloroform 
extraction followed by ethanol precipitation. The second method for carrying out ChIP 
involves cross-linking of DNA and protein within chromatin with paraformaldehyde, and 
is referred to as X-ChIP. Following cross-linking, chromatin is sonicated, yielding a size 
distribution of nucleosome particles (mono-, di-, tri-, etc) depending on the sonication time.  
After completing the subsequent immunoprecipitation, protein-DNA cross-links are 
reversed and DNA is purified for qPCR analyses.   
 X-ChIP and N-ChIP each possess advantages and disadvantages, and these must be 
weighed when considering the application.  N-ChIP is advantageous in that the avoidance 
of cross-linking evades the isolation of DNA sequences non-specifically interacting with 
the protein of interest.  Additionally, antibody specificity and efficiency are generally 
tested against unfixed proteins by Western blot, so antibody efficiency for N-ChIP is better 
predicted by antibody testing than for X-ChIP, which can damage the epitope with 
paraformaldehyde treatment [213].  However, nucleosomal rearrangements may occur 
during the process of N-ChIP in the absence of cross-linking [213], a problem which is 
generally avoided with X-ChIP.  
 Experiments in Future Direction I, which are currently underway, are directed 
toward determining if exogenously delivered plasmid DNA interacts with a core histone 
using N-ChIP (experiment 1), and determining if lead epigenetic inhibitors facilitate 
interactions of plasmid DNA with specific functionally marked (methylation, acetylation) 
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core histones that are generally associated with transcriptionally active chromatin using X-
ChIP (experiment 2). 
 
5.1.2 Experiment 1 – Endogenous Histone H3 Interaction with Transfected Plasmids 
5.1.2A Hypothesis – 
 The first experiment in Future Direction 1 will be the use of ChIP to detect any 
intracellular interactions between Histone H3 and the two luciferase reporter plasmids used 
in Chapter 4 (pEF-Luc and pGL3).  Because the purpose of this experiment is to detect if 
any measurable interaction is occurring, it is important that any signal picked up with qPCR 
is due to specific histone/DNA interactions.  For this reason, N-ChIP, as opposed to X-
ChIP, will be used for this experiment in an effort to avoid non-specific cross-linking of 
proximal histone and DNA not interacting with each other.  It is hypothesized that ChIP-
qPCR will detect a statistically significant increase in plasmid signal when 
immunoprecipitation is carried out with a Histone H3 antibody relative to a negative 
control (IgG) antibody using the fold-enrichment method of quantification, indicating 
intracellular histone-plasmid interaction. 
5.1.2B Experimental Plan and Anticipated Results–  
 Polymer-mediated transfections will be carried out similarly to those conducted in 
chapter 4 with the neomycin-resorcinol diglycidyl ether (NR) polymer complexed with the 
pEF-Luc and the pGL3 plasmids in both CHO-K1 and UMUC3 cells.  However, 
transfections will be scaled up from 96- and 24-well plate formats to a 6-well plate format 
in order to increase the number of cells to meet ChIP requirements. Following 48 hours of 
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transfection, cells will be trypsinized and washed once with 1X PBS.  Cell preparation for 
N-ChIP will then be carried out following a modified protocol combining components of 
two established N-ChIP protocols (Figure 5.1) [213, 214]. Briefly, sucrose gradient 
separation will be used in parallel with cell lysis to extract nuclei of targeted cells.  Nuclei 
will then be subjected to MNase treatment at the optimally found treatment time (6, 9, 12, 
and 15 minutes will be tested).  The goal is to obtain a distribution of nucleosomes with a 
detectable mononucleosomal band.   Subsequently, the enzymatic cleavage of nucleosomal 
Figure 5.1 General Native ChIP (N-ChIP) protocol to be followed in order to quantify 
transfected pEF-Luc and pGL3 plasmid interaction with a core histone in nuclei of CHO-K1 
and UMUC3 cells 
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DNA will be halted, and a centrifugation step will be carried out.  The supernatant, rich in 
small nucleosomes (eg. mono- and di-nucleosomes), will be isolated and saved (S1 
fraction).  The pellet, rich in heavier nucleosome oligomers, will be resuspended and 
further purified by dialysis and centrifugation (supernatant S2 fraction); the pellet will be 
saved and also gauged by gel electrophoresis for the presence of large nucleosomal 
particles.  The chromatin fraction(s) richest in mono-,di-, and tri-nucleosomes will be 
treated with an anti-Histone H3 antibody (Cell Signaling #4620); a negative control 
antibody (IgG) will also be used for an immunoprecipitation for normalization in the fold-
enrichment calculation following qPCR.  Using Protein A(G)-conjugated beads, which 
recognize the antibodies, antibody-bound chromatin will be separated from the unbound 
chromatin via centrifugation steps; unbound and bound fractions will both be saved.  
Following several wash steps of the bound fraction, the chromatin will be eluted from the 
beads, and subsequently DNA will be separated from the protein components of chromatin 
(including histones) via phenol:chloroform:iaa extraction and ethanol precipitation.  qPCR 
analyses will then be carried out using the SYBR Green detection system (Roche) to 
quantify fold-enrichment of plasmid sequence-specific signal relative to the negative 
control IgG antibody.  
 While promoter sites are common targets for histone interactions, histones can 
interact with DNA regions upstream of the promoter and even on or downstream of 
regulated genes.  Therefore, primers must be designed to detect histone-plasmid 
interactions at many sites over the plasmid to assure an exhaustive probing for histone-
plasmid nucleosomes.  Many primers have been designed and purchased to detect these 
interactions via ChIP-qPCR, and they are illustrated in Figure 5.2.    
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 Quantification of qPCR signal will be carried out by comparison of Ct values, using the 
formula 2^ΔCt to calculate fold-change in signal between the Histone H3 antibody 
immunoprecipitation (IP) and the negative control IgG IP.  It is anticipated that the Histone 
H3 IP reaction will generate a stronger qPCR signal than the negative control IgG IP for at 
least one set of primers, indicating specific interaction between Histone H3 and transfected 
plasmid.     
5.1.3 Experiment 2 – Association of Transcriptionally Active Histone Marks with Plasmid 
in Presence of Single and Dual Inhibitor Combination Treatments 
5.1.3A Hypothesis –  
While Experiment 1 aims to determine if transfected plasmid DNA interacts with 
target cell core histones, forming nucleosome-like particles, Experiment 2 is designed to 
elucidate the pattern of plasmid interaction with modified histones in the presence of lead 
epigenetic enzyme inhibitors.  The experiments outlined in this section go beyond the 
question from experiment 1 of “do histones and delivered plasmid DNA interact in the 
nucleus?” and seek the answer to “how do they interact, and how do these interactions 
regulate plasmid transcription?”  As discussed in chapters 3 and 4, core histones marked 
Figure 5.2 Primer amplicon regions for detection of pEF-Luc/histone and pGL3/histone interactions 
using ChIP-qPCR are roughly shown by brackets  
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with particular functional groups on specific amino acid residues are more commonly 
found in chromatin regions of high transcription (euchromatin) than in regions of silenced 
genes (heterochromatin).  To determine if similar mechanisms regulate plasmid expression, 
polymer-mediated plasmid transfections will be carried out in CHO-K1 cells in the 
presence of lead inhibitors in the manner discussed in section 5.1.3B. 
In chapter 4, inhibitors of HDAC, LSD1, and EZH2 were each discovered to 
enhance transient plasmid expression in at least one of the two cell lines included in the 
small molecule epigenetics inhibitor screening. In subsequent experiments, dual inhibitor 
combinations of these targets were introduced to plasmid-transfected cells (chapter 4).  
Interestingly, in CHO-K1 cells, combinations of HDAC and LSD1 inhibition resulted in 
synergistic enhancement in plasmid expression; this phenomenon also appeared to occur 
with combinatorial LSD1 and EZH2 inhibition in CHO-K1 cells. In UMUC3 cells, 
combinations of HDAC and LSD1 inhibitors resulted in additive enhancement in plasmid 
expression, but synergy did not appear to be present.  However, enhancement in plasmid 
expression with individual target inhibition was different in the two cell lines. In UMUC3 
cells, HDAC inhibition drastically enhanced transgene expression while very little 
enhancement was observed in CHO-K1 cells.  In UMUC3 cells, EZH2 inhibition did not 
enhance transgene expression; however, in CHO-K1 cells enhancement was observed.  
LSD1 inhibition resulted in enhanced expression in both cell lines.  These cell line 
differences in the propensity of plasmid expression to be enhanced by inhibitors of these 
epigenetic enzymes suggests that epigenetic regulation may differ due to differences in 
pathways, or possibly in expression or activity levels of downstream targets.  The 
synergistic enhancement of transgene expression observed with dual enzyme inhibition in 
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CHO-K1 cells, however, suggests that these other pathway members may indeed be the 
other inhibited enzyme; in other words, inhibition of one target (eg. LSD1) may affect the 
activity of the other target (eg. HDAC or EZH2).  There are instances of this indeed being 
the case, as many enzyme-induced epigenetic marks on histones are facilitated by the 
cooperation of other enzymes placing other marks at another site. 
HDAC1 and LSD1 are both eraser enzymes that catalyze the removal of a 
functional group from core histones, promoting transcriptional silencing of local target 
genes.  HDAC1 removes acetyl groups from a number of histone lysine residues, while 
LSD1 primarily removes methyl groups from di- or mono-methylated histone H3 lysine 4 
(H3K4me2 or H3K4me). However, LSD1 and HDAC1 are mutually present in 
transcriptionally repressive complexes containing the protein CoREST [215].  In a 2005 
study that identified an LSD1-CoREST-HDAC1 complex by MS/MS, it was found that 
LSD1-CoREST-mediated H3K4 demethylation in HeLa cell-isolated nucleosomes was 
reduced 4-fold when they were first hyperacetylated by treatment with an HDAC inhibitor 
[198], suggesting synergistic cooperation between HDAC and LSD1 activity.  
Additionally, a 2013 study demonstrated a two-way cooperation between HDAC1 and 
LSD1 in embryonic stem cells and embryonic carcinoma cells; in this study, inhibition of 
either HDAC1 or LSD1 increased both the acetylation of H4K16 (HDAC target) and 
methylation of H3K4 (LSD1 target) in pluripotent systems (although the same behavior 
was not observed in tested non-pluripotent systems) [215].  Given the synergistic nature by 
which simultaneous inhibition of LSD1 and HDAC were found to enhance transgene 
(plasmid) expression in CHO-K1 cells (Figure 4.8) and the known complexation of LSD1 
and HDAC, it is hypothesized that 1) individual inhibition of LSD1 and HDAC inhibition 
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in pEF-Luc plasmid transfected CHO-K1 cells will increase the interaction of H3K4me2- 
and H3K9ac-marked Histone H3, respectively, with pEF-Luc isolated from cell nuclei and 
2) combined inhibition of HDAC and LSD1 will further increase pEF-Luc association with 
H3K4me2 due to hyperacetylation-induced sensitization of nucleosomes to H3K4me2.  
While acetylation of H3K9ac is one of many HDAC1 targets to choose from, it was 
selected because HDAC inhibition with SB939 has already been verified to drastically 
increase H3K9ac in CHO-K1 by Western blot in the laboratory (Appendix V, Figure A4).   
A second combination of enzyme inhibitors identified to potentially induce 
synergistic transgene expression enhancement in CHO-K1 cells (Figure 4.8) was LSD1 
and EZH2.  While HDAC1 and LSD1 are known to interact in a number of complexes with 
the protein CoREST, EZH2 and LSD1 are physically tethered by a long intergenic 
noncoding RNA (lincRNA), HOTAIR (Figure 5.3).  HOTAIR has been demonstrated to 
not only physically link the EZH2-containing PRC2 complex and the LSD1-CoREST 
Figure 5.3 The lincRNA, HOTAIR, tethers the epigenetic silencing enzymes LSD1, which promotes 
H3K4 demethylation, and EZH2, which catalyzes H3K27me3.  HOTAIR assists in targeting these 
enzymes to their enzymatic sites, likely facilitating simultaneous transcriptional repressive histone 
marks on target gene promoters 
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complex, but also to target these enzymes to their respective functionalization target sites 
(H3K27 and H3K4) promoting these functional transcriptional silencing transfers on 
HOXD loci [216].  While this hasn’t been explicitly demonstrated, one hypothesis is that 
the binding of active LSD1 to its target site promotes binding of PRC2/EZH2 to its target 
site via HOTAIR and vice versa, therefore promoting synergistic silencing of target genes. 
If inhibition of one of these two enzymes in any way obstructs targeting of the other enzyme 
by HOTAIR, synergistic enhancement in transcriptional activation would be expected for 
target genes.  Given the synergy in plasmid expression observed in CHO-K1 cells with 
LSD1 and EZH2 inhibitors and this dual enzymatic targeting by HOTAIR, it is 
hypothesized that dual inhibition of LSD1 with 2-PCPA hydrochloride and EZH2 with 
UNC1999 will increase the association with plasmid promoter regions of H3K4me2 above 
and H3K27me3 below levels observed with either individual inhibitor treatment.  While it 
will not be tested, silencing of HOTAIR transcription may be a strategy to enhance 
polymer-mediated transgene expression by interrupting linked EZH2-LSD1 targeting to 
gene promoters. 
5.1.3B Experimental Plan and Anticipated Results – 
 Neomycin resorcinol diglycidyl ether polymer-mediated transfections of the pEF-
Luc plasmid will be carried out in the absence of enzyme inhibitors, in the presence of 
individual inhibitors, or with the dual inhibitor combinations discussed in section 5.1.3A.  
Following 48 hours, cross-linking ChIP (X-ChIP) will be carried out to quantify levels of 
plasmid/histone interactions.   In the experiments outlined in section 5.1.2, Native ChIP (N-
ChIP) was proposed to detect whether plasmid-histone interactions occur in the nuclei of 
transfected cells; N-ChIP, due to the absence of a cross-linking reaction, does not detect 
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non-specific interacting molecules, a very important characteristic when trying only to 
detect if an interaction is occurring at all.  However, the experiments outlined in this section 
are designed to be carried out under the assumption that there are histone-plasmid 
interactions occurring in transfected cells.  X-ChIP is a better-established method than N-
ChIP and cross-linking provides certain advantages, mainly the avoidance of nucleosome 
rearrangements during sample preparation. 
 The general X-ChIP procedure to be followed for quantification of histone-plasmid 
interactions is illustrated in Figure 5.4. Briefly, following 48 hours of transfection, media 
and inhibitors will be removed from cells and replenished with fresh media to avoid any 
drug interference with the paraformaldehyde (PFA) cross-linking reaction.  Histone and 
DNA (which includes chromosomal as well as plasmid) will be cross-linked for 10 minutes 
with 1% PFA. Following reaction quenching with glycine and washes, cells will be 
detached from their plates by scraping.  Sonication will then be carried out in lysis buffer 
for several different times to optimize this step. Following sonication, supernatant from 
each sample (each sonicated for a different amount of time) containing chromatin of 
different sizes will be collected.  Once sonication optimization is complete, chromatin 
sonicated for the optimal amount of time will be incubated with one of several antibodies.  
For experiments containing HDAC inhibitor, LSD1 inhibitor, or the combination, 
immunoprecipitations (IPs) will be conducted using an H3K9ac antibody, H3K4me2 
antibody, a second antibody detecting a common histone acetylation mark (H4K16), and 
111 
 
IgG.  For transfections in the presence of LSD1 inhibitor, EZH2 inhibitor, or the 
combination, IPs will be done with H3K4me2, H3K27me3, and IgG antibodies.  As with 
the N-ChIP procedure, immuno-linked chromatin will be incubated with protein A(G)-
conjugated beads.   Following washes, chromatin will be eluted from the beads and the 
protein-DNA cross-links reversed, protein degraded with proteinase k, DNA extracted, and 
histone-DNA interactions quantified via qPCR detection.  The percent input method will 
be used, with the pure chromatin isolated following sonication and centrifugation used as 
the positive control.  qPCR signals from all IPs will be expressed as a percentage of this 
Figure 5.4 General cross-linking ChIP (X-ChIP) protocol to be followed in order to quantify 
transfected pEF-Luc plasmid interaction with un-modified and modified histone H3 and modified 
histone H4 in nuclei of CHO-K1 cells 
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input sample.  For qPCR detection, the same primer pairs shown for the pEF-Luc plasmid 
in Figure 5.2 will be used. 
 It is anticipated that X-ChIP experiments will reveal interesting mechanistic 
information about epigenetic regulation of plasmid expression.  Regardless of ChIP results 
with inhibitor combination experiments, if individual inhibitor treatments increase plasmid 
association with the hypothesized marked histones, this evidence will point to some 
similarities between epigenetic transcriptional regulation of chromosomal and exogenously 
delivered plasmid.  If ChIP results on combination-inhibited samples provide evidence 
supporting the hypotheses proposed in this section, it will not only further substantiate the 
proposition that transgene and chromosomal expression are regulated by similar epigenetic 
mechanisms, but will supply a more thorough general understanding of the mechanisms 
behind epigenetic transcriptional repression by the addition of a new system on which 
histone writer and eraser enzymes and their marked histones function. 
 
5.2 FUTURE DIRECTION 2 – PATHWAY ARTICULATION IN REGULATION OF 
TRANSGENE EXPRESSION - SYSTEMS BIOLOGY 
 
 While Future Direction 1 highlighted a specific set of experiments focusing on 
understanding histone-plasmid interactions inside the nuclei of transfected cells, Future 
Direction 2 is a suggested broad perspective to take on the field of polymer-mediated 
transgene expression and, more vaguely, gene delivery in all forms, including viral and 
non-viral, transient and stable.  The findings in chapters 2-4 illuminated numerous targets 
affecting transient gene expression.  As more knowledge about gene delivery and 
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expression is accumulated, such as the targets and mechanisms described in the previous 
chapters, the ability to solve the puzzle of how a target cell can be modulated to control 
transgene expression will be on the horizon.  The first step in understanding this 
extremely complex puzzle is to identify individual targets; many were identified in this 
thesis and many more will be identified in the future.  The second step, which should be 
executed in parallel, is to connect these targets using a systems biology approach: are 
these targets completely independent of each other? It is unlikely that they are.  The work 
in this thesis took small steps in that direction by carrying out transfections in the 
presence of multiple target inhibitors simultaneously, and proposed specific experiments 
seek to understand how epigenetic enzymatic targets may functionally coordinate with 
each other to regulate transient gene expression.  Others have also begun applying a 
systems biology approach to understanding this complex puzzle [217].  
 This approach can be vastly improved by avoiding the classification of enzymes 
based on their most obvious function.   For instance, Gadd45 proteins (discussed briefly 
in chapters 1 and 4) can be activated in response to DNA damage.  They are known to 
promote global DNA demethylation, but they eventually promote G2/M cell cycle arrest.  
Overexpression of this protein has been shown to enhance polymer-mediated transgene 
expression (and inhibition found to decrease it in the epigenetic inhibitor screening in 
chapter 4).  While DNA methylation is a known transcriptional repressor, G2/M cell 
cycle arrest is generally regarded as the optimal phase for transient gene expression, so it 
is not obvious to which phenomenon this is attributable; perhaps DNA methylation and 
cell cycle arrest are not completely independent of each other.  
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 An example of an enzyme that may have multiple implicit effects on transgene 
expression is PLK1.  PLK1, as has been covered in depth in chapter 2, is a very potent 
regulator of the cell cycle at the G2/M checkpoint, driving cells into mitosis, with its 
inhibition arresting cells at this transition.  However, within the wake of carrying out its 
cell cycle functions, PLK1 affects other functions that could very well alter transgene 
expression.  For example. PLK1 phosphorylates vimentin, leading to the restriction of 
endosomal fusion upon mitotic entry [218].  Endosomes continually fuse along the 
endolysosomal pathway and the continued allowance of endosomal fusion accompanying 
inhibition of PLK1 may play a role in the intracellular trafficking of internalized 
transgenes and, ultimately, in transgene expression.  However, PLK1 has recently been 
found to positively regulate the formation of acetylated (i.e. stable) microtubules through 
phosphorylation of kindlin 1, a negative regulator of HDAC6 [219].  As we and others 
have found (previously discussed), stable, acetylated microtubules through HDAC6 
inhibition improve transgene cargo trafficking along microtubules toward the nucleus and 
enhance transgene expression.  Because PLK1 inhibition in this case would counter the 
effects of HDAC6 inhibition, it is likely that this combination strategy would yield poor 
results on transgene expression efficacy.   
 An example of an off-target epigenetic effect potentially improving transgene 
expression is with HDAC inhibition.  HDAC inhibition using trichostatin in colorectal 
cancer cells has been revealed to activate transcription of Suppressors of Cytokine 
Signaling (SOCS) genes by promoter hyperacetylation. Because these gene products are 
negative regulators of the JAK/STAT pathway, JAK2/STAT3 signaling was ultimately 
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downregulated with HDAC inhibition [220].  As discussed in chapter 2, JAK2 inhibition 
was found to enhance transgene expression and class I/II HDACs inhibition also 
enhances transgene expression.  As displayed in Figure 3.7, JAK2/STAT3 inhibition 
using the drug AG490 enhanced 1,4C-1,4Bis-mediated transgene expression 9.2-fold and 
HDAC inhibition with Entinostat enhanced it 15.4-fold; while the combination of these 
two drugs enhanced transfection 34.9-fold, greater than either individual inhibitor, if 
these two pathways were acting entirely independently of each other, the combination 
treatment likely would have yielded much greater enhancement.  It’s possible that 
inhibition of class I/II HDAC in combination with JAK2 inhibition was slightly 
redundant in that a portion of HDAC’s mechanism behind transgene expression 
enhancement may be to inhibit the JAK pathway through SOCS activation.   
 These are a just a few of countless examples demonstrating that while identifying 
molecular targets that affect gene delivery and expression is absolutely necessary, it is 
nowhere near sufficient for solving the puzzle.  Significant progress was made in the 
experiments completed in the previous chapters as well as by many other researchers.  
This work has begun to and continues to set the foundation for building a thorough 
understanding of not only the identified transgene expression protein targets and their 
molecular mechanisms, but what these mechanisms do physically to impose a certain fate 
on intracellular transgene cargo.  The mammalian cell is not simply a black box with a 
linear response upon an inhibitory perturbation, but rather it’s an amalgamation of many 
functioning pathways that affect each other mutually or through interference, and how 
these functions affect transgene expression requires a continued persistent effort and 
likely a systems biological approach. 
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Table A1 – Abbreviated/full names for the kinase targets of all 182 kinase 
inhibitors, along with some of the reported functions of each kinase 
Kinase Target Kinase Function Inhibitors Used 
Akt 
(Protein Kinase B) 
Metabolism, apoptosis, cell 
proliferation, transcription, cell 
migration 
MK-2206 
CCT128930 
A-674563 
AT7867 
Gefitinib 
ALK 
(Activin Receptor Like Kinase) 
Activates transforming growth factor- 
family proteins 
NVP-TAE684 
SB 431542 
SB 525334 
PF-2341066 
ATM  
(Ataxia telangiectasia mutated kinase) 
DNA damage repair 
KU-55933 
KU-60019 
NU7441 
Aurora Cell division/proliferation 
TAK-901 
AZD1152-HQPA 
MLN8237 
ZM-447439 
Aurora A Inhibitor I 
VX-680 
CCT129202 
Hesperadin 
AMG 900 
PHA-680632 
SNS-314 Mesylate 
JNJ-7706621 
PHA-739358 
ENMD-2076 
AT9283 
CYC116 
KW 2449 
AZ960 
Bcr-Abl Kinase 
Cell differentiation, division, adhesion, 
and stress responses 
Nilotinib 
PHA-739358 
AT9283 
KW 2449 (ABL) 
Dasatinib (Abl) 
AZD-0530 (ABL) 
DCC-2036 
WP1130 
BMP  
(Bone Morphogenic Protein Kinase) 
Signal transduction, specifically WNT 
repression, apoptosis 
LDN193189 
B-Raf 
Signal transduction and cell 
growth 
PLX-4720 
ZM 336372 
BAY 73-4506 
Caspase  VX-765 
CDK 
(cyclin dependent kinase) 
Cell division, transcription, mRNA 
processing, cell differentiation 
Flavopiridol HCl 
Flavopiridol Alvocidib 
AZD5438 
AT7519 
BS-181 HCl 
Roscovitine 
PHA-793887 
SNS-032 
PD0332991 
JNJ-7706621 
Mubritinib 
CHK  Initiation of mitosis AZD7762 
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(Checkpoint Kinase 1) LY2603618 
c-Kit Cell proliferation 
Imatinib Mesylate 
Masitinib 
OSI-930 
BAY 73-4506 
Ki8751 
Vatalanib 
Telatinib 
c-Met  
(Hepatocyte growth factor receptor) 
Embryonic development and wound 
healing 
SGX-523 
SU11274(PKI-SU11274) 
PF-04217903 
JNJ-38877605 
BMS 777607 
PF-2341066 
XL184 
XL880(GSK1363089) 
MGCD-265 
BMS 794833 
DNA-PK  
(DNA dependent protein kinase) 
DNA repair 
PP121 
NU7441 
EGFR  
(Endothelial Growth Factor Receptor) 
Cell Proliferation 
Apatinib 
Erlotinib Hydrochloride 
WZ3146 
WZ4002 
PD153035 HCl 
OSI-420 
WZ8040 
Gefitinib(Iressa) 
AEE788 
Lapatinib Ditosylate 
BMS-599626 
BIBW2992(Tovok) 
AG-490 
Mubritinib 
AZD8931 
CI-1033 
FAK  
(Focal Adhesion Kinase or PTK2) 
Cell adhesion and migration PF-562271 
FGFR  
(fibroblast growth factor receptor) 
Cell proliferation and differentiation 
BIBF1120(Vargatef) 
Masitinib 
TSU-68 
FLT-3  
(FMS-like tyrosine kinase 3) 
Cell development 
AC-220 
TG101209 
KW 2449 
Sunitinib Malate 
ENMD-2076 
XL184 
BMS 794833 
GSK-3  
(glycogen synthase kinase 3) 
Cell proliferation, migration, 
inflammation, glucose regulation, 
apoptosis 
CHIR-99021 
Indirubin 
SB 216763 
HER2  
(Human epidermal growth factor 
receptor 2) 
Cell proliferation, anti-apoptosis 
CP-724714 
Neratinib 
CI-1033(Canertinib) 
AEE788 
Lapatinib Ditosylate 
BMS-599626 
BIBW2992 
AZD8931 
IGF-1R  
(Insulin-like growth factor receptor 1) 
Cell survival and proliferation 
GSK1838705A 
NVP-ADW742| 
JAK  
(Janus Kinase) 
Signal Transduction (STAT  
transcription factor activation) 
LY2784544 
NVP-BSK805 
CP-690550(Tofacitinib) 
138 
 
Cyt387 
AZD1480 
AZ 960 
AT9283 
AG-490 
TG101209 
JNK  
(c-Jun N-terminal Kinase) 
Stress response, differentiation, 
apoptosis 
SP600125 
MEK  
(MAP kinase kinase) 
Signal transduction, growth regulation 
TAK-733 
GSK1120212 
PD0325901 
U0126-EtOH 
CI-1040 (PD184352) 
AZD8330 
BIX 02189 
AZD6244(Selumetinib) 
AS703026 
Mtor  
(mammalian target of rapamycin) 
Cell growth, proliferation, migration, 
survival, protein synthesis, 
transcription 
WYE-354 
WYE-687 
OSI027 
WAY-600 
PP242 
AZD8055 
KU-0063794 
WYE-125132 
Rapamycin(Sirolimus) 
Everolimus(RAD001) 
Deforolimus(MK-8669) 
PF-04691502 
GDC-0980 
PKI587 
NU7441 
PP121 
GSK1059615 
BEZ235 
PI-103 
p38 MAPK  
(p38 mitogen-activated protein kinase) 
Stress responses, cell differentiation, 
apoptosis, autophagy 
PH-797804 
BIRB 796 
SB 203580 
SB 202190 
LY2228820 
VX-745 
VX-702 
Vinorelbine(Navelbine) 
PDGFR  
(Platelet derived growth factor receptor) 
Cell proliferation, differentiation, 
growth, and development 
Crenolanib (CP-868569) 
Imatinib Mesylate 
Masitinib 
KI8751 
PP121 
Bibf1120 
Sunitinib Malate 
ABT-869 
Ap24534 
AV-951 
Imatinib 
TSU-68 
Sorafenib Tosylate 
Motesanib Diphosphate 
Telatinib 
PI3K  
(phosphoinositide 3-kinase) 
Cell growth, proliferation, 
differentiation, motility, survival, 
intracellular trafficking 
AS252424 
TGX-221 
PIK-75 Hydrochloride 
PIK-293 
PIK-93 
PIK-90 
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GDC-0941 
TG100-115 
AS604850 
AZD6482(PI3-kinase β inhibitor) 
AS-605240 
IC-87114 
XL765 
ZSTK474 
GSK2126458 
BKM-120 
CAL-101 
PIK-294 
A66 
GSK1059615 
BEZ235 
PI-103 
Pf-04691502 
Gdc-0980 
Pki587 
PKC  
(protein kinase c) 
Regulating signal transduction and 
transcription 
CX-4945 
Enzastaurin 
PLK  
(polo-like kinase 1) 
Cell cycle progression 
ON-01910 
HMN-214 
GSK461364 
BI 2536 
BI6727 
S6 Kinase  
(ribosomal s6 kinase 
Regulates transcription AT7867 
SRC 
Cell differentiation, motility, 
proliferation, and survival 
PCI-32765 
KX2-391 
Bosutinib(SKI-606) 
Dasatinib 
AZD0530(Saracatinib) 
DCC-2036 
ENMD-2076 
Vandetanib 
Motesanib 
NVP-BHG712 
Syk  
(spleen tyrosine kinase) 
Cell to cell communication 
R935788 
R406 
R406(free base) 
Tgf- Cell growth Sb 525334 
Tie2  
(TEK tyrosine kinase) 
Cell to cell communication 
XL184 
MGCD-265 
VEGFR  
(vascular endothelial growth factor 
receptor) 
Cell division and migration, 
microvascular permeability 
Pazopanib Hydrochloride 
Cediranib(AZD2171) 
KRN 633 
Axitinib 
Vatalanib 
BMS 794833 
Vandetanib 
AP24534 
AV-951(Tivozanib) 
Imatinib(STI571) 
TSU-68 
Sorafenib Tosylate 
Motesanib Diphosphate 
NVP-BHG712 
Telatinib 
CYC116 
OSI-930 
BAY 73-4506 
KI8751 
XL880 
MGCD-265 
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Table A2 – Effects of all 182 Kinase inhibitors on luciferase expression relative to 
the control (no drug) in PC3-PSMA cells  
*Statistically different than Polyplex/DMSO control (p <0.05) 
Poly/DNA (w/w) = 10:1, Conc. =     10xIC50, n=5 
 
Drug Ave StD 
BI6727 12.42 13.80 
*BI 2536 12.29 5.25 
*GSK461364 9.90 4.78 
*HMN-214 9.49 8.26 
Bosutinib(SKI-606) 6.64 10.96 
AG-490 6.43 10.66 
PD0332991 6.05 5.59 
SNS-314 Mesylate 5.97 6.07 
Imatinib Mesylate 5.31 4.67 
*Vinorelbine(Navelbine) 4.87 2.54 
VX-702 4.82 4.05 
PHA-680632 4.40 5.53 
KW 2449 4.38 4.09 
NVP-ADW742| 4.36 5.87 
*SNS-032(BMS-387032) 4.13 2.37 
KX2-391 3.97 4.37 
Neratinib 3.79 4.42 
*AS703026 3.56 2.33 
AMG 900 3.37 5.39 
*BMS 777607 3.32 1.97 
Hesperadin 3.30 2.48 
CCT129202 3.28 3.14 
*ON-01910 3.24 1.46 
*AT9283 3.24 1.35 
*VX-680 3.02 1.91 
WP1130 2.93 4.70 
*CI-1033(Canertinib) 2.71 0.93 
PKI587 2.70 4.42 
*AC-220 2.69 1.34 
*XL184 2.65 0.67 
AZD1480 2.65 2.99 
AEE788 
BIBF1120 
Sunitinib Malate 
ABT-869 
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*Aurora A Inhibitor I 2.62 0.82 
Deforolimus(MK-8669) 2.60 1.90 
MGCD-265 2.60 1.68 
LY2603618 2.57 2.22 
Everolimus(RAD001) 2.46 2.92 
*AZD7762 2.45 1.05 
*Vatalanib 2.43 1.35 
AZ 960 2.37 2.24 
*AZD6244(Selumetinib) 2.36 1.08 
ZM-447439 2.34 2.23 
Masitinib(AB1010) 2.34 2.17 
A-674563 2.32 1.88 
*PHA-793887 2.29 1.02 
SB 525334 2.27 2.26 
A66 2.26 2.08 
Axitinib 2.25 1.34 
TSU-68 2.21 1.66 
MLN8237 2.19 1.16 
R406(free base) 2.19 1.58 
Crenolanib  2.17 3.07 
VX-745 2.17 1.03 
AP24534 2.14 1.00 
PHA-739358 2.12 1.20 
ENMD-2076 2.12 0.94 
TG101209 2.09 2.00 
AZD8931 2.07 2.23 
CP-724714 2.03 0.66 
NVP-TAE684 2.02 1.27 
LY2228820 1.99 1.16 
LDN193189 1.92 1.85 
PF-2341066 1.92 1.44 
KRN 633 1.91 1.28 
BIX 02189 1.91 0.91 
JNJ-7706621 1.89 2.97 
ZM 336372 1.89 3.30 
Rapamycin(Sirolimus) 1.88 2.43 
XL880(GSK1363089) 1.85 1.34 
AEE788 1.78 1.18 
WYE-125132 1.78 1.32 
BAY 73-4506 1.77 1.22 
BIBW2992(Tovok) 1.76 1.40 
AT7867 1.75 1.36 
Sorafenib Tosylate 1.74 1.06 
AZD0530(Saracatinib) 1.70 1.10 
AZD8330 1.69 1.87 
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Motesanib Diphos 1.67 1.45 
JNJ-38877605 1.65 0.83 
SB 431542 1.63 2.23 
R406 1.61 2.42 
Enzastaurin 1.59 1.69 
KU-60019 1.58 1.66 
Roscovitine(CYC202) 1.58 0.53 
Imatinib(STI571) 1.53 1.13 
WZ8040 1.53 0.40 
VX-765 1.51 0.64 
PF-04217903 1.49 0.87 
SB 216763 1.48 0.95 
OSI-420 1.47 1.22 
BS-181 hydrochloride 1.47 1.39 
CX-4945 1.44 1.20 
PD153035 HCl 1.42 0.52 
KU-0063794 1.42 1.18 
Cediranib(AZD2171) 1.41 1.23 
Mubritinib 1.41 1.08 
CI-1040 (PD184352) 1.40 0.70 
AZD1152-HQPA 1.40 0.76 
SP600125 1.39 1.65 
PKI-SU11274 1.37 0.65 
BMS-599626 1.37 0.87 
PI-103 1.34 0.49 
Cyt387 1.33 1.38 
SGX-523 1.31 0.72 
KU-55933 1.28 0.75 
U0126-EtOH 1.28 0.39 
WZ4002 1.26 0.41 
PIK-294 1.26 0.78 
NVP-BHG712 1.23 1.24 
PD0325901 1.23 0.97 
Indirubin 1.23 1.06 
Ki8751 1.23 0.79 
Telatinib 1.20 0.89 
AV-951(Tivozanib) 1.20 0.52 
AZD8055 1.19 1.09 
CAL-101 1.18 1.11 
Pazopanib HCl 1.17 0.82 
CHIR-99021 1.15 1.39 
Gefitinib(Iressa) 1.14 0.65 
PLX-4720 1.14 0.61 
SB 202190 1.12 0.51 
PP242 1.11 1.00 
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BKM-120 1.11 0.86 
GSK2126458 1.10 1.05 
ZSTK474 1.10 1.09 
XL765 1.10 1.03 
Vandetanib 1.08 0.26 
NU7441 1.08 0.33 
PF-562271 1.08 0.84 
Polyplex only Control 1.05 1.19 
ABT-869(Linifanib) 1.05 1.40 
GSK1838705A 1.05 0.69 
Polyplex/DMSO  1.04 0.06 
MK-2206 1.04 0.74 
BMS 794833 1.04 0.48 
SB 203580 1.03 0.91 
CCT128930 1.02 0.55 
IC-87114 1.01 0.50 
Polyplex/DMSO  1.01 0.03 
Dasatinib 1.01 0.88 
GSK1120212 1.01 0.86 
CYC116 1.00 0.23 
PCI-32765 0.99 0.67 
AT7519 0.99 0.60 
AS-605240 0.99 0.80 
AZD6482 0.98 0.69 
AS604850 0.97 0.33 
TG100-115 0.96 1.38 
GDC-0941 0.95 0.84 
BIRB 796 0.95 0.80 
Lapatinib Ditosylate 0.94 0.22 
Sunitinib Malate 0.93 0.55 
WAY-600 0.91 0.61 
OSI027 0.90 0.42 
PIK-90 0.90 0.85 
PP121| 0.89 0.65 
Flavopiridol(Alvocidib) 0.89 1.24 
WZ3146 0.87 0.89 
Erlotinib HCl 0.86 0.31 
Nilotinib 0.86 0.36 
Apatinib 0.86 0.53 
PIK-93 0.86 0.77 
BEZ235 0.85 0.38 
PH-797804 0.83 0.35 
TAK-733 0.80 0.54 
Polyplex only Control 0.79 0.14 
GDC-0980 0.78 0.41 
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DCC-2036 0.78 0.17 
WYE-687 0.78 0.67 
PIK-293 0.76 0.57 
BIBF1120(Vargatef) 0.73 0.35 
OSI-930 0.71 0.24 
TAK-901 0.70 0.59 
CP-690550(Tofacitinib) 0.68 0.39 
R935788 0.66 0.48 
NVP-BSK805 0.66 0.22 
GSK1059615 0.66 0.52 
WYE-354 0.66 0.51 
PIK-75 Hydrochloride 0.58 0.56 
PF-04691502 0.57 0.76 
TGX-221 0.48 0.68 
AZD5438 0.46 0.54 
LY2784544 0.43 0.19 
Flavopiridol HCl 0.42 0.46 
AS252424 0.42 0.39 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1 1,4C-1,4Bis-mediated transfections carried out in PC3-PSMA cells in the presence of 
several doses of the pan-aurora kinase inhibitor PHA 680632. * = Student’s T-test, transgene 
expression enhancement significant relative to DMSO + polyplex control, denoted as “0” 
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APPENDIX II – ENTINOSTAT EFFECT ON GLOBAL PROTEIN AND TRANSIENT 
EXPRESSION 
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Table A3 -  Transgene expression, protein content, and cell count for PC3-PSMA 
cells treated with DMSO vehicle control or 33 μM Entinostat and transfected with 
pGL3 DNA using 1,4C-1,4Bis polymer as delivery vehicle (n=3 independent 
experiments, 48 hours following transfection) 
 Vehicle Control 33 μM Entinostat 
RLU/well 4.01X103±1.25X103 *3.33X104±1.30X104 
μg Protein/Well 365±40 297±58 
Cell Count/Well 4.66X105±3.04X104 *1.34X105±2.40X104 
RLU/Cell 8.6X10-3±2.7X10-3 *248.4X10-3±97.0X10-3 
ng Protein/Cell 0.78±0.09 *2.21±0.43 
Vehicle Control Normalized 
RLU/Cell 
1.0±0.3 *28.4±5.3 
Vehicle Control Normalized 
Protein/Cell 
1.0±0.1 *2.8±0.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
APPENDIX III – POLYMER MATERIALS USED FOR TRANSFECTIONS 
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Figure A2 Amine-containing monomer (paromomycin) and ether-containing cross-linker (glycerol 
diglycidyl ether) used in ring-opening reaction for synthesizing the P8 polymer used in gene delivery 
studies. Structures drawn using MarvinSketch drawing software (ChemAxon). Structures obtained from 
Sigma-Aldrich website 
Figure A3 Ether-containing monomer (1,4-cyclohexanedimethanol diglycidyl ether) and 
amine-containing monomer (1,4-Bis(3-aminopropyl)piperazine) used in ring-opening 
reaction to synthesize the 1,4C-1,4Bis polymer used in gene delivery studies. Structures 
drawn using MarvinSketch drawing software (ChemAxon). Structures obtained from Sigma-
Aldrich website 
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APPENDIX IV – EPIGENETIC ENZYME INHIBITORS INCLUDED IN CHAPTER 4 
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Table A4 – Screening inhibitors and their optimal concentrations for transgene 
expression enhancement plotted in figures 4.1 and 4.2  
Inhibitor Target 
High or 
Low Dose 
Candidate? 
Optimal Conc (μM) 
for Transgene 
Expression  
Phthalazinone pyrazole Aurora A Low 
0.05 (CHO-K1) / 0.5 
(UMUC3) 
(+)-JQ-1 BET  High 0.5 (both cell lines) 
PFI-1 BET  High 0.5 (both cell lines) 
2',3',5'-triacetyl-5-azacytidine DNMT High 50 (both cell lines) 
5-Azacytidine DNMT High 
0.5 (CHO-K1) / 5 
(UMUC3) 
Decitabine DNMT High 
0.5 (CHO-K1) / 50 
(UMUC3) 
RG-108 DNMT High 0.5 (both cell lines) 
Zebularine DNMT High 
5 (CHO-K1) / 50 
(UMUC3) 
Lomeguatrib DNMT - MGMT Low 
0.05 (CHO-K1) / 5 
(UMUC3) 
RSC-133 DNMT/HDAC High 50 (both cell lines) 
GSK343 EZH2 Low 5 (both cell lines) 
UNC1999 EZH2 Low 5 (both cell lines) 
3-Deazaneplanocin A EZH2 - indirectly High 0.5 (both cell lines) 
Gemicitabine Gadd45 Low 
Reduced Transgene 
Expression 
Mirin H2Ax phosphorylation High 
5 (CHO-K1) / 50 
(UMUC3) 
I-CBP112 (hydrochloride) HAT - CBP/p300 High 
50 (CHO-K1) / 5 
(UMUC3) 
CPTH2 (hydrochloride) HAT - Gcn5 High 
50 (CHO-K1) / 5 
(UMUC3) 
C646 HAT - p300 High 
5 (CHO-K1) / 0.5 
(UMUC3) 
Anacardic acid HAT - p300 and PCAF High 
0.5 (CHO-K1) / 5 
(UMUC3) 
CAY10669 HAT - PCAF High 50 (both cell lines) 
Delphinidin (chloride) HAT -p300/CBP High 
Reduced Transgene 
Expression 
(S)-HDAC-42 HDAC Low 0.5 (both cell lines) 
CAY10433 HDAC High 
5 (CHO-K1) / 50 
(UMUC3) 
Chidamide HDAC High 5 (both cell lines) 
HNHA HDAC High 
50 (CHO-K1) / 5 
(UMUC3) 
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Oxamflatin HDAC Low 0.5 (both cell lines) 
Sodium butyrate HDAC High 
50 (CHO-K1) / 5 
(UMUC3) 
Apicidin HDAC - Class I Low 0.05 (both cell lines) 
CBHA HDAC - Class I Low 
0.5 (CHO-K1) / 5 
(UMUC3) 
MS-275 HDAC - Class I High 0.5 (both cell lines) 
Pimelic diphenylamide 106 HDAC - Class I High 5 (both cell lines) 
Pyroxamide HDAC - Class I High 5 (both cell lines) 
Valproic Acid (sodium salt) HDAC - Class I High 
0.5 (CHO-K1) / 5 
(UMUC3) 
4-iodo-SAHA HDAC - Class I/II High 0.5 (both cell lines) 
ITF-2357 HDAC - Class I/II Low 0.05 (both cell lines) 
M 344 HDAC - Class I/II Low 
0.05 (CHO-K1) / 0.5 
(UMUC3) 
Scriptaid HDAC - Class I/II High 
5 (CHO-K1) / 0.5 
(UMUC3) 
Suberohydroxamic Acid 
(SBHA) HDAC - Class I/II High 
0.5 (CHO-K1) / 50 
(UMUC3) 
Suberoylanilide Hydroxamic 
Acid (SAHA) HDAC - Class I/II Low 0.5 (both cell lines) 
Trichostatin A HDAC - Class I/II Low 0.05 (both cell lines) 
CAY10603 HDAC - HDAC6 Low 
0.05 (CHO-K1) / 0.5 
(UMUC3) 
PCI 34051 HDAC - HDAC8 Low 
0.5 (CHO-K1) / 5 
(UMUC3) 
SB939 HDAC - minus HDAC6/7 Low 
0.05 (CHO-K1) / 0.5 
(UMUC3) 
Sodium 4-phenylbutyrate HDAC - weak High 
50 (CHO-K1) / 0.5 
(UMUC3) 
CAY10398 HDAC 1 High 5 (both cell lines) 
KD-5170 HDAC Class I/II High 0.5 (both cell lines) 
2,4-DPD HIF1α prolyl hydroxylase  High 50 (both cell lines) 
DMOG 
HIF1α prolyl 
hydroxylase  High 50 (both cell lines) 
Daminozide 
Histone Demethylase - 
Jumonji High 
0.5 (CHO-K1) / 50 
(UMUC3) 
GSK-J1 (sodium salt) 
Histone Demethylase - 
Jumonji High 
0.5 (CHO-K1) / 50 
(UMUC3) 
GSK-J4 (hydrochloride) 
Histone Demethylase - 
Jumonji High 
0.5 (CHO-K1) / 5 
(UMUC3) 
IOX1 
Histone Demethylase - 
Jumonji High 5 (both cell lines) 
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N-Oxalylglycine 
Histone Demethylase - 
Jumonji High 
0.5 (CHO-K1) / 50 
(UMUC3) 
2-PCPA (hydrochloride) 
Histone Demethylase - 
LSD1 High 50 (both cell lines) 
Chaetocin HMT High Very toxic 
Ellagic Acid HMT - CARM High 
Reduced Transgene 
Expression 
BIX01294 (hydrochlorie 
hydrate) HMT - G9a High 5 (both cell lines) 
UNC0224 HMT - G9a Low 
0.5 (CHO-K1) / 5 
(UMUC3) 
UNC-0321 Itrifluoroacetate 
salt) HMT - G9a Low 
5 (CHO-K1) / 0.05 
(UMUC3) 
UNC0638 HMT - G9a/GLP Low 
0.05 (CHO-K1) / 0.5 
(UMUC3) 
WDR5-0103 
HMT - WDR5-MLL 
complex High 50 (both cell lines) 
Sinefungin 
Methyltransferases - 
General High 50 (both cell lines) 
CCG-100602 Other High 
0.5 (CHO-K1) / 5 
(UMUC3) 
Isoliquiritigenin Other High 5 (both cell lines) 
Octyl-α-ketoglutarate Other High 
0.5 (CHO-K1) / 5 
(UMUC3) 
S-adenosylhomocysteine Other High 50 (both cell lines) 
Suramin (sodium salt) Other High 5 (both cell lines) 
trans-Resveratrol Other High 5 (both cell lines) 
UNC1215 
Other - L3MBTL3 
reader High 50 (both cell lines) 
MI-2 (hydrochloride) Other - MLL  High 5 (both cell lines) 
Cl-Amidine (trifluoroacetate 
salt) PAD4 deimination High 50 (both cell lines) 
F-Amidine (trifluoroacetate 
salt) PAD4 deimination High 
50 (CHO-K1) / 0.5 
(UMUC3) 
3-amino benzamide PARP High 
50 (CHO-K1) / 5 
(UMUC3) 
BSI-201 PARP High 0.5 (both cell lines) 
(-)-Neplanocin A SAH Hydrolase Low 0.05 (both cell lines) 
1-Naphthoic Acid Sirtuin High 50 (both cell lines) 
EX-527 Sirtuin High 0.5 (both cell lines) 
Nicotinamide Sirtuin High 5 (both cell lines) 
JGB1741 Sirtuin - SIRT1 High 
0.5 (CHO-K1) / 5 
(UMUC3) 
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Salermide Sirtuin - SIRT1/2 High 
0.5 (CHO-K1) / 5 
(UMUC3) 
SIRT1/2 Inhibitor IV Sirtuin - SIRT1/2 High 0.5 (both cell lines) 
Sirtinol Sirtuin - SIRT1/2 High 
50 (CHO-K1) / 0.5 
(UMUC3) 
Tenovin-1 Sirtuin - SIRT1/2 High 0.5 (both cell lines) 
Tenovin-6 Sirtuin - SIRT1/2/3 High 
5 (CHO-K1) / 0.5 
(UMUC3) 
AGK2 Sirtuin - SIRT2 High 5 (both cell lines) 
Splitomicin Sirtuin - yeast High 
50 (CHO-K1) / 0.5 
(UMUC3) 
CAY10591 Sirtuin Activator High 0.5 (both cell lines) 
Piceatannol Sirtuin Activator High 
0.5 (CHO-K1) / 5 
(UMUC3) 
PFI-3 SMARC High 
50 (CHO-K1) / 5 
(UMUC3) 
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APPENDIX V – SB939 TREATED CELLS AND HISTONE H3K9 ACETYLATION 
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Figure A4 CHO-K1 and UMUC3 cells were treated with the HDAC inhibitor 
SB939 (500 nM) and transfected with the pEF-Luc plasmid. Following 48 hours of 
transfection, cells were lysed and assayed for histone H3K9 acetylation via 
immunoblot 
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